



US 20250257126A1

(19) United States

(12) Patent Application Publication

De La Roche et al.

(10) Pub. No.: US 2025/0257126 A1

(43) Pub. Date: Aug. 14, 2025

(54) THERAPEUTIC ANTIBODIES

A61K 40/11 (2025.01)

(71) Applicants: CAMBRIDGE ENTERPRISE
LIMITED, Cambridge (GB);
RIGSHOSPITALET, Copenhagen
(DK); SYDDANSK UNIVERSITET,
Odense (DK)

A61K 40/15 (2025.01)

A61K 40/31 (2025.01)

A61K 40/42 (2025.01)

A61K 47/68 (2017.01)

A61P 35/00 (2006.01)

C12N 5/0783 (2010.01)

G01N 33/574 (2006.01)

(72) Inventors: Maike De La Roche, Cambridge (GB);
Marc Andrew De La Roche,
Cambridge (GB); Mikkel-Ole Skjodt,
Copenhagen (DK); Karsten Skjodt,
Odense (DK)

(52) U.S. Cl.

CPC C07K 16/28 (2013.01); A61K 40/11

(2025.01); A61K 40/15 (2025.01); A61K 40/31

(2025.01); A61K 40/4202 (2025.01); A61K

47/68031 (2023.08); A61K 47/6849 (2017.08);

A61P 35/00 (2018.01); C12N 5/0636

(2013.01); C12N 5/0646 (2013.01); G01N

33/57484 (2013.01); A61K 2039/505

(2013.01); C07K 2317/24 (2013.01); C07K

2317/34 (2013.01); C07K 2317/622 (2013.01);

C07K 2317/77 (2013.01); C07K 2317/92

(2013.01); C07K 2319/03 (2013.01); C12N

2510/00 (2013.01); G01N 2333/726 (2013.01)

(21) Appl. No.: 18/842,730

(22) PCT Filed: Mar. 3, 2023

(86) PCT No.: PCT/GB2023/050512

§ 371 (c)(1),

(2) Date: Aug. 29, 2024

(30) Foreign Application Priority Data

Mar. 3, 2022 (GB) 2202990.4
Jun. 10, 2022 (GB) 2208544.3

Publication Classification

(51) Int. Cl.

C07K 16/28 (2006.01)
A61K 39/00 (2006.01)

(57)

ABSTRACT

LGR5 binding agents, in particular antibodies or fragments thereof which bind to human LGR5, and the use of such binding agents in the treatment of disease, such as cancer and inflammatory disease, and the detection of LGR5.

Specification includes a Sequence Listing.




Figure 1




Figure 2




Figure 2 Cont.






Figure 3

A



B





Figure 4

A



B





Figure 4 Cont.

C



D





Figure 4 Cont.

E



F




Figure 5




Figure 6





Figure 7






Figure 8




Figure 9




Figure 10






Figure 11


A




B




C



D



E



F






Figure 12

A



B



C






Figure 13


A




B




C



D



E



F




Figure 14






Figure 14 Cont.

C



D



E




Figure 15





Figure 15 Cont.





Figure 16





Figure 16 Cont.





Figure 17

A



B




Figure 18





Figure 19

A



B





Figure 20

A



B




Figure 21




Figure 22




Figure 23




Figure 24





Figure 25

A



B




Figure 26





Figure 27



THERAPEUTIC ANTIBODIES

FIELD OF THE INVENTION

[0001] The invention relates to LGR5 binding agents, in particular antibodies or fragments and derivatives thereof which bind to LGR5, and the use of such binding agents in the treatment of disease, such as cancer and inflammatory disease, and the detection of LGR5.

INTRODUCTION

[0002] The Wnt pathway is one of a cadre of cell-to-cell signalling pathways that coordinates development in metazoans and regulates stem cell function in adult tissues. Stimulation of the Wnt pathway is initiated by engagement of extracellular ligands, generally Wnts, by cognate Wnt receptors on the cell surface and transmission of the signal inside the cell. A subsequent series of molecular interactions culminates on the activation of a context-specific transcriptional program that mediates biological outputs.

[0003] Principal roles for the Wnt pathway in sustaining adult stem cell self-renewal and proliferation have been functionally established in a wide range of tissues including epithelial stem cell compartments along the gastrointestinal tract, liver, mammary gland, skin and the maturing B cell compartment. Mutational deregulation of Wnt pathway leading to aberrant target gene expression is one of the key drivers for cancer development in these and a number of other tissues. The oncogenic form of the Wnt pathway has received considerable attention in colorectal cancer (CRC), where somatic mutations de-regulating pathway activity, most commonly deactivating mutation in the tumour suppressor adenomatous polyposis coli (APC), are early and pervasive lesions in disease aetiology. In other epithelial malignancies, a spectrum of cancer driver mutations in other Wnt pathway regulatory components may be present; for instance, in the development of hepatocellular carcinoma, approximately half of the cases acquire gain-of-function mutations in p-catenin or inactivating mutations in AXIN1. In some epithelial cancers aberrant pathway activity and de-regulated target gene expression is a frequent characteristic despite the lack of mutations in the Wnt pathway and might be the consequence of convergent regulation by other cell signalling pathways.

[0004] Determining the gene expression signature endemic to cancer cells has enabled the identification of prognostic disease markers and provided a foundation for determining molecular vulnerabilities that may be exploited therapeutically. One notable study identified a cohort of Wnt target genes in a CRC cell line harbouring somatically inactivated APC. Leucine-rich repeat containing G-protein receptor 5 (LGR5) was identified as a gene target of oncogenic Wnt pathway activity and subsequent work established it as the prototypical stem cell marker in the murine and human intestinal epithelia, gastric epithelia, hair follicle, fetal mammary gland, nephrons in the developing kidney and the regenerating liver.

[0005] LGR5 is a member of a cell surface G P C R-like receptor family that includes LGR4 and LGR6. While LGR4 is broadly expressed in proliferative cell compartments throughout the body, LGR6 displays a more restricted expression to specific stem cell compartments that include sweat glands, interfollicular epidermis, and nail stem cells. The three LGR family proteins are co-receptors for R-spon-

din family proteins, with RNF43 or ZNRF3 being the other co-receptors. RNF43 and ZNRF3 are ubiquitin ligases that downregulate cell surface associated Wnt receptors. Occlusion of RNF43/ZNRF3 from Wnt receptors through recruitment to LGR-bound R-spondin serves to increase steady-state levels of Wnt pathway receptors at the cell surface and the responsiveness of pathway activity to stimulation with Wnt ligands.

[0006] LGR5 has attracted a great deal of therapeutic interest owing to its overexpression in cancers with oncogenic mutations de-regulating pathway activity. A plethora of studies have demonstrated increased LGR5 expression in CRC tumours and intestinal adenocarcinomas relative to adjacent normal intestinal tissue and have shown that LGR5 is associated with cells at the invasive front of tumours and metastatic cells. As a prognostic marker in CRC, LGR5 transcript levels in patient samples are associated with shorter overall survival and reduced disease-free survival.

[0007] Functionally, LGR5 sufficiency studies in CRC cell lines have ascribed roles in proliferative capacity, migration, chemosensitivity, colony formation and in vivo transplantation ability. Studies using human CRC organoid xenografts have found that the LGR5 expressing cell compartment is more proliferative than their non-expressing counterparts.

[0008] A number of other malignancies are characterized by increased LGR5 overexpression: basal cell carcinoma, glioblastoma—where upregulated LGR5 co-localizing with the cancer stem cell marker CD133 predicts poor prognosis, ovarian tumours, ER negative breast cancers—where high LGR5 expression during cancer development correlates worse prognosis and B cell malignancies.

[0009] Taken together, while LGR5 may have positive, opposing or functionally redundant roles in cancer development, LGR5 overexpression on the cell surface is a characteristic of various cancer types, providing a molecular handle for discriminating cancer cells from non-malignant tissues.

[0010] Immune therapies are a class of promising therapeutics, some of which harnessing the specificity and efficacy of antibody binding for recognition of cell surface proteins overexpressed on cancer cells. Indeed, antibodies are one of the best-selling classes of drugs today; five of the top ten best selling drugs are antibodies. The versatility and specificity of antibodies have found widespread use for detection and specific killing of cancer cells in a number of cancer types. Therapeutic antibodies include modalities like antibody-dependent cellular cytotoxicity (ADCC), antibody-drug conjugates (ADCs), chimeric antigen receptors (CARs), and bispecific immune cell engagers (e.g. Bispecific T cell Engagers, BiTEs).

[0011] Despite the clinical potential of an antibody to LGR5, there are only few, if any, that have undergone robust validation, hampering efforts in determining relative LGR5 protein levels in normal tissues and disease, examining cellular biology or developing immune therapies towards specific cancer types.

[0012] The aim of the present invention is to address the need for antibody-based treatments for use in the treatment of disease, particularly in the treatment of cancer and inflammatory disease, for example. The aim of the present invention is also to provide antibodies against LGR5 for use as a research tool and for use in the treatment and diagnosis of disease.

SUMMARY OF THE INVENTION

[0013] The present invention relates to LGR5 binding agents. In particular, the present invention relates to antibodies which bind to human and cynomolgus (cyno) LGR5, wherein the antibody binds an epitope within amino acids 22-37 of LGR5 (SEQ ID NO.1) and related methods for treating disease, for example cancer and/or inflammatory disease, and identifying the presence of LGR5 in a biological sample. The invention is based, in part, on studies by the inventors in which they found that antibodies directed towards a specific epitope within amino acids 22-37 of LGR5 are highly specific, with high affinity and are taken up rapidly by LGR5 expressing cancer cells. The inventors have shown that the antibodies of the present invention are able to distinguish cells with high levels of LGR5 expression from cells with lower expression levels of LGR5. The antibodies of the present invention therefore represent excellent research tools as well as being particularly useful in therapy, such as the treatment of cancer, particularly cancers which express LGR5.

[0014] In one aspect, the invention relates to an antibody or fragment thereof which binds to human LGR5, wherein the antibody binds an epitope located within amino acids 22-37 of SEQ ID NO.1.

[0015] In one aspect, the invention relates to an antibody or fragment thereof which binds an epitope which comprises or consists of amino acids 22-37 of SEQ ID NO.1.

[0016] In one embodiment, the antibody is human or humanised. In one embodiment, the antibody is a murine antibody.

[0017] In one aspect the invention relates to an antibody or fragment thereof which binds to LGR5, wherein the V_H of the antibody comprises the following CDR1, CDR2 and CDR3:

[0018] a) a CDR1 of SEQ ID No. 2 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 3 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 4 or a sequence with at least 90% homology thereto; or

[0019] b) a CDR1 of SEQ ID No. 8 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 9 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 10 or a sequence with at least 90% homology thereto; or

[0020] c) a CDR1 of SEQ ID No. 14 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 15 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 16 or a sequence with at least 90% homology thereto; or

[0021] d) a CDR1 of SEQ ID No. 20 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 21 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 22 or a sequence with at least 90% homology thereto; or

[0022] e) a CDR1 of SEQ ID No. 26 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 27 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 28 or a sequence with at least 90% homology thereto; or

[0023] f) a CDR1 of SEQ ID No. 32 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 33 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 34 or a sequence with at least 90% homology thereto; or

[0024] g) a CDR1 of SEQ ID No. 38 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 39 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 40 or a sequence with at least 90% homology thereto; or

[0025] h) a CDR1 of SEQ ID No. 44 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 45 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 46 or a sequence with at least 90% homology thereto; or

[0026] i) a CDR1 of SEQ ID No. 50 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 51 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 52 or a sequence with at least 90% homology thereto; or

[0027] j) a CDR1 of SEQ ID No. 56 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 57 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 58 or a sequence with at least 90% homology thereto; or

[0028] k) a CDR1 of SEQ ID No. 62 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 63 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 64 or a sequence with at least 90% homology thereto; or

[0029] l) a CDR1 of SEQ ID No. 68 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 69 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 70 or a sequence with at least 90% homology thereto; or

[0030] m) a CDR1 of SEQ ID No. 74 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 75 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 76 or a sequence with at least 90% homology thereto.

[0031] In one aspect the invention relates to an antibody or fragment thereof which binds to LGR5, wherein the V_L of the antibody comprises the following CDR1, CDR2 and CDR3:

[0032] a) a CDR1 of SEQ ID No. 5 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 6 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 7 or a sequence with at least 90% homology thereto; or

[0033] b) a CDR1 of SEQ ID No. 11 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 12 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 13 or a sequence with at least 90% homology thereto; or

[0034] c) a CDR1 of SEQ ID No. 17 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 18 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 19 or a sequence with at least 90% homology thereto; or

[0035] d) a CDR1 of SEQ ID No. 23 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 24 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 25 or a sequence with at least 90% homology thereto; or

[0036] e) a CDR1 of SEQ ID No. 29 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 30 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 31 or a sequence with at least 90% homology thereto; or

- [0037] f) a CDR1 of SEQ ID No. 35 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 36 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 37 or a sequence with at least 90% homology thereto; or
- [0038] g) a CDR1 of SEQ ID No. 41 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 42 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 43 or a sequence with at least 90% homology thereto; or
- [0039] h) a CDR1 of SEQ ID No. 47 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 48 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 49 or a sequence with at least 90% homology thereto; or
- [0040] i) a CDR1 of SEQ ID No. 53 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 54 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 55 or a sequence with at least 90% homology thereto; or
- [0041] j) a CDR1 of SEQ ID No. 59 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 60 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 61 or a sequence with at least 90% homology thereto; or
- [0042] k) a CDR1 of SEQ ID No. 65 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 66 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 67 or a sequence with at least 90% homology thereto; or
- [0043] l) a CDR1 of SEQ ID No. 71 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 72 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 73 or a sequence with at least 90% homology thereto; or
- [0044] m) a CDR1 of SEQ ID No. 77 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 78 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 79 or a sequence with at least 90% homology thereto.
- [0045] In one aspect the invention relates to an antibody or fragment thereof which binds to LGR5, the antibody comprising a V_H sequence selected from SEQ ID NOS: 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104.
- [0046] In one aspect the invention relates to an antibody or fragment thereof which binds to LGR5, the antibody comprising a V_L sequence selected from SEQ ID NOS: 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105.
- [0047] In one aspect the invention relates to an antibody or fragment thereof which binds to LGR5, the antibody comprising:
- [0048] a) a V_H sequence of SEQ ID NO: 80 and a V_L sequence of SEQ ID NO: 81;
- [0049] b) a V_H sequence of SEQ ID NO: 82 and a V_L sequence of SEQ ID NO: 83;
- [0050] c) a V_H sequence of SEQ ID NO: 84 and a V_L sequence of SEQ ID NO: 85;
- [0051] d) a V_H sequence of SEQ ID NO: 86 and a V_L sequence of SEQ ID NO: 87;
- [0052] e) a V_H sequence of SEQ ID NO: 88 and a V_L sequence of SEQ ID NO: 89;
- [0053] f) a V_H sequence of SEQ ID NO: 90 and a V_L sequence of SEQ ID NO: 91;
- [0054] g) a V_H sequence of SEQ ID NO: 92 and a V_L sequence of SEQ ID NO: 93;
- [0055] h) a V_H sequence of SEQ ID NO: 94 and a V_L sequence of SEQ ID NO: 95;
- [0056] i) a V_H sequence of SEQ ID NO: 96 and a V_L sequence of SEQ ID NO: 97;
- [0057] j) a V_H sequence of SEQ ID NO: 98 and a V_L sequence of SEQ ID NO: 99;
- [0058] k) a V_H sequence of SEQ ID NO: 100 and a V_L sequence of SEQ ID NO: 101
- [0059] l) a V_H sequence of SEQ ID NO: 102 and a V_L sequence of SEQ ID NO: 103; or
- [0060] m) a V_H sequence of SEQ ID NO: 104 and a V_L sequence of SEQ ID NO: 105.
- [0061] In one aspect the invention relates to an antibody or fragment thereof which binds to LGR5, the antibody comprising the combination of V_H, C_H, V_L and C_L SEQ ID NOS: 106 to 156 for the clones shown in Table 3 or a sequence with at least 70%, 80% or 90% homology thereto or a sequence of an antibody clone as shown in Table 3 or a sequence with at least 70%, 80% or 90% homology thereto.
- [0062] In one embodiment, the antibody or fragment thereof binds to human LGR5. The may antibody or fragment may also bind to the corresponding sequence in cynomolgus (cyno) LGR5 (amino acids 22-37).
- [0063] In embodiments the antibody or fragment thereof is a monoclonal antibody.
- [0064] In embodiments the antibody or fragment thereof is a human, humanized, or chimeric antibody.
- [0065] In embodiments the antibody or fragment thereof is capable of binding LGR5 with a Kd of less than around 4 nM.
- [0066] In embodiments the fragment comprises a Fab, scFv or single domain antibody.
- [0067] In embodiments, the antibody or fragment thereof is conjugated to a toxin, enzyme, radioisotope, label, therapeutic molecule or other chemical moiety.
- [0068] In another aspect, the invention relates to an immunoconjugate comprising an antibody or fragment thereof according to the invention linked to a therapeutic agent.
- [0069] The therapeutic agent may be a toxin, enzyme, radioisotope or other chemical moiety.
- [0070] In another aspect, the invention relates to a pharmaceutical composition comprising an antibody or fragment thereof as described herein or an immunoconjugate as described herein and a pharmaceutical carrier.
- [0071] In another aspect, the invention relates to a method for treating a cancer comprising administering a therapeutically effective amount of an antibody or fragment thereof as described herein, an immunoconjugate as described herein or a pharmaceutical composition as described herein.
- [0072] In another aspect, the invention relates to the use of an antibody or fragment thereof as described herein, an immunoconjugate as described herein or a pharmaceutical composition as described herein in the manufacture of a medicament for the treatment of a cancer.
- [0073] In another aspect, the invention relates to an antibody or fragment thereof as described herein, an immunoconjugate as described herein or a pharmaceutical composition as described herein for use as a medicament.
- [0074] In another aspect, the invention relates to an antibody or fragment thereof as described herein, an immunoconjugate as described herein or a pharmaceutical composition as described herein for use in the treatment of a cancer.

- [0075] In embodiments the cancer is an LGR5-positive cancer.
- [0076] In embodiments the cancer overexpresses LGR5.
- [0077] In embodiments the cancer is selected from cancer of the head or neck, uterine cancer, colorectal cancer, stomach cancer, carcinoma of the endometrium, cancer of the oesophagus, leukaemia, such as acute lymphoblastic leukaemia (ALL), liver cancer, such as hepatocellular carcinoma or pancreatic cancer.
- [0078] In another aspect, the invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof as described herein.
- [0079] In another aspect, the invention relates to a vector comprising a nucleic acid as described herein.
- [0080] In another aspect, the invention relates to a host cell comprising a nucleic acid as described herein or a vector as described herein.
- [0081] The host cell may be a bacterial, viral or mammalian cell.
- [0082] In yet another aspect, the invention relates to method of producing an antibody as described herein comprising culturing a host cell as described herein under conditions suitable for expression of the polynucleotide encoding the antibody and isolating the antibody.
- [0083] In another aspect, the invention relates to a method of detecting LGR5 in a biological sample comprising contacting the biological sample with the antibody as described herein under conditions permissive for binding of the antibody to LGR5, and detecting whether a complex is formed between the antibody and LGR5.
- [0084] In embodiments the biological sample may be a cancer sample selected from cancer of the head or neck, uterine cancer, colorectal cancer, stomach cancer, carcinoma of the endometrium, cancer of the oesophagus, leukaemia, such as acute lymphoblastic leukaemia (ALL), liver cancer, such as hepatocellular carcinoma or pancreatic cancer.
- [0085] In another aspect, the invention relates to a kit comprising an antibody as described herein, an immunoconjugate as described herein, optionally with instructions for use, or a pharmaceutical composition as described herein.
- [0086] In another aspect, the invention relates to a binding agent, e.g. and antibody or fragment thereof, that binds to essentially the same epitope as the antibody described herein or an antibody or fragment thereof that competes with one of the antibodies provided herein for binding to human or cyno LGR5.
- [0087] In another aspect, the invention relates to an isolated synthetic or recombinant peptide comprising an epitope, the peptide consisting of residues 22 to 37 of SEQ ID NO: 1.
- [0088] In another aspect, the invention relates to chimeric antigen receptor (CAR) comprising an antibody or fragment thereof as described herein.
- [0089] In another aspect, the invention relates to a CAR comprising SEQ ID NO. 211 or a sequence with at least 70%, 80% or 90% homology thereto. In one embodiment, the CAR comprises the CDRs of clone 2.4
- [0090] In another aspect, the invention relates to cell or cell population expressing such CAR.
- [0091] In another aspect, the invention relates to such a cell or population of cells for use in adaptive immunotherapy.

[0092] In another aspect, the invention relates to a method for adaptive immunotherapy comprising administering such a cell or population of cells.

[0093] In another aspect, the invention relates to an immune cell engager, such as a bispecific T cell engager, i.e. a BiTE or a tri-Specific Killer Engager TriKE, comprising an antibody or fragment as described herein. In one embodiment, the BiTE or TriKE comprises the CDRs of clone 2.4

[0094] In another aspect, the invention relates to a BiTE comprising SEQ ID NO. 211 or a sequence with at least 70%, 80% or 90% homology thereto.

[0095] In another aspect, the invention relates to an isolated synthetic or recombinant peptide comprising an epitope, the peptide consisting of residues 22 to 37 of SEQ ID NO: 1.

[0096] In another aspect, the invention relates to a method of diagnosing or assessing progression of cancer comprising assessing expression of LGR5 and/or assessing protein levels of LGR5.

FIGURES

[0097] The invention is further described in the following non-limiting figures.

[0098] FIG. 1. Validation of novel LGR5-specific antibodies. A. Western blot analysis of HEK293T lysates expressing LGR family transgenes probed with α -LGR5 hybridoma clone 2 (Table 1, antibody 2) and antibodies raised against HA and vinculin. B. Epitope mapping of a-LGR5 hybridoma clone 2 using fragments of the 100 amino acid antigen sequence traces the epitope to Fragment 1A, composed of the N-terminal of human LGR5 (amino acids 22-37). C. Immunofluorescence of HEK293T cells expressing eGFP-fused human LGR4-6 transgenes and cynomolgus LGR5 (in green) using fluorescently labelled (Alexa647) FL- α -LGR5 in red. D. Flow cytometric analysis of HEK293T cells expressing human LGR4 and LGR5 transgenes using FL-a-LGR5 for detection. E. Pre-incubation of FL- α -LGR5 with supra-stoichiometric amounts of the Fragment 1A peptide abrogates the signal in LGR5-eGFP expressing cells.

[0099] FIG. 2. Specificity of LGR5 antibodies generated in the study. A. Amino acid sequence of the human LGR5 antigen used for immunization and generation of α -LGR5. The sequence is annotated with the Fragments used in the RAD display system to localize the a-LGR5 epitope to Fragment 1A (see FIG. 1A). Below—annotation of amino acid sequences of the Fragments used for epitope mapping and structural/topological model showing the antigenic region (in red) within the extracellular domain of LGR5 (structural coordinates taken from (Peng eta)). B. Configuration of the LGR family transgenic constructs used for antibody validation. All expressed LGR proteins contain a common N-terminal hemagglutinin (HA) tag and fusion at the C-terminus to the vasopressin V2 receptor C-terminal tail followed by eGFP. C. Western blot analysis of HEK293T lysates expressing the human LGR family transgenes probed with α -LGR5 hybridoma clones 1, 3 and 4 and antibodies to HA and vinculin, as noted. Immune reactivity was also observed for hybridoma clone 12 (data not shown). No specific immune reactivity was observed when probing the western blots with the other 13 hybridoma clones. D. Sequence conservation amongst the α -LGR5 hybridoma clones within the complementary determining regions (CDRs). Conserved amino acids relative to α -LGR5 clone 1 for clones 2-4 are represented by a dash. Amino acid

differences are shown with a closed circle. E. Epitope mapping for a-LGR5 hybridoma clones 1, 3 and 4, as in FIG. 1B, using Fragments delineated in FIG. 2A. F. Sequence alignment of the N-terminal 15 amino acids of human LGR5, corresponding to Fragment 1A, with the corresponding region in other LGR family members. Sequence alignments were based on the three invariant cysteine residues, boxed. Amino acid differences in the cyno sequence are in red. G. Wnt pathway reporter assays (SuperTopFlash assays) for HEK293T cells treated with Wnt3A ligand, R-spondin and either IgG1 or a-LGR5 at levels of approximately 10-fold molar excess over R-spondin. ns, no significant difference, determined by two-tailed t-test. H. Immune fluorescence using FI- α -LGR5 for HEK293T cells expressing transgenic LGR4 or LGR5, as in FIG. 1C.

[0100] FIG. 3. Census of healthy tissues and cancers for LGR5 expression levels. A. Quantitation of LGR5 expression levels on normal tissue from 27 fallopian tube samples (FT), 28 ovarian cancer cases (OvC) and 14 omentum cancer cases (OmC) from the Cambridge ovarian cancer TMA. Level of significance calculated using two-tailed t-test comparing ovarian cancer cases (OvC) and omentum cancer cases (OmC) with levels of LGR5 protein in fallopian tube (FT) samples. B. Quantitation of LGR5 expression levels in samples from the Cambridge Brain cancer TMA in 5 samples each of normal brain tissue (Brain), low grade glioma (LGG) and glioblastoma (GBB). Level of significance calculated using two-tailed t-test comparing either low grade glioma (LGG) or glioblastoma (GBM) cases with normal brain tissue.

[0101] FIG. 4. LGR5 expression analysis in cancers A. Normalised (log 2 median-centered) LGR5 gene expression levels are shown for each cancer type, ordered by median LGR5 gene expression (black point). The grey horizontal line indicates the median LGR5 expression across all cancer samples. Samples with lower or higher than median (grey line) LGR5 expression are shown in light or dark red, respectively. Cancer types for which more than 70% of samples had higher than median LGR5 expression were defined as "high LGR5 tumours" and are printed in bold. B. Comparison of LGR5 gene expression in tumour (red) vs. normal tissues (gray), where available, for high LGR5 tumours. The grey horizontal line indicates the median LGR5 expression across all pan-cancer tumours. Significance levels of the difference of cancer versus healthy tissue (Wilcoxon test) are indicated: **p 0.01, ***p 0.001, ****p 0.0001. C. Representative images for fallopian tube tissue (left panel set), ovarian cancers (middle panel set) and omentum cancer (right panel set). Arrows shown on one of the fallopian tube sample sets indicate very rare instances of epithelial cells containing LGR5 positive intracellular puncta. Inset white numbers refer to the relative corresponding level of LGR5 expression consistent with the scoring for the Cambridge ovarian cancer TMA. D. Relative expression levels of p-catenin in the fallopian tube, ovarian cancer and omentum cancer sample sets. Levels of significance between fallopian tube (FT) and either ovarian cancer (OvC) or omentum cancer (OmC) expression datasets were calculated by two-tailed t-test. E. Representative images for brain tissue (left panel set), G BM (middle panel set) and LGG (right panel set). Inset white numbers refer to LGR5 expression levels based on the criteria used for TMA scoring. F. Quantification of LGR5 protein expression in B cells, CD4+ T cells and CD8+ T cells from healthy donor PBMCs. There

were no significant differences in cellular LGR5 expression (mean fluorescence intensity or % LGR5 expressing cells) in the presence or absence of a-LGR5 blocking peptide.

[0102] FIG. 5. Characterisation of LGR5 expression in NALM6 and LoVo cell lines. A. LGR5 transcript levels in LoVo and SW480 cell lines measured by RT-PCR using TBP as a housekeeping gene. B. LGR5 western blot analysis of lysates from 5 CRC cell lines. An antibody raised against vinculin was used as a loading control. C. Flow cytometric analysis of LoVo and SW480 cells with FI- α -LGR5 (red plots) or with the antibody pre-incubated with the Fragment 1A peptide (black plots). D. Relative LGR5 transcript levels in the NALM6, REH and 697 pre-B-ALL cell lines measured by RT-PCR using TBP as a housekeeping gene. E. Western blot analysis of LGR5 protein levels in lysates from the pre-B-ALL cell lines. F. LGR5 protein levels in the three pre-B-ALL cell lines, 697, REH and NALM6 analysed by flow cytometry.

[0103] FIG. 6. Intracellular localisation of LGR5. A. Detection of LGR5 in NALM6 and LoVo cell lines using immune fluorescence with FI- α -LGR5. B. Co-immune fluorescence detection of puncta decorated with either LGR5 and LAMP1 in LoVo cells using FI- α -LGR5 or an antibody raised against LAMP1.

[0104] FIG. 7: Rapid internalisation of cell surface LGR5
[0105] Murine clone 2 modified with a fluorescent tag was used (see clone 2 in Tables 1 and 2).

[0106] A. Time course of FL- α -LGR5 internalisation by LGR5-eGFP expressing HEK293T cells. Top right panel—enlarged image showing association of FL- α -LGR5 with the cell periphery after 5 minutes, followed by co-localisation with the internal LGR5-eGFP associated puncta within 30 minutes (middle right panel). Bottom right panel—no association or internalisation of FL- α -LGR5 for cells expressing LGR4-eGFP. Scale bar, 10 μ M.

[0107] B. Time course of FI- α -LGR5v4 (red) internalisation by NALM6 cells detected by immunofluorescence. At the timepoints, fixed cells were probed with fluorescent (Alexa488) phalloidin (green) and Hoechst (blue). Bottom panels, FI- α -LGR5v4, substituted with FI-L-LGR5v6 (red) as isotype control. In the bottom right panel, the signal from the fluorescent Alexa488 phalloidin has been omitted. Scale bar, 10 μ M.

[0108] C. Time course of FI- α -LGR5 (red) internalisation by LoVo cells. F-actin and nuclei were visualised by Alexa488-Phalloidin and Hoechst probes, respectively. For the two panels on the right, FI- α -LGR5 was pre-incubated with Frag1A. In the rightmost image, the signal from Alexa488 phalloidin has been omitted. Scale bars, 10 μ M.

[0109] D. Flow cytometric detection of FI- α -LGR5 (red histograms) or fluorescent isotype control (grey histograms) association with NALM6 cells after 1 hour incubation at 4° C. (top panel) or 37° C. (bottom) panel. Numbers represent percentage of cells with detectable fluorescence.

[0110] E. Internalisation of FL- α -LGR5 by the c18 control or the c20 CRISP R/Cas9-LGR5 targeted LoVo cell lines monitored detected by flow cytometry.

[0111] F. Flow cytometric analysis of LoVo and NALM6 cells after 60 minutes incubation with FI-IgG1 (orange), and FI- α -H ER 2 (blue) with either FI- α -LGR5v4 (red).

[0112] G. Time course of FI- α -LGR5v4 and FI- α -HER2 association with LoVo cells. Percent association was scored as fraction of cells associated with fluorescent signals from FI-□-HER2 (light grey bars) or FI- α -LGR5v4 (dark grey bars) at the indicated timepoints per field of view. Data points are average of 6 individual scoring experiments, each measuring at 80 to 200 cells over for 2 independent experiments. Error bars indicate SD amongst scoring experiments. There were no significant differences between FI- α -LGR5v4 or FI- α -HER2 association with LoVo cells or amongst any of the timepoints.

[0113] H. Time course of percent internalisation of FI- α -LGR5v4 and FI- α -H ER 2 by LoVo cells. Internalisation data scores 6 experimental counts of 80-200 cells over 2 independent experiments. Error bars indicate SD. Significant differences in internalisation between FI- α -LGR5v4 or FI- α -H ER 2 are at the *, p<0.001 level of significance, determined by two-tailed t-test, for the 5- to 180-minute timepoints.

[0114] I. Co-localisation between internalized FL- α -LGR5v4 puncta and markers of various intracellular compartments and IQGAP1 in LoVo cells. Co-localisation data were derived from automatic scoring of puncta in images of internalised FL- α -LGR5v4 and intracellular markers detected by indirect immunofluorescence and is the composite of a minimum of 200 cells over 2 individual experiments. Right—wheel graph indicating fractional association of internalised FL- α -LGR5v4 with specific intracellular vesicle markers in LoVo cells.

[0115] J. Co-localisation between internalized FL- α -LGR5 puncta and markers of various intracellular compartments and IQGAP1 in NALM6 cells, scoring as above. Right- wheel graph showing fractional association of internalised FL- α -LGR5v4 with specific intracellular vesicle markers in NALM6 cells.

[0116] FIG. 8. CRISPR/Cas9 targeting of exon 1 of LGR5. Sequencing of the LGR5 locus exon 1 indicates that clone 20 (c20) harbours an in-frame deletion of 7 amino acids of the coding region for the signal peptide.

[0117] FIG. 9. In vitro killing of LGR5-expressing cell lines by α -LGR5-ADC. A. NALM6 or REH cell lines were treated with α -LGR5-ADC and cell survival was determined after 72 hours. Cell killing data was fit to a non-linear EC50 shift model yielding EC50 values of 4 and 10 nM, respectively. As control, NALM6 cells were treated with the non-cleavable a-LGR5-ADC^{NC} which did not reduce the cell count after 72 hours, relative to non-treated controls. B. LoVo cells were treated with either α -LGR5-ADC or α -LGR5-ADC^{NC} as non-cell killing control. Modelling of a-LGR5-ADC mediated cell killing data yielded an EC50 of 9 nM. In this figure, murine clone 2 modified with a MMAE conjugate is used. The sequence is shown in Tables 1 and 2.

[0118] FIG. 10. Format and chemistry underpinning the IgG and α -LGR5-based ADCs used in the study (Walsh S J, Omarjee S, Galloway W R J D, Kwan T T L, Sore H F, Parker J S, Hyvönen M, Carroll J S, Spring D R. A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates. Chem Sci. 2019; 10(3):694-700)

[0119] FIG. 11. In vivo targeting of NALM6 tumours with murine α -LGR5-ADC. A. Experimental design. B. NALM6 tumour burden measured by IVIS imaging over the course of

the treatment with either a-LGR5-ADC or IgG1-ADC control. *p<0.01, **p<0.001 C. IVIS images of control and a-LGR5-ADC treated mice, dorsal view, at experimental endpoint. D. Spleen mass and absolute number of NALM6 tumour cells in the spleen at experimental endpoint. E. Relative number of NALM6 cells per gram blood in mice treated with a-LGR5-ADC or IgG1-ADC control. F. Number of NALM6 cells extracted from femurs of mice from the two treatment groups. (D-F) *p<0.001. In this figure, murine clone 2 modified with a MMAE conjugate is used. The sequence is shown in Tables 1 and 2.

[0120] FIG. 12. α -LGR5-ADC targeting of NALM6 tumours. A. H&E staining of tissue sections from IgG1-ADC (top row) and a-LGR5-ADC (bottom row) treated mice. No differences in gross morphology were observed, nor did we take any differences in the number of NALM6 cells in tissue between experimental groups except for spleen where we observed >20-fold more NALM6 cells (see inset) B. Immune fluorescence of intestinal epithelial sections from IgG1-ADC (top row) and α -LGR5-ADC treated (bottom row) mice using antibodies to Ki67 antigen and β -catenin. No differences in gross morphology of the intestinal epithelial monolayer were observed. C. Evaluation of β -catenin staining at the cell periphery juxtaposed to cell-cell contacts (left graph) and average number of Ki67 positive nuclei per confocal section of intestinal epithelial sections from IgG1-ADC (top row) and α -LGR5-ADC treated mice.

[0121] FIG. 13. In vivo targeting of NALM6 tumours with humanised α -LGR5v4-ADC. A. Experimental design. B. NALM6 tumour burden measured by IVIS imaging, dorsal view, over the course of the treatment with either a-LGR5v4-ADC or a-LGR5v4-ADC control. *p<0.01, **p<0.001 C. IVIS images of mice treated with α -LGR5v4-ADC or α -LGR5v6-ADC control at experimental endpoint. D. Spleen mass and absolute number of NALM6 cells in the spleen at experimental endpoint*, p<0.001. E. Number of NALM6 cells in the blood of mice treated with α -LGR5v4-ADC and α -LGR5v6-ADC control. F. Number of NALM6 cells in the bone marrow of α -LGR5v4-ADC and α -LGR5v6-ADC treated mice at experimental endpoint. (D-F) *p<0.001.

[0122] FIG. 14. α -LGR5v4 specifically binds human and cynoLGR5 and α -LGR5v4-ADC targeting of NALM6 tumours. A. Western blot analysis of lysates from transgenic murine, human and cyno LGR5 expressing HEK293T cells using antibodies to HA and the humanised antibodies α -LGR5v4 and a-LGR5v6. Note, humanised α -LGR5v6 has lost all binding to LGR5. B. Indirect immune fluorescence analysis of human and murine LGR family expressing HEK293T cells using the a-LGR5v4 antibody (in red), the Alexa488-coupled Phalloidin F-actin probe alongside eGFP fluorescence imaging. In the bottom row of images, LGR5-expressing HEK293T cells were stained with a-LGR5v6. C. H&E staining of tissue sections from a-LGR5v6-ADC (top row) and a-LGR5v4-ADC (bottom row) treated mice. No differences in gross morphology were observed, nor did we detect any differences in the number of NALM6 cells in tissue between experimental groups except for spleen where we observed >20-fold more NALM6 cells (see inset) D. Immune fluorescence of intestinal epithelial sections from α -LGR5v6-ADC (top row) and α -LGR5v4-ADC (bottom row) treated mice using antibodies to Ki67 antigen and β -catenin. No differences in gross morphology of the intes-

tinal epithelial monolayer were observed. Evaluation of β -catenin staining at the cell periphery juxtaposed to cell-cell contacts (left graph) and average number of Ki67 positive nuclei per confocal section of intestinal epithelial sections from IgG1-ADC (top row) and α -LGR5-ADC treated mice. (C-E) from experiment shown in FIG. 13.

[0123] FIG. 15. CAR cell killing. α -LGR5-CAR cell killing. HEK293 cells were transfected with human (A) and cynomolgus (B) LGR5 and served as target cells in killing assays. (C) α -LGR5 CAR NK92 cells form productive synapses with tumour target cells. (D) tumour cell killing of NALM6, R E H, and 647 ALL tumour cell lines at indicated effector:target ratios after 5 h.

[0124] FIG. 16. α -LGR5 Bispecific T cell engagers (BiTEs) are activating T cells and lead to efficient tumour cell destruction. (A) PBMCs were incubated with NALM6 tumour cells in the presence of α -LGR5 scFv control, α -LGR5LC or CL BiTE, respectively. CD4+ and CD8+ T cell activation was determined by flow cytometric analysis of CD69 and CD25 expression after 24 hours. (B) NALM6 tumour cells were co-cultured with cytotoxic CD8+ T cells generated from healthy donor PBMC in the presence of α -LGR5 scFv control, α -LGR5LC or CL BiTE, respectively. Tumour cell killing was assessed at an effector to target ratio of 5 to 1 after 5 hours.

[0125] FIG. 17. Analysis of LGR5 expression. A. LGR5 mRNA expression in NALM6 (ALL), LoVo (CRC) and HepG2 (HCC) human cell lines. RNA was extracted from cell lines at multiple timepoints and subjected qRT-PCR analysis of LGR5 using Taqman probes. TBP served as a housekeeping gene. B. Western blot analysis of LGR5 protein expression levels in HepG2 cells. HepG2 cells were lysed and 40pg of protein was loaded per well. Membranes were incubated with α -LGR5 antibody (19-24-1, (1:1000), 4° C., overnight) followed by incubation with a goat anti-mouse IgG-HRP ((1:15000), RT, 1 hr). Actin serves as a loading control.

[0126] FIG. 18. Sensitivity of CRC organoid lines expressing different levels of LGR5 to treatment with α -LGR5-ADC. A. Immunofluorescent imaging of CRC organoid lines 1 and 2 using the humanized antibody to LGR5 was used to quantify relative levels of the LGR5 protein. LGR5 protein expression was detectable in CRC organoid line 1 and was approximately 4-fold higher in CRC organoid 2. B. The presence of cleaved caspase 3 in CRC organoid lines 1 and 2 24 hours post α -LGR5-ADC treatment was used as a surrogate for cells undergoing apoptosis in response to treatment with α -LGR5-ADC. CRC organoid line 1 was less sensitive to treatment with α -LGR5-ADC than CRC organoid line 2; estimated EC50 levels for organoid cell apoptosis were 5 nM and 100 nM, respectively.

[0127] FIG. 19. α -LGR5-BiTEs lead to specific activation of human CD4+ and CD8+ T cells in the presence of LGR5+ tumour cells and induce efficient tumour cell destruction in vitro. A. CL (CD3/LGR5)—and LC (LGR5/CD3)-BiTE mediated activation of CD4+ T cells (left panel) and CD8+ T cells (right panel) in healthy donor PBMCs in the presence or absence of NALM6 tumour cells determined as percent cells with combined expression of CD25 and CD69 by flow cytometry after 24 hours. Control (ctrl), no addition of molecule, scFv refers to treatment with the α -LGR5^{scFv} fragment. Error bars represent SD for three independent activation assays using different healthy donor PBMCs. Significant differences in T cell activation in between addi-

tion of scFv and either the LC or CL BiTE molecules were determined by two-tailed t-test and shown at the ***, p<0.001 level of significance. B. α -LGR5-BiTEs lead to efficient tumour cell destruction in vitro. NALM6 target cell killing by cytotoxic CD8+ T cells in the absence (ctrl) or with the addition of scFv or LC or CL BiTE s after 5 hours is shown. Data shown is from three donors and error bars represent SD. The effector to target cell ratios are 10:1 and 5:1, respectively. Significant differences in CD8+ T cell killing were determined by two-tailed t-test at the *, p<0.005 and ***, p<0.001 level of significance.

[0128] FIG. 20. α -LGR5-CAR NK92 cells efficiently kill HEK293 cells overexpressing LGR5 and preferentially kill LGR5^{HIGH} expressing tumour cells. A. α -LGR5-CAR NK92 cells efficiently kill HEK293 cells overexpressing LGR5. Cell killing activity of NK92 cells, or NK92 cells expressing α -LGR5-CAR-CD28- or α -LGR5-CAR-4-1BB. hLGR5-eGFP-overexpressing HEK293T target cells were incubated with effector NK92 cells at effector to target ratios of 2.5:1 and 10:1 for 5 h or 9 h, respectively. Error bars represent SD for three independent experiments. Significant differences in target cell killing were determined by two-tailed t-test and shown at *, p<0.05 and ***, p<0.001. There were no significant differences in target cell killing between cellular ratios of 5:1 or 10:1. B. α -LGR5-CAR NK92 cells preferentially kill LGR5^{HIGH} expressing tumour cells. NALM 6 (left panel, LGR5^{HIGH}) and REH (right panel, LGR5^{LOW}) target cell killing activity of NK92 cells or NK92 cells expressing the α -LGR5-CAR-CD28 or the α -LGR5-CAR-4-1BB CARs with effector to target ratios of 2.5:1 and 10:1 after 12 hours incubation (top and bottom panels, respectively). Error bars represent SD for three independent experiments. Significant differences in target cell killing were determined by two-tailed t-test, at the *, p<0.05 and ***, p<0.01.

[0129] FIG. 21 α -LGR5-CAR NK92 cells efficiently kill HepG2 tumour cells. HepG2 cells were pre-seeded 24 h prior to the assay in a 96-well plate. NK92 cells and α -LGR5-CAR NK92 cells were added to the target cells at a ratio of 5:1. Cell death was assessed using Apotransfer Green and monitored for 15 h using the Incucyte SX5 (Sartorius). Error bars represent SEM of six different wells.

[0130] FIG. 22 α -LGR5-CAR NK92 cells kill NALM6 tumours in vivo. 1×10^6 NALM6 cells were injected i.v. into NSG mice; on day 5, 7 and 10 the mice received either 10×10^6 parental NK92 cells or α -LGR5-CAR NK92 cells i.v. Mice were taken on day 12, and Nalm6 cells were counted in the spleen. (Mean for Nalm6 count for NK92 cell treated NSG mice: 20664, for a-LGR5-CAR NK92 cell treated NSG mice: 11630). One outlier was removed after Grubbs' test.

[0131] FIG. 23 α -LGR5-CAR T cells efficiently kill HepG2 tumour cells. HepG2 cells were pre-seeded 24 h prior to the assay in a 96-well plate. Untransduced T cells and a-LGR5-CAR T cells were added to the target cells at a ratio of 5:1 (A) or 10:1 (B). Cell death was assessed using Apotransfer Green and monitored for 15 h using the Incucyte SX5 (Sartorius). Error bars represent SEM of six different wells.

[0132] FIG. 24 α -LGR5-CAR T cells efficiently kill LoVo tumour cells. LoVo cells were pre-seeded 24 h prior to the assay in a 96-well plate. Untransduced T cells and α -LGR5-CAR T cells were added to the target cells at a ratio of 5:1 (A) or 10:1 (B). Cell death was assessed using Apotransfer

Green and monitored for 15 h using the Incucyte SX5 (Sartorius). Error bars represent SEM of six different wells. [0133] FIG. 25 α -LGR5-CAR T cells kill NALM6 tumour cells in vivo. 1×10^6 NALM 6-LucYFP cells were injected i.v. into NSG mice. On day 4 and 7, mice received 2.5×10^6 a untransduced T cells or α -LGR5-CAR T cells or 1×10^6 a CD19-CAR T cells, respectively. A. IVIS imaging on day 10. NALM6 cell count in the bone marrow (taken from one tibia) of NSG mice on day 11 treated with untransduced T cells (negative control), α -LGR5-CAR T cells, or α -CD19-CAR T cells (positive control, benchmark). B. Mean for NALM6 count for untransduced T cell treated NSG mice: 22355, for α -LGR5-CAR T cell treated NSG mice: 6296, for α -CD19-CAR T cell treated NSG mice: 10

[0134] FIG. 26 α -LGR5-CAR-NK92 cells do not kill HEK cells overexpressing human LGR4, LGR6 or mouse Lgr5. α -LGR5-CAR NK92 cells do not target HEK293 cells overexpressing human LGR4, LGR6 and to much reduced degree mouse Lgr5. Cell killing activity of NK92 cells, or NK92 cells expressing a-LGR5-CAR-CD28- or a-LGR5-CAR-4-1BB. HEK293T target cells overexpressing the indicated proteins were incubated with effector NK92 cells at effector to target ratios of 2.5:1 and 10:1 for 9h. Error bars represent SD for three independent experiments.

[0135] FIG. 27 α -LGR5-CAR-T cells targeting of NALM6 cells. α -LGR5-CAR T cells efficiently kill NALM 6 tumour cells. NALM 6 tumour target cell killing activity of α -LGR5-41BB CAR-T cells at indicated effector to target ratios was assessed after 6 hours by VITAL assay. Error bars represent SD of three α -LGR5-CAR T cell batches generated from three different healthy donor PBMCs.

DETAILED DESCRIPTION

[0136] The present invention will now be further described. In the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

[0137] Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, pathology, oncology, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Green and Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012); Therapeutic Monoclonal Antibodies: From Bench to Clinic, Zhiqiang An (Editor), Wiley, (2009); and Antibody Engineering, 2nd Ed., Vols 1 and 2, Ontermann and Dubel, eds., Springer-Verlag, Heidelberg (2010).

[0138] Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceu-

tical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[0139] The inventors of the present invention have surprisingly identified antibodies which bind a specific epitope of human LGR5 within amino acids 22-37. As demonstrated in the examples, the antibodies are highly specific, with high affinity and are taken up rapidly by cells making the antibodies highly effective research tools as well as being extremely useful in therapy.

[0140] Leucine-rich repeat-containing G-protein receptor 5 (LGR5) has been characterised as a stem cell and cancer stem cell marker. Previous analyses of LGR5 transcript levels indicate high level expression discriminates malignancies such as colorectal cancer (CRC) and pre-B acute lymphoblastic leukaemia (pre-B ALL) from healthy tissues suggesting LGR5 protein expression may provide a molecular handle for prognosis and treatment. The inventors have developed highly specific, high affinity antibodies to the extracellular domain of human LGR5 45 (α -LGR5) that detect high LGR5 protein levels in colorectal cancer (CRC), hepatocellular carcinoma (HCC), and pre-B ALL. In contrast, there is low to undetectable levels of LGR5 protein in normal colon and rectal epithelia, liver, ovarian tissues, brain and immune cell types. LGR5 is rapidly internalised from the plasma membrane and trafficked to intracellular vesicular compartments including lysosomes.

[0141] The inventors have shown that treatment of high LGR5-expressing CRC and pre-B ALL cancer cell lines with an antibody-drug conjugate version of a-LGR5 (α -LGR5-ADC) lead to effective cell killing at nanomolar concentrations. Interventional treatment of pre-B ALL tumours with a-LGR5-ADC in vivo led to rapid tumour attrition. The inventors have demonstrated the therapeutic utility of humanised α -LGR5 by using the corresponding scFv fragment for the generation of α -LGR5 chimeric antigen receptors (CARs) and a Bispecific T cell Engager (BiTE). The inventors have demonstrated that α -LGR5-CAR-NK92 cells were effective at killing LGR5-expressing cells while α -LGR5/ α -CD3 BiTEs induce T cell activation and killing of NALM6 cells by cytotoxic CD8+ T cells. Taken together, the invention establishes α -LGR5-based therapeutic modalities that effectively discriminate and target CRC, HCC and pre-B ALL tumour cells.

[0142] The inventors have also established elevated LGR5 expression as a characteristic of CRC, HCC and pre-B ALL. Importantly, their tissue census, both transcriptional and at the level of LGR5 protein, indicates that normal tissues harbour very low to undetectable LGR5 levels, paving the way for therapeutic targeting of malignancies that overexpress the protein. Indeed, our approach has established CRC, HCC and pre-B ALL as priority cancer targets for a-LGR5-based therapeutics and enables future studies to determine other targetable cancer types and stratifying LGR5 overexpression as a prognostic marker. This is particularly relevant to the assessment of LGR5 protein levels in HCC—high LGR5 protein expression may be used to further stratify the HCC subset with activating mutations in β -catenin, which are characterised by low T cell infiltration and thus referred to as immune deserts. The prediction is that this HCC subset will be refractory to both checkpoint inhibition and cellular therapies.

[0143] Indeed, recent reporting from the CheckMate 459 trial (NCT02576509) evaluating nivolumab (PD1 checkpoint inhibitor) versus sorafenib (small molecule kinase inhibitor) in HCC failed to meet its endpoint target of improved overall survival. However, the inventors propose that exclusion of the high LGR5 expressing patient cohort may prove to be important in the outcome of the trial. Hence, stratification of HCC patients with high levels of LGR5 using anti-LGR5 presents an intriguing biomarker opportunity that both reports the β -catenin mutant subset and supports the use of therapeutic molecules such as α -LGR5-ADC, where drug efficacy is not dependent on immune infiltration. Thus, the invention also relates to the use of LGR5 expression as a prognostic marker and related methods as described herein.

[0144] The invention therefore provides an antibody or fragment thereof which binds to human LGR5, wherein the antibody binds an epitope located within amino acids 22-37 of SEQ ID NO.1 or binds an epitope which comprises of consists of amino acids 22-37 of SEQ ID NO.1, immunoconjugates and pharmaceutical compositions comprising such antibodies, as well as isolated nucleic acid molecules, vectors and host cells for producing such antibodies. Also provided are methods of using the antibodies disclosed herein to detect human LGR5, methods of diagnosis and methods of treating disease, particularly cancer and/or inflammatory disease.

[0145] The antibodies of the present invention bind to LGR5 with high affinity and specificity. In addition, the inventors have shown that the antibodies of the present invention can be rapidly internalised by cells. Thus, antibodies as described herein are capable of binding to the extracellular domain of LGR5 and being internalised. The inventors also we also benchmarked to Trastuzumab and showed exceptionally quick internalisation (within 5 min) while only 40% of Teas is internalised after 3 hours. Moreover, when conjugated to a payload, the conjugated antibodies mediate effective cell killing at nanomolar concentrations.

[0146] These properties of the antibodies mean that they can be exploited therapeutically, for example in the treatment of cancer and/or inflammatory disease. For example, the antibodies can be used to bring a therapeutic molecule, for example a drug, into close proximity with LGR5. The antibodies of the present invention can therefore be used to deliver therapeutic molecules specifically to cancers, particularly those which express or overexpress LGR5. The inventors' studies have shown that the specific antibodies of the present invention display no off-target toxicities, further validating their use in therapy.

[0147] Furthermore, the antibodies of the present invention can be used as imaging agents, for example in methods for diagnosing cancer and/or inflammatory disease or other biomarker related methods, in addition to their use as highly effective research tools.

[0148] The antibodies and fragments of the present invention bind specifically to wildtype human LGR5 (UniProt Accession No. 075473). The amino acid sequence for wildtype human LGR5 is shown below (SEQ ID NO: 1).

```
MDTSRLGVLLSLPVLLQLATGGSSPRSGVLLRGCPTHCHCEPDGRMLLRV  
DCSDLGLSELPNSNLVFTSYLDLSMNNISQLLPNPLPSLRFLEELRLAGN
```

-continued

```
ALTYIPKGFTGLYSLKVLMLQNNQLRHVPTEALQNRLSLSQLRDLANHII  
SYVPPSCFSGLHSLRHLWLDDNALTEIPVQAFRSLSALQAMTLALNKHIIH  
IPDYAFGNLSSLVVLHLHNRRHSLGKKCFDGLHSLETLDLNYYNNLDEFP  
TAIRTLSNLKELGFHSNNIIRSPEKAFCVGNPSSLITIHFYDNPIQFVGRSA  
FQHLPELRTLTLNGASQITEFPDLTGTANLESLTLTGAQISSLPQTVCNQ  
LPNLQVLDLSYNLLEDLPSFSVCQKLQKIDLRHNEIYEIKVDTFQQLSSL  
RSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLKL  
TGNHALQSLISSENFPPELKVIEMPTYAYQCQCAFVGVCENAYKISNQWNKGDN  
SSMDDLHKKDAGMFQAQDERDLEDPLLFEEDLKALHSVQCSPSPGPFKP  
CEHLLDGWLIRIGVWTIAVLALTCAVLVTSTVFRSPLYISPICKLLIGVIA  
AVNMLTGVSAAVLAGVDAFTFGSFARHGAWWENGVGCHVIGFLSIPASES  
SVPLLTLAALERGFSVKYSAKFETKAPFSSLKVIIILCALLALTMAAVPL  
LGGSKYGAAPLCLPLPFGEPSTMGYMALILLNSLCFLMMTIAYTKLYCN  
LDKGDLHENIWDCSMVKHIALLLETCNCILNCPVAFLSFSSLINLTFISPEV  
IKFILLVVVPLPACLNPLLYILFNPHPKEDLVSLRKQTYVWTRSKHPSLM  
SINSDDVEKQSCDSTQALVFTSSITYDLPSSVPSPAYPVTESCHLSS  
VAFVPC
```

[0149] Unless otherwise specified, the term LGR5 as used herein refers to human LGR5. The term LGR5 includes variants, isoforms and species homologs of human LGR5. The antibodies bind the extracellular domain. Antibodies that bind LGR5 are referenced herein as a-LGR5, aLGR5 or α -LGR5 or α LGR5. These terms are used interchangeably.

[0150] The antibodies of the present invention bind to LGR5. The term "binds" as used herein, means that the antibody binds the antigen with sufficient affinity such that the antibody is useful as a therapeutic agent in targeted a cell or tissue expressing the antigen. The binding reaction may be shown by standard methods, for example with reference to a negative control test using an antibody of unrelated specificity.

[0151] The invention provides antibodies, specifically humanised antibodies, that bind specifically to human LGR5. In other words, binding to the LGR5 antigen is measurably different from a non-specific interaction. As shown in the examples, the antibodies of the present invention that bind to human do not cross react with mouse LGR5 or human LGR4 or 6. Preferably the antibodies of the invention bind to human LGR5 and also bind to cyno LGR5.

[0152] The term "specific binding" or "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a Kd for the target of at least about 10^{-4} M, alternatively at least about 10^{-5} M, alternatively at least about 10^{-6} M, alternatively at least about 10^{-7} M, alternatively at least about 10^{-8} M, alternatively at least about 10^{-9} M, alternatively at least about 10^{-10} M, alternatively at least about 10^{-11} M, alternatively at least about 10^{-12} M, or greater. In one embodiment, the antibody or antibody fragment has a Kd of 0.7-3 nM. In one embodiment, the term "specific binding" refers to binding where a molecule binds to a particular polypep-

tide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

[0153] The term “antibody” broadly refers to any immunoglobulin (Ig) molecule, or antigen binding portion thereof, comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule. Such mutant, variant, or derivative antibody formats are known in the art. The term “antibody” as used herein encompasses monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) and antibody fragments, provided they retain the antigen-binding ability of the antibody. The term “antibody” as used herein also encompasses, for example, a T-cell Engager for example a Bispecific T-cell Engager (BiTE). As will be appreciated by the skilled person Bispecific T-cell Engagers (BiTEs) are fusion proteins including two scFvs of different antibodies wherein one of the scFvs binds to T cells via the CD3 receptor, and the other to a tumor cell via a tumor specific molecule.

[0154] In one embodiment, the BiTE or CAR described herein comprises a scFv as shown in SEQ ID NO: 211 or a sequence with at least sequence 70%, 80% or 90% homology thereto or a sequence having the CDRs of SEQ ID NO. 211. Thus, one embodiment, the BiTE comprises CDRs of clone 2.4, also numbered as SEQ ID NO. 212, 213 and 214 and the heavy chain CDRs of 215, 216 and 217. In one embodiment, the BiTE or CAR described herein comprises the VH and VL of clone 2.4 or a sequence having at least 90% sequence identity thereto. In embodiments, the antibody may comprise a monoclonal antibody. The term “monoclonal antibody” refers to an antibody obtained from a single clone of cells or cell line. The individual antibodies are identical and/or bind the same epitope. Unlike polyclonal antibodies, which include different antibodies directed against different epitopes, each monoclonal antibody in a preparation is directed against a single epitope.

[0155] In a full-length antibody, each heavy chain is comprised of a heavy chain variable region or domain (abbreviated herein as HCVR) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, C_{H1} , C_{H2} and C_{H3} . Each light chain is comprised of a light chain variable region or domain (abbreviated herein as LCVR) and a light chain constant region. The light chain constant region is comprised of one domain, C_L .

[0156] The heavy chain and light chain variable regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each heavy chain and light chain variable region is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG2, IgG 3, IgG4, IgA1 and IgA2) or subclass.

[0157] The term “CDR” refers to the complementarity-determining region within antibody variable sequences. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term “CDR set” refers to a group of three CDRs that

occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs can be defined differently according to different systems known in the art.

[0158] The Kabat Complementarity Determining Regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., (1971) Ann. N Y Acad. Sci. 190:382-391 and Kabat, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.

[0159] Department of Health and Human Services, NIH Publication No. 91-3242). Chothia refers instead to the location of the structural loops (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). The Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain).

[0160] The system described by Kabat is used herein. The terms “Kabat numbering”, “Kabat definitions” and “Kabat labelling” are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion.

[0161] A chimeric antibody is a recombinant protein that contains the variable domains including the complementarity determining regions (CDRs) of an antibody derived from one species, such as a rodent antibody, while the constant domains of the antibody molecule are derived from those of a human antibody. For veterinary applications, the constant domains of the chimeric antibody may be derived from that of other species, such as a cat or dog.

[0162] A humanized antibody is recombinant protein in which the CDRs from an antibody from one species; e.g., a rodent antibody, are transferred from the heavy and light variable chains of the rodent antibody into human heavy and light variable domains (e.g., framework region sequences). The constant domains of the antibody molecule are derived from those of a human antibody. In certain embodiments, a limited number of framework region amino acid residues from the parent (rodent) antibody may be substituted into the human antibody framework region sequences.

[0163] The term “antigen binding site” refers to the part of the antibody or antibody fragment that comprises the area that specifically binds to an antigen. An antigen binding site may be provided by one or more antibody variable domains. Preferably, an antigen binding site is comprised within the associated V_H and V_L of an antibody or antibody fragment.

[0164] An antibody fragment according to the invention is a functional portion of an antibody, for example a $F(ab')_2$, Fab, Fv, scFv and the like. The term refers thus to an antigen binding fragment and is interchangeably used with antigen binding portion of an antibody. Functional fragments of a full-length antibody retain the target specificity of a full-length antibody. Recombinant functional antibody fragments, such as Fab (Fragment, antibody), scFv (single chain variable chain fragments) and single domain antibodies (dAbs) have therefore been used to develop therapeutics as an alternative to therapeutics based on mAbs. Derivatives of antibodies are also within the scope.

[0165] scFv fragments (~25 kDa) consist of the two variable domains, V_H and V_L . Naturally, V_H and V_L domain are non-covalently associated via hydrophobic interaction and tend to dissociate. However, stable fragments can be engineered by linking the domains with a hydrophilic flexible

linker to create a single chain Fv (scFv). In one embodiment, the scFv comprises SEQ ID NO: 211 or a sequence with at least sequence 70%, 80% or 90% homology thereto or a sequence having the CDRs of SEQ ID NO. 211. In one embodiment, the scFv comprises CDRs of SEQ ID NO. 212, 213 and 214 and the heavy chain CDRs of 215, 216 and 217.

[0166] The smallest antigen binding fragment is the single variable fragment, namely the V_H or V_L domain. Binding to a light chain/heavy chain partner respectively is not required for target binding. Such fragments are used in single domain antibodies. A single domain antibody (~12 to 15 kDa) therefore consists of or comprises either the V_H or V_L domain.

[0167] As used herein, the term "homology" generally refers to the percentage of amino acid residues in a sequence that are identical with the residues of the reference polypeptide with which it is compared, after aligning the sequences and in some embodiments after introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Thus, as used herein, the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences. Neither N- or C-terminal extensions, tags or insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known. The percent identity or homology between two amino acid sequences can be determined using well known mathematical algorithms.

[0168] As used herein, when the term homology is used, this is interchangeably used with identity. Thus, when reference is made to sequence homology, these values also refer to sequence identity respectively.

[0169] Sequence identity is commonly defined with reference to the algorithm GAP (Wisconsin GCG package, Accelrys Inc, San Diego USA). GAP uses the Needleman and Wunsch algorithm to align two complete sequences, maximising the number of matches and minimising the number of gaps. Generally, default parameters are used, with a gap creation penalty equalling 12 and a gap extension penalty equalling 4. Use of GAP may be preferred but other algorithms may be used, e.g. BLAST (which uses the method of Altschul et al. (1990) J. Mol. Biol. 215: 405-410), FASTA (which uses the method of Pearson and Lipman (1988) PNAS USA 85: 2444-2448), or the Smith-Waterman algorithm (Smith and Waterman (1981) J. Mol Biol. 147: 195-197), or the TBLASTN program, of Altschul et al. (1990) supra, generally employing default parameters. In particular, the psi-Blast algorithm (Altschul et al (1997) Nucl. Acids Res. 25 3389-3402) may be used. Sequence identity may be defined using the Bioedit, ClustalW algorithm. Alignments were performed using Snapgene and based on MUSCLE (Multiple Sequence Comparison by Log-Expectation) algorithms (Edgar (2004a) Nucleic Acids Res 32: 1792-7; Edgar (2004b) BMC Bioinformatics 5: 113.).

[0170] The present invention relates to an antibody or fragment thereof that binds to an epitope of LGR5 located within amino acids 22-37 of human LGR5 (SEQ ID NO:1).

[0171] Thus, the antibody of the present invention binds to an epitope of LGR5 which includes one or more of residues 22-37 of human LGR5 (SEQ ID NO:1). For example, the antibody of the present invention binds to an epitope of

LGR5 which includes one or more, e.g. all of the following residues: G²², S²³, S²⁴, P²⁵, R²⁶, S²⁷, G²⁸, V²⁹, L³⁰, L³¹, R³², G³³, C³⁴, P³⁵, T³⁶, H³⁷.

[0172] The present invention also relates to an antibody that binds to an epitope which consists of amino acids 22-37 of LGR5 (SEQ ID NO:1).

[0173] Such an epitope is a linear epitope, as described fully below.

[0174] The term "epitope" or "antigenic determinant" refers to a site on the surface of an antigen (e.g., LGR5) to which an immunoglobulin, antibody or antibody fragment specifically binds.

[0175] Generally, an antigen has several or many different epitopes and reacts with many different antibodies. The term specifically includes linear epitopes and conformational epitopes.

[0176] Epitopes within protein antigens can be formed both from contiguous amino acids (usually a linear epitope) or non-contiguous amino acids juxtaposed by tertiary folding of the protein (usually a conformational epitope). Epitopes formed from contiguous amino acids are typically, but not always, retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation. Methods for determining what epitopes are bound by a given antibody or antibody fragment (i.e., epitope mapping) are well known in the art and include, for example, immunoblotting and immunoprecipitation assays, wherein overlapping or contiguous peptides from are tested for reactivity with a given antibody or antibody fragment.

[0177] In the present invention, the epitope was mapped by peptide mapping. In particular, the epitope was mapped by testing the reactivity of the antibody with overlapping peptide fragments and performing Western blot analysis.

[0178] In one embodiment, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_L CDR3 sequence as shown in Table 1 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. In one aspect, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_L CDR3 sequence selected from SEQ ID NO. 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of SEQ ID NO. 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0179] In one embodiment, the antibody has a V_L CDR3 sequence comprising or consisting of an amino acid sequence selected from SEQ ID NO. 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79 or a sequence having at least at least 90%, or at least 95% homology thereto.

[0180] In one embodiment, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_L CDR1 sequence as shown in Table 1 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. In one aspect, the invention relates

to an antibody which binds LGR5, wherein the antibody comprises a V_L CDR1 sequence selected from SEQ ID NO. 5, 11, 17, 23, 29, 35, 41, 47, 53, 59, 65, 71, 77 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of SEQ ID NO. 5, 11, 17, 23, 29, 35, 41, 47, 53, 59, 65, 71, 77. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0181] In one embodiment, the antibody has a V_L CDR1 sequence comprising or consisting of an amino acid sequence selected from SEQ ID NO. 5, 11, 17, 23, 29, 35, 41, 47, 53, 59, 65, 71, 77 or a sequence having at least at least 90%, or at least 95% homology thereto.

[0182] In one embodiment, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_L CDR2 sequence as shown in Table 1 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. In one aspect, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_L CDR2 sequence selected from SEQ ID NO. 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of SEQ ID NO. 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0183] In one embodiment, the antibody has a V_L CDR2 sequence comprising or consisting of an amino acid sequence selected from SEQ ID NO. 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78 or a sequence having at least at least 90%, or at least 95% homology thereto.

[0184] In one embodiment, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_H CDR3 sequence as shown in Table 1 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. In one aspect, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_H CDR3 sequence selected from SEQ ID NO. 4, 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of SEQ ID NO. 4, 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0185] In one embodiment, the antibody has a V_H CDR3 sequence comprising or consisting of an amino acid sequence selected from SEQ ID NO. 4, 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76 or a sequence having at least at least 90%, or at least 95% homology thereto.

[0186] In one embodiment, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_H CDR1 sequence as shown in Table 1 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. In one aspect, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_H CDR1 sequence selected from SEQ ID NO. 2, 8, 14, 40, 26, 32, 38, 44, 50, 56, 62, 68, 74 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of SEQ ID NO. 2, 8, 14, 40, 26, 32, 38, 44, 50, 56, 62, 68, 74. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0187] In one embodiment, the antibody has a V_H CDR1 sequence comprising or consisting of an amino acid sequence selected from SEQ ID NO. 2, 8, 14, 40, 26, 32, 38, 44, 50, 56, 62, 68, 74 or a sequence having at least at least 90%, or at least 95% homology thereto.

[0188] In one embodiment, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_H CDR2 sequence as shown in Table 1 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. In one aspect, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_H CDR2 sequence selected from SEQ ID NO. 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of SEQ ID NO. 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0189] In one embodiment, the antibody has a V_H CDR2 sequence comprising or consisting of an amino acid sequence selected from SEQ ID NO. 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75 or a sequence having at least at least 90%, or at least 95% homology thereto.

[0190] In one embodiment, the antibody comprises a combination of V_H and V_L CDR1, 2 and 3 sequences selected from the sequences in Table 1. In one aspect, the invention also relates to an antibody which has combinations of V_H and V_L CDR1, CDR2 and CDR3 as shown for the clones in Table 1.

[0191] In one embodiment, the antibody comprises a set of V_H and V_L CDR1, 2 and 3 sequences selected from the sets of CDR1, 2 and 3 sequences as shown for the any of the clones in Table 1. In one embodiment, the antibody comprises V_H CDR1 having SEQ ID No. 2, V_H CDR2 having SEQ ID No. 3, V_H CDR3 having SEQ ID No. 4, V_L CDR1 having SEQ ID No. 5, V_L CDR2 having SEQ ID No. 6 and V_L CDR3 having SEQ ID No. 7. In one embodiment, the antibody comprises V_H CDR1 having SEQ ID No. 8, V_H CDR2 having SEQ ID No. 9, V_H CDR3 having SEQ ID No. 10, V_L CDR1 having SEQ ID No. 11, V_L CDR2 having SEQ ID No. 12 and V_L CDR3 having SEQ ID No. 13. In one

12 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 13 or a sequence with at least 90% homology thereto; or

[0209] c) a CDR1 of SEQ ID No. 17 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 18 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 19 or a sequence with at least 90% homology thereto; or

[0210] d) a CDR1 of SEQ ID No. 23 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 24 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 25 or a sequence with at least 90% homology thereto; or

[0211] e) a CDR1 of SEQ ID No. 29 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 30 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 31 or a sequence with at least 90% homology thereto; or

[0212] f) a CDR1 of SEQ ID No. 35 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 36 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 37 or a sequence with at least 90% homology thereto; or

[0213] g) a CDR1 of SEQ ID No. 41 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 42 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 43 or a sequence with at least 90% homology thereto; or

[0214] h) a CDR1 of SEQ ID No. 47 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 48 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 49 or a sequence with at least 90% homology thereto; or

[0215] i) a CDR1 of SEQ ID No. 53 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 54 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 55 or a sequence with at least 90% homology thereto; or

[0216] j) a CDR1 of SEQ ID No. 59 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 60 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 61 or a sequence with at least 90% homology thereto; or

[0217] k) a CDR1 of SEQ ID No. 65 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 66 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 67 or a sequence with at least 90% homology thereto; or

[0218] l) a CDR1 of SEQ ID No. 71 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 72 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 73 or a sequence with at least 90% homology thereto; or

[0219] m) a CDR1 of SEQ ID No. 77 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 78 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 79 or a sequence with at least 90% homology thereto.

TABLE 1

CDR sequences of antibodies of the invention						
Name	V _H CDR1 sequence	V _H CDR2 sequence	V _H CDR3 sequence	V _L CDR1 sequence	V _L CDR2 sequence	V _L CDR3 sequence
1	SEQ ID NO: 2 SYWMQ	SEQ ID NO: 3 EIDPSDYY TNYNQKFK G	SEQ ID NO: 4 SLSGYVD Y	SEQ ID NO: 5 RASQDIRN RLN	SEQ ID NO: 6 YRSRLQS	SEQ ID NO: 7 QQGNTLPP T
2	SEQ ID NO: 8 NYWMQ	SEQ ID NO: 9 EIDPSDSY TNYNQKFK G	SEQ ID NO: 10 SLSGYVD Y	SEQ ID NO: 11 RASQDISN RLN	SEQ ID NO: 12 YRSRLHS	SEQ ID NO: 13 QQGNSLPP T
3	SEQ ID NO: 14 SYWMQ	SEQ ID NO: 15 EIDPSDSY SNYNQKFK G	SEQ ID NO: 16 SLSGYVD Y	SEQ ID NO: 17 RASQDISN RLN	SEQ ID NO: 18 YRSRLQS	SEQ ID NO: 19 QQGNTLPP T
4	SEQ ID NO: 20 DYWMQ	SEQ ID NO: 21 EIDPSDSY TNYNQKFQ G	SEQ ID NO: 22 SLSGSVD Y	SEQ ID NO: 23 RASQDISN RLN	SEQ ID NO: 24 YRSRLQS	SEQ ID NO: 25 QQGNTLPP T
12	SEQ ID NO: 26 DYYMN	SEQ ID NO: 27 DINPNNGG TIYNQKFK G	SEQ ID NO: 28 GYLFDY	SEQ ID NO: 29 KSSQSLLN SSNQKNY LA	SEQ ID NO: 30 FASTRES	SEQ ID NO: 31 QQHYSTPL T
2.1	SEQ ID NO: 32 NYWMQ	SEQ ID NO: 33 EIDPSDSY TNYNQKFQ G	SEQ ID NO: 34 SLSGYVD Y	SEQ ID NO: 35 RASQDISN RLN	SEQ ID NO: 36 YRSRLHS	SEQ ID NO: 37 QQGNSLPP T

TABLE 1-continued

CDR sequences of antibodies of the invention						
Name	V _H CDR1 sequence	V _H CDR2 sequence	V _H CDR3 sequence	V _L CDR1 sequence	V _L CDR2 sequence	V _L CDR3 sequence
2.2	SEQ ID NO: 38 NYWMQ	SEQ ID NO: 39 EIDPSDSY TNYNQKFQ G	SEQ ID NO: 40 SLSGYVD Y	SEQ ID NO: 41 RASQDISN RLN	SEQ ID NO: 42 YRSRLHS	SEQ ID NO: 43 QQGNSLPP T
2.3	SEQ ID NO: 44 NYWMQ	SEQ ID NO: 45 EIDPSDSY TNYNQKFQ G	SEQ ID NO: 46 SLSGYVD Y	SEQ ID NO: 47 RASQDISN RLN	SEQ ID NO: 48 YRSRLHS	SEQ ID NO: 49 QQGNSLPP T
2.4	SEQ ID NO: 50 NYWMQ	SEQ ID NO: 51 EIDPSDSY TNYNQKFQ G	SEQ ID NO: 52 SLSGYVD Y	SEQ ID NO: 53 RASQDISN RLN	SEQ ID NO: 54 YRSRRHT	SEQ ID NO: 55 QQGNSLPP T
2.9	SEQ ID NO: 56 NYWMQ	SEQ ID NO: 57 EIDPSDSY TNYNQGFT G	SEQ ID NO: 58 SLSGYVD Y	SEQ ID NO: 59 RASQDISN RLN	SEQ ID NO: 60 YRSRLHS	SEQ ID NO: 61 QQGNSLPP T
2.11	SEQ ID NO: 62 NYWMQ	SEQ ID NO: 63 EIDPSDSY TNYNQGFT G	SEQ ID NO: 64 SLSGYVD Y	SEQ ID NO: 65 RASQDISN RLN	SEQ ID NO: 66 YRSRLHS	SEQ ID NO: 67 QQGNSLPP T
2.12	SEQ ID NO: 68 NYWMQ	SEQ ID NO: 69 EIDPSDSY TNYNQGFT G	SEQ ID NO: 70 SLSGYVD Y	SEQ ID NO: 71 RASQDISN RLN	SEQ ID NO: 72 YRSRRHT	SEQ ID NO: 73 QQGNSLPP T
2.16	SEQ ID NO: 74 NYWMN	SEQ ID NO: 75 EIDPSDSY TNYNQGFT G	SEQ ID NO: 76 SLSGYVD Y	SEQ ID NO: 77 RASQDISN RLN	SEQ ID NO: 78 YRSRRHT	SEQ ID NO: 79 QQGNSLPP T

[0220] In Table 1, the clones 1, 2, 3, 4 and 12 are mouse antibodies and clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 are humanized antibodies based on clone 2.

[0221] In embodiments in which the antibodies are humanized antibodies, the antibodies may comprise CDR1, CDR2 and CDR3 sequences as shown in Table 1 for clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 or sequences with at least 90% homology thereto. In one embodiment, the CDR1, CDR2 and CDR3 sequences as shown in Table 1 for clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 but include 1, 2 or 3 amino acid modifications, e.g. a substitution, deletion or insertion.

[0222] In one embodiment, the antibody provided comprise CDR1, CDR2 and CDR3 sequences as shown in Table 1 for Clone 2.4. Clone 2.4 is also referred to herein as α -LGR5v4, α -LGR5 variant 4 or human variant 4, see e.g. Table 5.

[0223] In one embodiment, the invention relates to an antibody or fragment thereof which binds human LGR5, wherein the antibody comprises a V_H sequence selected from those shown in Table 2 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity

thereto. In one aspect, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_H sequence selected from SEQ ID NOS: 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of SEQ ID NOS: 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0224] In one embodiment, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_L sequence selected from those shown in Table 2 below or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence identity thereto. In one aspect, the invention relates to an antibody which binds LGR5, wherein the antibody comprises a V_L sequence selected from SEQ ID Nos. 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more

sequence homology to one of SEQ ID Nos. 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In one embodiment, said sequence homology is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0225] The invention also provides an antibody which binds to LGR5, the antibody comprising the V_H and V_L sequences shown in Table 2. Thus, the invention provides antibodies which bind to LGR5, and comprise:

- [0226] a) a V_H sequence of SEQ ID NO: 80 and a V_L sequence of SEQ ID NO: 81;
- [0227] b) a V_H sequence of SEQ ID NO: 82 and a V_L sequence of SEQ ID NO: 83;
- [0228] c) a V_H sequence of SEQ ID NO: 84 and a V_L sequence of SEQ ID NO: 85;
- [0229] d) a V_H sequence of SEQ ID NO: 86 and a V_L sequence of SEQ ID NO: 87;

[0230] e) a V_H sequence of SEQ ID NO: 88 and a V_L sequence of SEQ ID NO: 89;

[0231] f) a V_H sequence of SEQ ID NO: 90 and a V_L sequence of SEQ ID NO: 91;

[0232] g) a V_H sequence of SEQ ID NO: 92 and a V_L sequence of SEQ ID NO: 93;

[0233] h) a V_H sequence of SEQ ID NO: 94 and a V_L sequence of SEQ ID NO: 95;

[0234] i) a V_H sequence of SEQ ID NO: 96 and a V_L sequence of SEQ ID NO: 97;

[0235] j) a V_H sequence of SEQ ID NO: 98 and a V_L sequence of SEQ ID NO: 99;

[0236] k) a V_H sequence of SEQ ID NO: 100 and a V_L sequence of SEQ ID NO: 101

[0237] l) a V_H sequence of SEQ ID NO: 102 and a V_L sequence of SEQ ID NO: 103; or

[0238] m) a V_H sequence of SEQ ID NO: 104 and a V_L sequence of SEQ ID NO: 105.

[0239] In one embodiment, the antibody comprises comprise V_H and V_L sequences as shown in Table 2 for clone 2.4.

TABLE 2

V _H and V _L sequences of antibodies of the invention		
Name	V _H	V _L
1	SEQ ID NO: 80 QVQLQQPGAEVLVKPGASVKLSCK ASGYTFTSYWMQWVKQRPGQGL EWIGEIDPDSYTNYNQKFKGKAT LTVDTSSSTAYMQLSSLTSEDAV YYCARSLSGYVWDYWGQGTTLTVS S	SEQ ID NO: 81 DIQMTQSTSLSASLGDRVТИCRA SQDIRNRLNWYQQKPDGTVKLLISY RSRLQSGVPSPRFSGSGSGTDYSLTI SNLEQEDIATYFCQQGNTLPPTFG GGTKLEVR
2	SEQ ID NO: 82 QVQLQQPGAEVLVKPGASVKLSCK ASGYTFTSYWMQWVKQRPGQGL EWIGEIDPDSYTNYNQKFKGKAT LTVDTSSSTAYMQLSSLTSEDAV YYCARSLSGYVWDYWGQGTTLTVS S	SEQ ID NO: 83 DIQMTQTSSLSASLGDRVТИCRA SQDISNRLNWYQQKPDGTVKLLISY RSRLHSGVPSPRFSGSGSGTDYSLTI SNLEQEDIATYFCQQGNSLPPTFG GGTKLEVR
3	SEQ ID NO: 84 QVQLQQPGAEVLVKPGASVKLSCK ASGYTFTSYWMQWVKQRPGQGL EWIGEIDPDSYTNYNQKFKGKAT LTVDTSSSTAYMQLSSLTSEDAV YYCARSLSGYVWDYWGQGTTLTVS S	SEQ ID NO: 85 DIQMTQTSSLSASLGDRVТИCRA SQDISNRLNWYQQKPDGTVKLLISY RSRLQSGVPSPRFSGSGSGTDYSLT ISNLNEEDIATYFCQQGNTLPPTFG GGTKLEVR
4	SEQ ID NO: 86 QVQLQQPGAEVLVKPGASVKLSCK ASGYTFTDYWMQWVKQRPGQGL EWIGEIDPDSYTNYNQKFQFGKAT LTVDTSSSTAYIQLSSLTSEDAV YYCARSLSGSVWDYWGQGTTLTVS	SEQ ID NO: 87 DIQMTQTSSLSASLGDRVТИCRA SQDISNRLNWYQQKPDGTVKLLISY RSRLQSGVPSPRFSGSGSGTDYSLT ITNLNEEDIATYFCQQGNTLPPTFG GGTKLEVR
12	SEQ ID NO: 88 EVQLQQSGPELVKPGASVKISCKA SGYTFTDYYMNWVKQSHGKSLEW IGDINPNNGGTIYNQKEFKGKATLTV DKSSSTAYMELRSLTSEDAVYYC ASGYLFDWGPGBTTLTVSS	SEQ ID NO: 89 DIVMTQSPSSLSASVGDRVТИCRA SSQSLNNSSNQKNYLAWYQQKPG QSPKLVVYFASTRESGPDRFIGSG SGTDFTLTISSVQAEDLAAYFCQQH YSTPLTFAGTKLELK
2 . 1	SEQ ID NO: 90 QVQLVQSGAEVKKPGASVKVSCK ASGYTFTSYWMQWVRQAPGQGL EWIGEIDPDSYTNYNQKFQGRVT LTVDTSTSTAYMELSSLRSEDTAV YYCARSLSGYVWDYWGQGTTTVTS S	SEQ ID NO: 91 DIQMTQSPSSLSASVGDRVТИCRA SQDISNRLNWYQQKPDGTVKLLISY RSRLHSGVPSPRFSGSGSGTDYTLTI SSLQPEDFATYFCQQGNSLPPTFG GGTKLEIK

TABLE 2-continued

V _H and V _L sequences of antibodies of the invention		
Name	V _H	V _L
2.2	SEQ ID NO: 92 QVQLVQSGAEVKPGASVKVSCK ASGYTFTNYWMQWVRQAPGQGL EWIGEIDPSDSYTNYNQKFQGRVT LTVDTSTSTAYMELSSLRSEDTV YYCARSLSGYVDYWGQGTTVTVSS	SEQ ID NO: 93 DIQMTQSPSSLASAVGDRVTITCRA SQDISNRLNWYQQKPGKAVKLLISY RSRLHSGVPNSRFSGSGSGTDYTLTI SSLQPEDFATYYCQQGNSLPPTFG GGTKLEIK
2.3	SEQ ID NO: 94 QVQLVQSGAEVKPGASVKVSCK ASGYTFTNYWMQWVRQAPGQGL EWIGEIDPSDSYTNYNQKFQGRVT LTVDTSTSTAYMELSSLRSEDTV YYCARSLSGYVDYWGQGTTVTVSS	SEQ ID NO: 95 DIVMTQSPATLSLSPGERATLSCRA SQDISNRLNWYQQKPGQAVRLLIS YRSRLHSGVPNSRFSGSGSGTDYTL TISSLEPEDFAVYFCQQGNSLPPTFG GGTKLEIK
2.4	SEQ ID NO: 96 QVQLVQSGAEVKPGASVKVSCK ASGYTFTNYWMQWVRQAPGQGL EWIGEIDPSDSYTNYNQKFQGRVT LTVDTSTSTAYMELSSLRSEDTV YYCARSLSGYVDYWGQGTTVTVSS	SEQ ID NO: 97 EIVMTQSPATLSLSPGERATLSCRA SQDISNRLNWYQQKPGQAVRLLIS YRSRRHTGIPARFSGSGSGTDYTL TISSLEPEDFAVYFCQQGNSLPPTFG GGTKLEIK
2.9	SEQ ID NO: 98 QVQLVQSGSELKKPGASVKVSCK ASGYTFTNYWMQWVRQAPGQGL EWIGEIDPSDSYTNYNQGFTGRFV LSVDTSVSTAYLQISSLKAEDTAVY YCARSLSGYVDYWGQGTTVTVSS	SEQ ID NO: 99 DIQMTQSPSSLASAVGDRVTITCRA SQDISNRLNWYQQKPGKAVKLLISY RSRLHSGVPNSRFSGSGSGTDYTLTI SSLQPEDFATYFCQQGNSLPPTFG GGTKLEIK
2.11	SEQ ID NO: 100 QVQLVQSGSELKKPGASVKVSCK ASGYTFTNYWMQWVRQAPGQGL EWIGEIDPSDSYTNYNQGFTGRFV LSVDTSVSTAYLQISSLKAEDTAVY YCARSLSGYVDYWGQGTTVTVSS	SEQ ID NO: 101 DIQMTQSPSSLASAVGDRVTITCRA SQDISNRLNWYQQKPGKAVKLLISY RSRLHSGVPNSRFSGSGSGTDYTLTI SSLQPEDFATYYCQQGNSLPPTFG GGTKLEIK
2.12	SEQ ID NO: 102 QVQLVQSGSELKKPGASVKVSCK ASGYTFTNYWMQWVRQAPGQGL EWIGEIDPSDSYTNYNQGFTGRFV LSVDTSVSTAYLQISSLKAEDTAVY YCARSLSGYVDYWGQGTTVTVSS	SEQ ID NO: 103 DIVMTQSPATLSLSPGERATLSCRA SQDISNRLNWYQQKPGQAVRLLIS YRSRLHSGVPNSRFSGSGSGTDYTL TISSLEPEDFAVYFCQQGNSLPPTFG GGTKLEIK
2.16	SEQ ID NO: 104 QVQLVQSGSELKKPGASVKVSCK ASGYTFTNYWMQWVRQAPGQGL EWIGEIDPSDSYTNYNQGFTGRFV VFSVDTSVSTAYLQISSLKAEDTAVY YCARSLSGYVDYWGQGTTVTVSS	SEQ ID NO: 105 EIVMTQSPATLSLSPGERATLSCRA SQDISNRLNWYQQKPGQAVRLLIS YRSRRHTGIPARFSGSGSGTDYTL TISSLEPEDFAVYFCQQGNSLPPTFG GGTKLEIK

[0240] In Table 2, clones 1, 2, 3, 4 and 12 are murine antibodies and clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 are humanized antibodies.

[0241] In embodiments in which the antibodies are humanized antibodies, the antibodies may comprise V_H and V_L sequences as shown in Table 2 for clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 or sequences with at least 90% homology thereto.

[0242] In one embodiment, the V_H and V_L sequences as shown in Table 2 for clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 but include 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, e.g. a substitution, deletion or insertion.

[0243] The antibody may comprise a CH2 domain. The CH2 domain is preferably located at the N-terminus of the CH3 domain, as in the case in a human IgG molecule. The

CH2 domain of the antibody is preferably the CH2 domain of human IgG1, IgG2, IgG3, or IgG4, more preferably the CH2 domain of human IgG1. The sequences of human IgG domains are known in the art.

[0244] The antibody may comprise an immunoglobulin hinge region, or part thereof, at the N-terminus of the CH2 domain. The immunoglobulin hinge region allows the two CH2-CH3 domain sequences to associate and form a dimer. Preferably, the hinge region, or part thereof, is a human IgG1, IgG2, IgG3 or IgG4 hinge region, or part thereof. More preferably, the hinge region, or part thereof, is an IgG1 hinge region, or part thereof.

[0245] The sequence of the CH3 domain is not particularly limited. Preferably, the CH3 domain is a human immuno-

globulin G domain, such as a human IgG1, IgG2, IgG3, or IgG4 CH3 domain, most preferably a human IgG1 CH3 domain.

[0246] An antibody of the invention may comprise a human IgG1, IgG2, IgG3, or IgG4 constant region. The sequences of human IgG1, IgG2, IgG3, or IgG4 CH3 domains are known in the art. An antibody of the invention may comprise a non-human IgG constant region, e.g., a rabbit IgG 1 constant region.

[0247] In another embodiment, the antibody comprises or consists of a polypeptide sequence as shown for any one of the antibody clones in Table 3 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology thereto. Thus, the antibody comprises or consists of an amino acid sequence selected from the combination of V_H , C_H , V_L and C_L sequences for the clones shown in Table 3 or a sequence with at least 60%, 70%, 80%, 90%, 95% or more sequence homology thereto. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0248] Thus, the invention provides antibodies which bind to LGR5, and comprise:

- [0249] a) a V_H sequence of SEQ ID NO: 106; a C_H sequence of SEQ ID NO:107; a V_L sequence of SEQ ID NO: 108; and a C_L sequence of SEQ ID NO: 109;
- [0250] b) a V_H sequence of SEQ ID NO: 110; a C_H sequence of SEQ ID NO:111; a V_L sequence of SEQ ID NO: 112; and a C_L sequence of SEQ ID NO: 113;

[0251] c) a V_H sequence of SEQ ID NO: 114; a C_H sequence of SEQ ID NO:115; a V_L sequence of SEQ ID NO: 116; and a C_L sequence of SEQ ID NO: 117;

[0252] d) a V_H sequence of SEQ ID NO: 118; a C_H sequence of SEQ ID NO:119; a V_L sequence of SEQ ID NO: 120; and a C_L sequence of SEQ ID NO: 121;

[0253] e) a V_H sequence of SEQ ID NO: 122; a C_H sequence of SEQ ID NO:123; a V_L sequence of SEQ ID NO: 124; and a C_L sequence of SEQ ID NO: 125;

[0254] f) a V_H sequence of SEQ ID NO: 126; a C_H sequence of SEQ ID NO:127; a V_L sequence of SEQ ID NO: 128; and a C_L sequence of SEQ ID NO: 129;

[0255] g) a V_H sequence of SEQ ID NO: 130; a C_H sequence of SEQ ID NO:131; a V_L sequence of SEQ ID NO: 132; and a C_L sequence of SEQ ID NO: 133;

[0256] h) a V_H sequence of SEQ ID NO: 134; a C_H sequence of SEQ ID NO:135; a V_L sequence of SEQ ID NO: 136; and a C_L sequence of SEQ ID NO: 137;

[0257] i) a V_H sequence of SEQ ID NO: 138; a C_H sequence of SEQ ID NO:139; a V_L sequence of SEQ ID NO: 140; and a C_L sequence of SEQ ID NO: 141;

[0258] j) a V_H sequence of SEQ ID NO: 142; a C_H sequence of SEQ ID NO:143; a V_L sequence of SEQ ID NO: 144; and a C_L sequence of SEQ ID NO: 145;

[0259] k) a V_H sequence of SEQ ID NO: 146; a C_H sequence of SEQ ID NO:147; a V_L sequence of SEQ ID NO: 148; and a C_L sequence of SEQ ID NO: 149;

[0260] l) a V_H sequence of SEQ ID NO: 150; a C_H sequence of SEQ ID NO:151; a V_L sequence of SEQ ID NO: 152; and a C_L sequence of SEQ ID NO: 153; or

[0261] m) a V_H sequence of SEQ ID NO: 154; a C_H sequence of SEQ ID NO:155; a V_L sequence of SEQ ID NO: 156; and a C_L sequence of SEQ ID NO: 157.

TABLE 3

Full sequences of antibodies of the invention				
	V_H	C_H	V_L	C_L
1	SEQ ID NO: 106 QVQLQQPGABEL VKPGASVVKLSCK ASGYTFTSYWM QWVKQRPQGQGL EWIGEIDPDSYY TNYNQFKGKA TLTVDTSSSTAY MQLSSLTSEDSA VYYCARSLSGYV DYWGQGTTLTV SS	SEQ ID NO: 107 AKTPPSVYPLAPGSAAQTNMSMV TLGLCLVKGYFPEPVTVTWNNSGL SSGVHTFPAVLQSDLYTLSSSVTV PSSTWPSQTVCNVAHPASSTKV DKKIVPRDCGCKPCICTVPEVSSV FIFPPPKDVLTTILTPKVTCVVVVDI SKDDPEVQFSWFVDDVEVHTAQ KPREEQINSTFRSVEELPPIMHQD WLNKGKEFKCRVNSAAPPAPIEKTI SKTKGRPKAQPVYTIPPPKEQMA KDKVSLTCMITNFEPDITVEWQW NGQPAENYKNTQPMTDGSYFV YSKLNVQKSNWEGANTFTCSVLYH EGLHNHHTEKSLSHSPKG	SEQ ID NO: 108 DIQMTQSTSSL SASLGDRVTIN CRASQDIRNRL NWYQQKPDPGT VKLLISYRSRL QSGVPSRFG SGSGTEYSLTI SNLEQEDIATY FCQQGNTLPP TFGGGTKLEV R	SEQ ID NO: 109 RADAAPTVSIF PPSSEQLTSG GASVVCFLNNF YPKDINVWKWI DGSERQNGVL NSWTDDQDSKD STYSMSSTLTL TKDEYERHNS YTCEATHKTST SPIVKSFNRNE C
2	SEQ ID NO: 110 QVQLQQPGABEL VKPGASVVKLSCK ASGYTFTSYWM QWVKQRPQGQGL EWIGEIDPDSY TNYNQFKGKA TLTVDTSSSTAY MQLSSLTSEDSA VYYCARSLSGYV DYWGQGTTLTV SS	SEQ ID NO: 111 AKTPPSVYPLAPGCGDGTGSSV TLGLCLVKGYFPESTVTVTWNNSGL SSSVHTFPALLQSGLYTMSSSVTV PSSTWPSQTVCNVAHPASSTTV DKKLEPSGPISTINCPCKECKH CPAPNLEGGPSVFIFPPNIKDVLMI SLTPKVTCVVVDSEDDPDVRIS WFVNNEVHTAQQTTHREDYNS TIRVVSALPIQHQDWMSGKEFKC KVNNDLPLSPIERTLSIKGLVRAP QVYILPPPAAEQLSRKDVLSTCLVV GFNPQDIDSWEVTSNGHTEENYKD TAPVLDSDGSYFIYSKLDIKTSKW EKTDSFSCNVRHEGLKNYYLKKTI SRSPKG	SEQ ID NO: 112 DIQMTQTTSSL SASLGDRVTIS CRASQDISNRL NWYQQKPDPGT VKLLISYRSRL HSGVPSRFG SGSGTDYSLTI SNLEQEDIATY FCQQGNSLPP TFGGGTKLEV R	SEQ ID NO: 113 RADAAPTVSIF PPSSEQLTSG GASVVCFLNNF YPKDINVWKWI DGSERQNGVL NSWTDDQDSKD STYSMSSTLTL TKDEYERHNS YTCEATHKTST SPIVKSFNRNE C

TABLE 3 -continued

Full sequences of antibodies of the invention				
	V _H	C _H	V _L	C _L
3	SEQ ID NO: 114 QVQLQOPGAE VKPGASVKLSCK ASGYFTTSYWM QWVKQRPGQGL EWIGEIDPBSDY SNYNQFKFGKA TLTVDTSSSTAY MQLSLTSEDSA VYYCARSLSGVY DYWGQGTTLV SS	SEQ ID NO: 115 AKTTPPSVYPLAPGSAAQTNSMV TLGCLVKGYFPEPVTVWNNSGL SSGVHTFPAVLQSDLTYLTSSSVTV PSSTWPSQTVTCAVNPASSSTKV DKKIVPRDCGKPCITCVPVEVV F1FPPPKPDVLTIITLPKVTCVV SKDDPEVWQSFWFVDDDVHQA KPREEQINSTFRVSELPMHQD WLNKEFKCRVNSAAPPAPIEKTI SKTKGRPKAPQVYTIPPKKEQMA KDKVSLTCMITNFPPEDITVEWQW NGQPAENYKNTQPIMDTDGSYFV YSKLNQKSNWEAGNIFTCSVLVH EGLHNHHTEKSLSHSPGK	SEQ ID NO: 116 DIQMTQTTSSL SASLGDRVTIS CRASQDISNRL NWYQQKPDGT VKLLISYRSRL QSGVPSRFSG SGSGTDYSLTI SNLEEEDIATY FCQQGNTLPP TFGGGTKEV R	SEQ ID NO: 117 RADAAPTVSIF PPSSEQLTSG GASVVCFLNNF YPKDINWKWI DGSERQNGVL NSWTDQDSKD STYSMSSTLTL TKDEYERHNS YTCEATHKTST SPIVKSFNRNE C
4	SEQ ID NO: 118 QVQLQOPGAE VKPGASVKLSCK ASGYFTTDYWM QWVKQRPGQGL EWIGEIDPBSDY TNYNQFKFGKA TLTVDTSSSTAYI QLSSLTSDSAV YYCARSLSGVY DYWGQGTTLV SS	SEQ ID NO: 119 AKTTPPSVYPLAPCGCDTTGSSV TLGCLVKGYFPEPVTVWNNSGL SSSVHTFPALLQSGLYTMSSSVTV PSSTWPSQTVTCAVNPASSSTTV DKKLEPGPSVISTINCPCKECHK CPAPNLEGGPSVFIFPPNIKDVLMI SLTPKVTCVVVDVSEDDPDVRIS WFVNNEVHTAQQTQTHREDYNS TIRVVSALPIQHODWMSGKEFKC KVNNKDLPLSPIERTISKIGLVRAP QVYILPPPAAEQLSRKDVSLLCLVV GFNPQDI SVEWTSNGHTEENYKD TAPVLDSDGSYFIYSKLDIKTSKW EKTDSFSCNVRHEGLKNYYLKKTI SRSPGK	SEQ ID NO: 120 DIQMTQTTSSL SASLGDRVTIS CRASQDISNRL NWYQQKPDGT VKLLISYRSRL QSGVPSRFSG SGSGTDYSLTI TNLEEEDIATY FCQQGNTLPP TFGGGTKEV R	SEQ ID NO: 121 RADAAPTVSIF PPSSEQLTSG GASVVCFLNNF YPKDINWKWI DGSERQNGVL NSWTDQDSKD STYSMSSTLTL TKDEYERHNS YTCEATHKTST SPIVKSFNRNE C
12	SEQ ID NO: 122 EVQLQSGPDEL VKPGASVKISCK ASGYFTTDYWM NWVKQSHGKSL EWIGEIDPNNGG TIYNQFKFGKAT LTVKSSSTAAYM ELRSLTSEDSA YYCASGYLFDY WGPGBTTLTVSS	SEQ ID NO: 123 AKTTAPSVPYPLAPCGGGTTGSSV TLGCLVKGYFPEPVTVWNNSGL SSGVHTFPALLQSGLYTMSSSVTV TSNTWPSQITCNCVNPASSSTKV DKKIEPRVPITQNPCCPPLKECPP AAPDLLGGPSVFIFPPKIKDVLMS LSPMVTCVVVDVSEDDPDVQ1SW FVNNNEVHTAQQTQTHREDYNS RVVSALPIQHODWMSGKEFKC NNRALPSPIEKTISKPRGPVRAPQ VYVLPPAAEMTKKEFSLTCMITG FLPAEIADVWTSNGRTEQNYKNT ATVLDSDGSYFMYSKLRVQKSTW ERGSLFACSVVHEGLHNHLLTTKI SRSLKG	SEQ ID NO: 124 DIVMTQSPSSL AMSVGQKVMT SCKSSQSSLNS SNQKNYLAWY QQKPGQSPKL LVYFASTRESG VPDRFIGGSSG TDFTLTISSVQ AEDLAAYFCQ QHYSTPLTFGA GKLELK	SEQ ID NO: 125 RADAAPTVSIF PPSSEQLTSG GASVVCFLNNF YPKDINWKWI DGSERQNGVL NSWTDQDSKD STYSMSSTLTL TKDEYERHNS YTCEATHKTST SPIVKSFNRNE C
2.1	SEQ ID NO: 126 QVQLVQSGAEV KKPGASVKVSC KASGYFTFTNYW MQWRQAPGQ GLEWIGEIDPBSD SYTNYQKFGQ RVTLTVDTST AYMELSSLRSED TAVYYCARSLSG YVDYWGQGTTV TVSS	SEQ ID NO: 127 ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWNNSGAL TSGVHTFPAVLQSGLYLSSSVTV VPSSSLGTQTYICCNVNHKPSNTKV DKKVEPKSCDKTHTCPCPAP LGGPSVFLFPKPKDPTLMISRPE VTCVVVDVSHEDPEVKFNWYD GVEVHNAKTKPREEQYNTYRV SVLTVLHQDWLNGKEYKCKVSN ALPAPIEKTIISKAKGQPREPV LPPSRDELTKNQVSLTCLVKGFY SDIAVEWESNGQPENNYKTT LDSDGSFLYSLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSL SPGK	SEQ ID NO: 128 DIQMTQSPSSL SASVGDRVTIT CRASQDISNRL NWYQQKPGKA VKLLISYRSRL HSGVPSRFSG SGSGTDYSLTI SSLQPEDFATY FCQQGNLPP TFGGGTKEIK	SEQ ID NO: 129 RTVAAPSVFIF PPSDEQLKSG TASVVCLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSLT LSKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
2.2	SEQ ID NO: 130 QVQLVQSGAEV KKPGASVKVSC KASGYFTFTNYW MQWRQAPGQ	SEQ ID NO: 131 ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWNNSGAL TSGVHTFPAVLQSGLYLSSSVTV VPSSSLGTQTYICCNVNHKPSNTKV	SEQ ID NO: 132 DIQMTQSPSSL SASVGDRVTIT CRASQDISNRL NWYQQKPGKA	SEQ ID NO: 133 RTVAAPSVFIF PPSDEQLKSG TASVVCLNNF YPREAKVQWK

TABLE 3 -continued

Full sequences of antibodies of the invention					
	V _H	C _H	V _L	C _L	
	GLEWIGEIDPSD SYTNYNQKFGQ RVTLTVDTSTST AYMELSSLRSED TAVYYCARSLSG YVDYWGQGTTV TVSS	DKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTIKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYP	VKLЛИSYRSRL HSGVPSRFSG SGSGTDYTLTI SSLQPEDFATY YCQQGNSLPP TFGGGTKEIK SDIAVEWESNGQPENNYKTPPV LDSDGSFFLYSKLTVDKSRWQOG NVFSCSVMHEALHNHYTQKSLSL SPGK	VDNALQSGNS QESVTEQDSK DSTYSLSSTLT LSKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC	
2.3	SEQ ID NO: 134	SEQ ID NO: 135 QVQLVQSGAEV KKPGASVKVSC KASGYTFTNYW MQWRQAPGQ GLEWIGEIDPSD SYTNYNQKFGQ RVTLTVDTSTST AYMELSSLRSED TAVYYCARSLSG YVDYWGQGTTV TVSS	ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWSN GAL TSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHPKSNTKV DKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTIKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYP	SEQ ID NO: 136 DIVMTQSPATL SLSPGERATLS CRASQDISNRL NWYQQKPGQ AVRLLISYRSR LHSGVPARFS GSGSGTDYTL TISSLEPEDFA VYPCQQGNSL PPTFGGGTKE IK	SEQ ID NO: 137 RTVAAPS VIF PPSDEQLKSG TASVVCLLNINF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTLT LSKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
2.4	SEQ ID NO: 138	SEQ ID NO: 139 QVQLVQSGAEV KKPGASVKVSC KASGYTFTNYW MQWRQAPGQ GLEWIGEIDPSD SYTNYNQKFGQ RVTLTVDTSTST AYMELSSLRSED TAVYYCARSLSG YVDYWGQGTTV TVSS	ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWSN GAL TSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHPKSNTKV DKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTIKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYP	SEQ ID NO: 140 EIVMTQSPATL SLSPGERATLS CRASQDISNRL NWYQQKPGQ AVRLLISYRSR RHTGIPARFS SGSGTDYTL SSLEPEDF VYPCQQGNSL TFGGGTKEIK	SEQ ID NO: 141 RTVAAPS VIF PPSDEQLKSG TASVVCLLNINF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTLT LSKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
2.9	SEQ ID NO: 142	SEQ ID NO: 143 QVQLVQSGSEL KKPGASVKVSC KASGYTFTNYW MQWRQAPGQ GLEWIGEIDPSD SYTNYNQGFTG RFVLSDVTSVST AYLISSLKAED TAVYYCARSLSG YVDYWGQGTTV TVSS	ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWSN GAL TSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHPKSNTKV DKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTIKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYP	SEQ ID NO: 144 DIQMTQSPSSL SASVGDRVTIT CRASQDISNRL HSGVPSRFSG SGSGTDYTL SSLQPEDF VYFCQQGNSL TFGGGTKEIK	SEQ ID NO: 145 RTVAAPS VIF PPSDEQLKSG TASVVCLLNINF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTLT LSKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
2.11	SEQ ID NO: 146	SEQ ID NO: 147 QVQLVQSGSEL KKPGASVKVSC KASGYTFTNYW MQWRQAPGQ GLEWIGEIDPSD SYTNYNQGFTG RFVLSDVTSVST AYLISSLKAED TAVYYCARSLSG SVLTVLHQDWLNGKEYKCKVSNK	ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWSN GAL TSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHPKSNTKV DKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNK	SEQ ID NO: 148 DIVMTQSPATL SLSPGERATLS CRASQDISNRL AVRLLISYRSR LHSGVPARFS GSGSGTDYTL TISSLEPEDFA VYFCQQGNSL	SEQ ID NO: 149 RTVAAPS VIF PPSDEQLKSG TASVVCLLNINF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTLT LSKADYEKHKV YACEVTHQGL

TABLE 3 -continued

Full sequences of antibodies of the invention					
	V _H	C _H	V _L	C _L	
	YVDYWGQGTTV TVSS	ALPAPIEKTIKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTPPV LDSDGSFLYSKLTVDKSRWQOG NVFSCSVMHEALHNHYTQKSLSL SPGK	PPTFGGGTKLE IK	SSPVTKSFNR GEC	
2.12	SEQ ID NO: 150	SEQ ID NO: 151 QVQLVQSGSEL KKPGASVKVSC KASGYTFNTYW MNWVRQAPGQ GLEWIGEIDPSD SYTNYNQGFTG RFVLVDTSVST AYLQISSLKAED TAVYYCARSLSG YVDYWGQGTTV TVSS	ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWSNSGAL TSGVHTPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPFPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTIKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTPPV LDSDGSFLYSKLTVDKSRWQOG NVFSCSVMHEALHNHYTQKSLSL SPGK	SEQ ID NO: 152 EIVMTQSPATL SLSPGERATLS CRASQDINSRNL NWYQQKPGQ AVRLLISYRSR RHTGIPARFSG SGSGTDYTLTI SSLEPEDFAVY YCQQGNSLPP TFGGGTKLEIK	SEQ ID NO: 153 RTVAAPS VFIF PPSDEQLKSG TASVVCLLNINF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSLT LSKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
2.16	SEQ ID NO: 154	SEQ ID NO: 155 QVQLVQSGSEL KKPGASVKVSC KASGYTFNTYW MNWVRQAPGQ GLEWIGEIDPS DSYTNYNQGFT GRFVFSVDTSVS TAYLQISSLKAED DTAVYYCARSLSG GYVDYWGQGTT TVSS	ASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVWSNSGAL TSGVHTPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPFPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTIKAKGQPREPQVYT LPPSRDELTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTPPV LDSDGSFLYSKLTVDKSRWQOG NVFSCSVMHEALHNHYTQKSLSL SPGK	SEQ ID NO: 156 EIVMTQSPATL SLSPGERATLS CRASQDINSRNL NWYQQKPGQ AVRLLISYRSR RHTGIPARFSG SGSGTDYTLTI SSLEPEDFAVY YCQQGNSLPP TFGGGTKLEIK	SEQ ID NO: 157 RTVAAPS VFIF PPSDEQLKSG TASVVCLLNINF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSLT LSKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC

[0262] In Table 3, clones 1, 2, 3, 4 and 12 are murine antibodies and clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 are humanized antibodies.

[0263] In embodiments in which the antibodies are humanized antibodies, the antibodies may comprise sequences as shown in Table 3 for clones 2.1, 2.2, 2.3, 2.4, 2.9, 2.11, 2.12 and 2.16 or a sequence with at least 90% homology thereto.

[0264] In some embodiments, the invention provides an antibody that is a variant of any of the above antibodies or fragments having one or more amino acid modifications, e.g. substitutions, deletions, additions, insertions or other modifications, and which retains a biological function of the antibody. Thus, variant antibodies can be sequence engineered. Modifications include at least one substitution, deletion or insertion of one or more codons encoding the antibody or polypeptide that results in a change in the amino acid sequence as compared with the native antibody or polypeptide. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having

similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence. A variant of an antibody described herein has at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology to the non-variant molecule, preferably at least 95%, 96%, 97%, 98% or 99% sequence homology.

[0265] In one embodiment, the modification is a conservative sequence modification. As used herein, the term "conservative sequence modifications" is intended to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications

include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the CDR regions of an antibody of the invention can be replaced with other amino acid residues from the same side chain family and the altered antibody can be tested for retained function (i.e., the functions set forth in (c) through (I) above) using the functional assays described herein.

[0266] In some embodiments, the invention provides an antibody that is a variant of an antibody selected from those shown in Table 3 that comprises one or more sequence modifications and has improvements in one or more of a property such as binding affinity, specificity, thermostability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility as compared to the unmodified antibody. Sequence modifications may reside in the CDR1, CDR2 and/or CDR3 or in one or more of the framework regions.

[0267] An antibody of the invention may comprise a human IgG Fc with effector function.

[0268] Fc receptors (FcRs) are key immune regulatory receptors connecting the antibody mediated (humoral) immune response to cellular effector functions. Receptors for all classes of immunoglobulins have been identified, including FcyR (IgG), FcsRI (IgE), FcaRI (IgA), FcpR (IgM) and FcbR (IgD). There are three classes of receptors for human IgG found on leukocytes: CD64 (FcyRI), CD32 (FcyRIIa, FcyRIIb and FcyRIIc) and CD16 (FcyRIIa and FcyRIIb). FcyRI is classed as a high affinity receptor (nanomolar range Kd) while FcyRII and FcyRIII are low to intermediate affinity (micromolar range Kd).

[0269] In antibody dependent cellular cytotoxicity (ADCC), FcvRs on the surface of effector cells (natural killer cells, macrophages, monocytes and eosinophils) bind to the F c region of an IgG which itself is bound to a target cell. Upon binding a signalling pathway is triggered which results in the secretion of various substances, such as lytic enzymes, perforin, granzymes and tumour necrosis factor, which mediate in the destruction of the target cell. The level of ADCC effector function varies for IgG subtypes. Although this is dependent on the allotype and specific FcvR in simple terms ADCC effector function is high for human IgG1 and IgG3, and low for IgG2 and IgG4. See below for IgG subtype variation in effector functions, ranked in decreasing potency.

[0270] FcyRs bind to IgG asymmetrically across the hinge and upper CH2 region. Knowledge of the binding site has resulted in engineering efforts to modulate IgG effector

functions Antibodies of the invention may have an Fc with effector function, with enhanced effector function or with reduced effector function.

[0271] The potency of antibodies can be increased by enhancement of the ability to mediate cellular cytotoxicity functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADC P). A number of mutations within the F c domain have been identified that either directly or indirectly enhance binding of Fc receptors and significantly enhance cellular cytotoxicity: the mutations S239D/A330L/I332E ("3M"), F243L or G236A. Alternatively enhancement of effector function can be achieved by modifying the glycosylation of the Fc domain, FcyRs interact with the carbohydrates on the CH2 domain and the glycan composition has a substantial effect on effector function activity. Afucosylated (non-fucosylated) antibodies, exhibit greatly enhanced ADCC activity through increased binding to FcyRIIa.

[0272] Activation of ADCC and CDC may be desirable for some therapeutic antibodies, however, in some embodiments, an antibody that does not activate effector functions is preferred. Due to their lack of effector functions, IgG4 antibodies are the preferred IgG subclass for receptor blocking without cell depletion. However, IgG4 molecules can exchange half molecules in a dynamic process termed Fab-arm exchange. This phenomenon can occur between therapeutic antibodies and endogenous IgG4. The S228P mutation has been shown to prevent this recombination process allowing the design of IgG4 antibodies with a reduced propensity for Fab-arm exchange. Fc engineering approaches have been used to determine the key interaction sites for the IgG1 Fc domain with Fey receptors and C1 q and then mutate these positions to reduce or abolish binding. Through alanine scanning the binding site of C1 q to a region covering the hinge and upper CH2 of the F c domain was identified. The CH2 domain of an antibody or fragment of the invention may comprise one or more mutations to decrease or abrogate binding of the CH2 domain to one or more Fey receptors, such as FcyRI, FcyRIIa, FcyRIIb, FcyRIII and/or to complement. CH2 domains of human IgG domains normally bind to Fey receptors and complement, decreased binding to Fey receptors is expected to decrease antibody-dependent cell-mediated cytotoxicity (ADCC) and decreased binding to complement is expected to decrease the complement-dependent cytotoxicity (CDC) activity of the antibody molecule. Mutations to decrease or abrogate binding of the CH2 domain to one or more Fey receptors and/or complement are known in the art. An antibody molecule of the invention may comprise an Fc with modifications K322A/L234A/L235A or L234F/L235E/P331S ("TM"), which almost completely abolish FcyR and C1q binding. An antibody molecule of the invention may comprise a CH2 domain, wherein the CH2 domain comprises alanine residues at EU positions 234 and 235 (positions 1.3 and 1.2 by IMGT numbering) ("LALA mutation"). Furthermore, complement activation and ADCC can be decreased by mutation of Pro329 (position according to EU numbering), e.g., to either P 329A or P 329G. The antibody molecule of the invention may comprise a CH2 domain, wherein the CH2 domain comprises alanine residues at EU positions 234 and 235 (positions 1.3 and 1.2 by IMGT numbering) and an alanine (LALA-PA) or glycine (LALA-PG) at EU position 329 (position 114 by IMGT numbering). Additionally or

alternatively an antibody molecule of the invention may comprise an alanine, glutamine or glycine at EU position 297 (position 84.4 by IMGT numbering).

[0273] Modification of glycosylation on asparagine 297 of the Fc domain, which is known to be required for optimal FcR interaction may confer a loss of binding to FcRs; a loss of binding to FcRs has been observed in N297 point mutations. An antibody molecule of the invention may comprise an Fc with an N297A, N297G or N297Q mutation. An antibody molecule of the invention with an aglycosyl Fc domain may be obtained by enzymatic deglycosylation, by recombinant expression in the presence of a glycosylation inhibitor, or following the expression of Fc domains in bacteria.

[0274] IgG naturally persists for a prolonged period in the serum due to FcRn-mediated recycling, giving it a typical half-life of approximately 21 days. Half-life can be extended by engineering the pH-dependent interaction of the Fc domain with FcRn to increase affinity at pH 6.0 while retaining minimal binding at pH 7.4. The T250Q/M428L variant, conferred an approximately 2-fold increase in IgG half-life (assessed in rhesus monkeys), while the M252Y/S254T/T256E variant (“YTE”), gave an approximately 4-fold increase in IgG half-life (assessed in cynomolgus monkeys). Extending half-life may allow the possibility of decreasing administration frequency, while maintaining or improving efficacy.

[0275] The antibodies of the invention preferably have Kd value of less than around 4 nM, less than around 3 nM, less than around 3 nM, less than around 2 nM, less than around 1 nM, as shown in the examples.

[0276] The term “Kd” refers to the “equilibrium dissociation constant” and refers to the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate constant (Koff) by the association rate constant (Kon). “Ka” refers to the affinity constant. The association rate constant, the dissociation rate constant and the equilibrium dissociation constant are used to represent the binding affinity of an antibody to an antigen. Methods for determining association and dissociation rate constants are well known in the art. Using fluorescence-based techniques offers high sensitivity and the ability to examine samples in physiological buffers at equilibrium. Other experimental approaches and instruments such as a BIACore® (biomolecular interaction analysis) assay can be used.

[0277] In embodiments, the antibody according to the invention has a Kd value in the nanomolar range.

[0278] The invention provides an antigen-binding protein, such as an antibody or antigen binding fragment thereof, capable of competing with an antibody of the invention described herein (e.g., comprising a set of HCDR and LCDRs, defined by Kabat nomenclature, and/or VH and VL amino acid sequence of any one of clones in Tables 1 to 3) for binding to an epitope within an isolated peptide comprising or consisting of residues 22-37 (SEQ ID NO: 1).

[0279] Competition assays include cell-based and cell-free binding assays including an immunoassay such as ELISA, HTRF; flow cytometry; fluorescent microvolume assay technology (FMAT) assay, Mirrorball, high content imaging based fluorescent immunoassays, radioligand binding assays, bio-layer interferometry (BLI), surface plasmon resonance (SPR) and thermal shift assays.

[0280] An antibody that binds to the same epitope as, or an epitope overlapping with, a reference antibody refers to an

antibody that blocks binding of the reference antibody to its binding partner (e.g., an antigen or “target”) in a competition assay by 50% or more, and/or conversely, the reference antibody blocks binding of the antibody to its binding partner in a competition assay by 50% or more. Such antibodies are said to compete for binding to an epitope of interest.

[0281] The present invention further provides an isolated nucleic acid encoding an antibody of the present invention. Nucleic acid may include DNA and/or RNA.

[0282] In one aspect, the invention thus also relates to nucleic acid sequences comprising or consisting of a sequence selected from the combination of V_H, C_H, V_L and C_L sequences for the clones shown in Table 4. The nucleic acid sequences in Table 4 encode the antibodies shown in Table 3.

[0283] Thus, the invention provides antibodies or fragments thereof which bind to LGR5, and comprise the following nucleic acid sequences:

[0284] a) a V_H sequence of SEQ ID NO: 158; a C_H sequence of SEQ ID NO:159; a V_L sequence of SEQ ID NO: 160; and a C_L sequence of SEQ ID NO: 161;

[0285] b) a V_H sequence of SEQ ID NO: 162; a C_H sequence of SEQ ID NO:163; a V_L sequence of SEQ ID NO: 164; and a C_L sequence of SEQ ID NO: 165;

[0286] c) a V_H sequence of SEQ ID NO: 166; a C_H sequence of SEQ ID NO:167; a V_L sequence of SEQ ID NO: 168; and a C_L sequence of SEQ ID NO: 169;

[0287] d) a V_H sequence of SEQ ID NO: 170; a C_H sequence of SEQ ID NO:171; a V_L sequence of SEQ ID NO: 172; and a C_L sequence of SEQ ID NO: 173;

[0288] e) a V_H sequence of SEQ ID NO: 174; a C_H sequence of SEQ ID NO:175; a V_L sequence of SEQ ID NO: 176; and a C_L sequence of SEQ ID NO: 177;

[0289] f) a V_H sequence of SEQ ID NO: 178; a C_H sequence of SEQ ID NO:179; a V_L sequence of SEQ ID NO: 180; and a C_L sequence of SEQ ID NO: 181;

[0290] g) a V_H sequence of SEQ ID NO: 182; a C_H sequence of SEQ ID NO:183; a V_L sequence of SEQ ID NO: 184; and a C_L sequence of SEQ ID NO: 185;

[0291] h) a V_H sequence of SEQ ID NO: 186; a C_H sequence of SEQ ID NO:187; a V_L sequence of SEQ ID NO: 188; and a C_L sequence of SEQ ID NO: 189;

[0292] i) a V_H sequence of SEQ ID NO: 190; a C_H sequence of SEQ ID NO:191; a V_L sequence of SEQ ID NO: 192; and a C_L sequence of SEQ ID NO: 193;

[0293] j) a V_H sequence of SEQ ID NO: 194; a C_H sequence of SEQ ID NO:195; a V_L sequence of SEQ ID NO: 196; and a C_L sequence of SEQ ID NO: 197;

[0294] k) a V_H sequence of SEQ ID NO: 198; a C_H sequence of SEQ ID NO:199; a V_L sequence of SEQ ID NO: 200; and a C_L sequence of SEQ ID NO: 201;

[0295] l) a V_H sequence of SEQ ID NO: 202; a C_H sequence of SEQ ID NO:203; a V_L sequence of SEQ ID NO: 204; and a C_L sequence of SEQ ID NO: 205; or

[0296] m) a V_H sequence of SEQ ID NO: 206; a C_H sequence of SEQ ID NO:207; a V_L sequence of SEQ ID NO: 208; and a C_L sequence of SEQ ID NO: 209.

[0297] In one embodiment, the nucleic acid is SEQ ID NO. 218.

TABLE 4

Nucleic acid sequences encoding antibodies of the invention as shown in Table 3

	V _H	C _H	V _L	C _L
1	SEQ ID NO: 158	SEQ ID NO: 159	SEQ ID NO: 160	SEQ ID NO:
	CAGGTCAAC	GCCAAACAGACACCCCATCTGTC	GATATCCAGA	160
	TGCAGCAGCC	TATCCACTGGCCCTGGATCTGCT	TGACACAGAG	CGGGCTGAT
	TGGGCTGAG	GCCAAACTAACCTCATGGTACC	TACATCCTCC	GCTGCACCA
	CTTGTGAAGC	CTGGATGCTGGTAACGGCTAT	CTGTCGCCCT	ACTGTATCC
	CTGGGCTTC	TTCCCCTGAGGACAGTGACC	CTCTGGGAGA	ATCTTCCA
	AGTGAACATG	TGAAACTCTGGATCCCTGTCAGC	CAGACTCAC	CCATCCAGT
	TCCTGCAAGG	GGTGTGCACACCTCCAGCTGTC	ATCAATTGCA	GAGCAGTTA
	CTTCTGGCTA	CTGCAAGTCTGACATCTCTGA	GGGAAAGTCA	ACATCTGGA
	CACCTTCACC	GCAGCTCAGTGACTGCCCCCT	GGACATTAGA	GGTGCCCTCA
	AGCTACTGGA	GCACCTGGCCCAGCCAGCGTCA	AATCGTTAAA	GTCTGTGTC
	TGCACTGGGT	CTCTGCAACGTTGCCACCGGCCA	CTGGTATCAG	TTCTTGAAACA
	AAAACAGAGG	GCAGCACCAAGGGTGGAAAGAAA	CAGAACCCAG	ACTTCTACC
	CCTGGACAGG	TTGTGGCCAGGATTGGGTTGTA	ATGGAACTGT	CCAAAGACA
	GCCCTGAGTG	GCCTTGATATGTCAGTCCAGAA	TAAACTCTG	TCAATGTCA
	GATCGGAGAG	GTATCATCTGTCCTCATCTCCCC	ATCAGCTACA	AGTGGAAAGA
	ATTGATCCTTC	CAAAGGCCAAGGATGTGTCACCA	GATAAAGATT	TTGATGGCA
	TGATTAACATA	TTACTCTGACTCTAACGGTACGTG	ACAGTCAGGA	GTGAACGAC
	CTAACTACAA	TGTTGTGGTAGACATCAGCAAGGAT	GTCCCATCAA	AAAATGGCG
	CAAAAGTTCA	GATCCCAGGTCAGTCAGCTGG	GGTTCAGTGG	TCCTGAACA
	AGGGCAAGGC	TTTGTAGATGATGTGGAGGTGACA	CAGTGGGTCT	GTTGGACTG
	CACATTGACT	CAGCTCAGGAAACCCGGGAGG	GGCACAGAGT	ATCAGGACA
	GTAGACACAT	AGCAGATCACACCACTTCCGTT	ATTCTCTCACC	GCAAAGACA
	CCTCCAGCAC	AGTCAGTGAACTTCCATCATGCAC	ATTAGCAACC	GCACCTACA
	AGCCTCATG	CAGGACTGGCTCAATGGCAAGGAG	TGGAGCAAGA	GCATGAGCA
	CAGCTCAGCA	TTCAATATGGCTAACAGTCAGTCA	AGACATTGCC	GCACCTCTCA
	GCCCTGACATC	GCTTCCCTGCCCCATCGAGAAA	ACTTATTTTG	CGTTGACCA
	TGAGGACTCT	ACCATCTCCAAAACCAAGGAGA	CCAACAGGGC	AGGACGAGT
	GCGGTCTATT	CCGAAGGCTCCACAGGTACACC	AATACGCTTC	ATGAACGAC
	ACTGTGCAAG	ATTCACCTCCAAAGGAGCAGATG	CTCCCCAGTT	ATAACAGCT
	ATCCCTCTCA	GCCAAGGATAAAAGTCAGTCTGACC	CGGAGGGGG	ATACCTGTG
	GGCTACGTT	TGCTGATAACAAACTCTTCCCTG	GACAAAGCTG	AGGCCACTC
	ACTACTGGGG	AAGACATTACTGTGGAGTGGCAGT	GAAGTGAGA	ACAAGACAT
	CCAAGGCACC	GGAAUTGGGACGCCAGGGAGAACT		CAACTTCAC
	ACTCTCACAG	ACAAGAACACTCAGCCCCATCGG		CCATTGTC
	TCTCCCTCA	ACACAGATGGCTTACTTCGTC		AGACGTTCA
		CAGCAAGCTCAATGTGCAAGAG		ACAGGAATG
		CAACTGGGAGGAGGAAATACTTT		AGTGT
		CACTTGCTCTGTTACATGAGGG		
		CCTGCAACACCAACCATACTGAGAA		
		GAGCCTCTCCACTCTCTGGTAAA		
2	SEQ ID NO: 162	SEQ ID NO: 163	SEQ ID NO: 164	SEQ ID NO:
	CAAGTCAAC	GCCAAACAAACACCCCATCAGTCT	GATATCCAGA	165
	TGCAGCAGCC	ATCCACTGGCCCTGGGTGTGGAG	TGACACAGAC	CGGGCTGAT
	TGGGCTGAG	ATACAACTGGTCTCTGTGACTCT	TACATCCTCC	GCTGCACCA
	CTTGTGAAGC	GGGATGCGCTGGTAACGGCTACTT	CTGTCGCCCT	ACTGTATCC
	CTGGGCTTC	CCCTGAGTCAGTGACTGTGACTTG	CTCTGGGAGA	ATCTTCCA
	AGTGAAGCTG	GAACCTGGATCCCTGTCAGCAG	CAGACTCAC	CCATCCAGT
	TCCGTCAAGG	TGTCACACCTCCAGCTCTCTG	ATCAGTGCA	GAGCAGTTA
	CTTCTGGCTA	CAGTCAGGACTCTACACTATGAGCA	GGGAAAGTCA	ACATCTGGA
	CACCTTCACC	GCTCAAGTGACTGCCCCCTCCAGCA	GGACATTAGC	GGTGCCCTCA
	AAACTACTGGA	CCTGGCCAAGTCAGACCGTCACCT	AATCGTTAAA	GTCTGTGTC
	TGCACTGGGT	GCAGCGTTGCTCACCACCGCAGCA	CTGGTATCAG	TTCTTGAAACA
	AAAACAGAGG	GCACACGGTGGACAAAAACTTG	CAGAACACAG	ACTTCTACC
	CCTGGACAGG	AGCCCAGGGGCCATTCAACAA	ATGGAACCTG	CCAAAGACA
	GCCCTGAGTG	TCAACCCCTGTCCTCATGCAAGG	TAAACTCTG	TCAATGTCA
	GATCGGAGAG	AGTGTCAAAATGCCAGCTCTAA	ATCAGCTACA	AGTGGAAAGA
	ATTGATCCTTC	CCTCGAGGGTGACCATCGCTT	GATCAAGATT	TTGATGGCA
	TGATAGTTATA	CATCTCCCTCAAATATCAAGGAT	ACACTCAGGA	GTGAACGAC
	CTAACTACAA	GTACTCATGATCTCCCTGACACCCA	GTCCCATCAA	AAAATGGCG
	CAAAAGTTCA	AGGTCACGTGTTGGTGGGATG	GGTTCAGTGG	TCCTGAACA
	AGGGCAAGGC	TGAGCGAGGAGTACCCAGACGTC	CAGTGGGTCT	GTTGGACTG
	CACATTGACT	GGATCAGTGGTTGTAACAAAGC	GGCACAGATT	ATCAGGACA
	GTAGACACAT	TGGAAGTACACACAGCTCAGACAC	ATTCTCTCACC	GCAAAGACA
	CCTCCAGCAC	AAACCCATAGAGAGGATTACACAG	ATTAGCAACC	GCACCTACA
	AGCCTACATG	TACTATCAGGCTGGTCACTGCCCT	TGGAGCAAGA	GCATGAGCA
	CAGCTCAGCA	CCCCATCCAGCACAGGACTGGAT	AGACATTGCC	GCACCTCTCA
	GCCGTACATC	GAGTGGCAAGGAGTCAATGCAA	ACTTATTGTTG	CGTTGACCA
	TGAGGACTCT	GGTCAACAAACAAAGACCTCCATCA	CCAACAGGGT	AGGACGAGT
	GCGGTCTATT	CCCATCGAGAGAACCATCTCAAAA	AATTGCGTT	ATGAACGAC
	ACTGTGCAAG	TTAAAGGGCTAGTCAGAGCTCCAC	CTCCCACGTT	ATAACAGCT
	ATCCCTCTCA	AACTATACATCTGCGCCACCGC	CGGAGGGGG	ATACCTGTG

TABLE 4-continued

TABLE 4-continued

TABLE 4-continued

Nucleic acid sequences encoding antibodies of the invention as shown in Table 3

	V _H	C _H	V _L	C _L
	CGGGGCCGA	CGACCTCCGGAGGCACTGCCGCC	CCCTAGCAGC	GCCGCC
	GGTGAAGAAG	TGGGCTGCTTGTCAAGGACTATT	CTGAGCCAA	GTCAGTGT
	CCCGGGCAA	CCCCGAACCTGTACCGGTGTCTG	GCGTGGCGA	TATCTCCCT
	GCGTGAAGGT	GAACAGCGGCCCTGACTTCCGG	CAGAGTGACC	CCATCGGAT
	GAGCTGCAAG	AGTGCACACCGCCGCTCTCT	ATCACCTGCA	GAACAGCTT
	GCAAGCGGCT	GCAATCCAGCGGCCGTGACTCACT	GAGCAAGCCA	AAGTCCGGC
	ACACCTTCAC	GTCATCCCTTGTGACTGTCCCGTC	AGACATCAGC	ACGGCGTCT
	CAACTACTGG	GTCCAGCCTGGAACCCAAACCTA	AACAGACTGA	GTGGCTGTC
	ATGCACTGGG	CATTGCAACGTGAATCACAAACCA	ACTGGTATCA	CTGCTCAAT
	TGAGACAAGC	TCGAATACCAAGGTGATAAGAAAG	GCAGAAGCCC	AACTTTTAC
	CCCCGGCAA	TCGAGCCGAAGTCATGCCACAAGA	GGCAAGGCCG	CTAGGGAAG
	GGCCTGGAGT	CTCACACCTGTCCGCCCTG	TGAAGCTGCT	CTAAAGTCC
	GGATCGCGA	CCCCAGAACCTGCGGCCCTT	GATCAGCTAC	AATGGAAG
	GATGACCCCT	CGGTGTTTGTCTCGCCGAAGGCC	AGAACGAC	TGGATAACG
	AGCGACAGCT	GAAGGACACTCTGATCATCTACG	TGCACAGCGG	CCCTGCAGT
	ACACCAACTA	CACTCCAGAGGTGACTTGCGTGGT	CGTGCCTAGC	CAGGAAACA
	CAATCAGAAG	GGTCGATTTTCCGACAGGAGGCC	AGATTTCAGC	GCCAGGAAT
	TTCAAGGCA	GGAAAGTAAATTCACCTGGTATGTC	GCAGCGGAG	CGGTACCG
	GAGTGAACCT	GACGGGTTGGAAGTCATAATGCC	CGGACCCGAC	AAACAGACA
	GACCGTGGAC	AAGACGAAGCCGAGGGAGGAACAG	TACACCCCTGA	GCAAGGACA
	ACAAGCACAA	TACAACCTCACCTACAGAGTGGTT	CCATCAGCAG	GCACCTACT
	GCACCGCTTA	CACTCTTACCGTCCATCAAGA	CCTGCAGCCT	CCTTGTGCGT
	CATGGAGCTG	TTGGCTTACGGGACAGGAGCTG	GAGGACTTCG	CGACTCTTA
	AGCAGCTGA	ATGTAAGGTGTCGAACAAAGCGTT	CCACCTACTT	CTCTGAGCA
	GGTGAAGAAG	CATTGCAACGTGAATCACAAACCA	ACTGGTATCA	CTGCTCAAT
	CCCCGGCAA	TCGAATACCAAGGTGATAAGAAAG	GCAGAAGCCC	AACTTTTAC
	GCGTGAAGGT	TCGAGCCGAAGTCATGCCACAAGA	GGCAAGGCCG	CTAGGGAAG
	GAGCTGCAAG	CTCACACCTTCCGCCGCTCT	CGTGCCTAGC	CTAAAGTCC
	GCAAGCGGCT	GCAATCCAGCGCCGTGACTCACT	GAGCAAGCCA	AAGTCCGGC
	ACACCTTCAC	GTCATCCCTTGTGACTGTCCCGTC	AGACATCAGC	ACGGCGTCT
	CAACTACTGG	GTCCAGCCTGGAACCCAAACCTA	AACAGACTGA	GTGGCTGTC
	ATGCACTGGG	CATTGCAACGTGAATCACAAACCA	ACTGGTATCA	CTGCTCAAT
	TGAGACAAGC	TCGAATACCAAGGTGATAAGAAAG	GCAGAAGCCC	AACTTTTAC
	CCCCGGCAA	TCGAGCCGAAGTCATGCCACAAGA	GGCAAGGCCG	CTAGGGAAG
	GGCCTGGAGT	CTCACACCTTCCGCCCTG	TGAAGCTGCT	CTAAAGTCC
	GGATCGCGA	CCCCAGAACCTGCGGCCCTT	GATCAGCTAC	AATGGAAG
	GATGACCCCT	CGGTGTTTGTCTCGCCGAAGGCC	AGAACGAC	TGGATAACG
	AGCGACAGCT	GAAGGACACTCTGATCATCTACG	TGCACAGCGG	CCCTGCAGT
	ACACCAACTA	CACTCCAGAGGTGACTTGCGTGGT	CGTGCCTAGC	CAGGAAACA
	CAATCAGAAG	GGTCGATTTTCCGACAGGAGGCC	AGATTTCAGC	GCCAGGAAT
	TTCAAGGCA	GGAAAGTAAATTCACCTGGTATGTC	GCAGCGGAG	CGGTACCG
	GAGTGAACCT	GACGGGTTGGAAGTCATAATGCC	CGGACCCGAC	AAACAGACA
	GACCGTGGAC	AAGACGAAGCCGAGGGAGGAACAG	TACACCCCTGA	GCAAGGACA
	ACAAGCACAA	TACAACCTCACCTACAGAGTGGTT	CCATCAGCAG	GCACCTACT
	GCACCGCTTA	CACTCTTACCGTCCATCAAGA	CCTGCAGCCT	CCTTGTGCGT
	CATGGAGCTG	TTGGCTTACGGGACAGGAGTCAA	GAGGACTTCG	CGACTCTTA
	AGCAGCTGA	ATGTAAGGTGTCGAACAAAGCGTT	CCACCTACTA	CTCTGAGCA
	GAAGCGAGGA	CGGCGCCCTTATGAAAGAAGCTAT	CTGTCAGCAA	AGGCGATT
	CACCGCGTG	CAGCAAGGCCAAGGAGCAGCGCG	GGCACACGCC	ACGAGAAC
	TACTACTGCG	GGAGCCGAAGTCATGCCACAAGA	TGCCCCCCAC	ACAAGGCT
	CTAGAAGCCT	GCCTTCGCGGGACAGGCTGACCAA	CTTCGGCGC	ACGCCTGCG
	GAGCGGCTAC	GAATCAGGTGTCCTTACTTGCGCTG	GGCACCAAGC	AGGTACCC
	GTGGACTACT	GTGAAGGGATTCTACCCCTCGGAT	TCGAGATCAA	ATCAGGGAC
2.2	SEQ ID NO: 182	SEQ ID NO: 183	SEQ ID NO: 184	SEQ ID NO:
	CAAGTGCAGC	GCCAGCACCCAAAGGCTTATCGTG	GACATTCTAGA	185
	TGGTGCAGAG	TTTCGGCTCGCCCGTCTCAAAGT	TGACACAGAG	AGAACTGTG
	CCGGGCCGA	CGACCTCCGGAGGCACTGCCGCC	CCCTAGCAGC	GCCGCC
	GGTGAAGAAG	TGGGCTGCTTGTCAAGGACTATT	CTGAGCCAA	GTCAGTGT
	CCCGGGCAA	CCCCGAACCTGTACCGGTGTCTG	GCGTGGCGA	TATCTCCCT
	GCGTGAAGGT	GAACAGCGGCCCTGACTTCCGG	CAGAGTGACC	CCATCGGAT
	GAGCTGCAAG	AGTGCACACCTTCCGCCGCTCT	ATCACCTGCA	GAACAGCTT
	GCAAGCGGCT	GCAATCCAGCGCCGTGACTCACT	GAGCAAGCCA	AAGTCCGGC
	ACACCTTCAC	GTCATCCCTTGTGACTGTCCCGTC	AGACATCAGC	ACGGCGTCT
	CAACTACTGG	GTCCAGCCTGGGAACCCAAACCTA	AACAGACTGA	GTGGCTGTC
	ATGCACTGGG	CATTGCAACGTGAATCACAAACCA	ACTGGTATCA	CTGCTCAAT
	TGAGACAAGC	TCGAATACCAAGGTGATAAGAAAG	GCAGAAGCCC	AACTTTTAC
	CCCCGGCAA	TCGAGCCGAAGTCATGCCACAAGA	GGCAAGGCCG	CTAGGGAAG
	GGCCTGGAGT	CTCACACCTTCCGCCCTG	TGAAGCTGCT	CTAAAGTCC
	GGATCGCGA	CCCCAGAACCTGCGGCCCTT	GATCAGCTAC	AATGGAAG
	GATGACCCCT	CGGTGTTTGTCTCGCCGAAGGCC	AGAACGAC	TGGATAACG
	AGCGACAGCT	GAAGGACACTCTGATCATCTACG	TGCACAGCGG	CCCTGCAGT
	ACACCAACTA	CACTCCAGAGGTGACTTGCGTGGT	CGTGCCTAGC	CAGGAAACA
	CAATCAGAAG	GGTCGATTTTCCGACAGGAGGCC	AGATTTCAGC	GCCAGGAAT
	TTCAAGGCA	GGAAAGTAAATTCACCTGGTATGTC	GCAGCGGAG	CGGTACCG
	GAGTGAACCT	GACGGGTTGGAAGTCATAATGCC	CGGACCCGAC	AAACAGACA
	GACCGTGGAC	AAGACGAAGCCGAGGGAGGAACAG	TACACCCCTGA	GCAAGGACA
	ACAAGCACAA	TACAACCTCACCTACAGAGTGGTT	CCATCAGCAG	GCACCTACT
	GCACCGCTTA	CACTCTTACCGTCCATCAAGA	CCTGCAGCCT	CCTTGTGCGT
	CATGGAGCTG	TTGGCTTACGGGACAGGAGTCAA	GAGGACTTCG	CGACTCTTA
	AGCAGCTGA	ATGTAAGGTGTCGAACAAAGCGTT	CCACCTACTA	CTCTGAGCA
	GAAGCGAGGA	CGGCGCCCTTATGAAAGAAGCTAT	CTGTCAGCAA	AGGCGATT
	CACCGCGTG	CAGCAAGGCCAAGGAGCAGCGCG	GGCACACGCC	ACGAGAAC
	TACTACTGCG	GGAGCCGAAGTCATGCCACAAGA	TGCCCCCCAC	ACAAGGCT
	CTAGAAGCCT	GCCTTCGCGGGACAGGCTGACCAA	CTTCGGCGC	ACGCCTGCG
	GAGCGGCTAC	GAATCAGGTGTCCTTACTTGCGCTG	GGCACCAAGC	AGGTACCC
	GTGGACTACT	GTGAAGGGATTCTACCCCTCGGAT	TCGAGATCAA	ATCAGGGAC

TABLE 4 -continued

Nucleic acid sequences encoding antibodies of the invention as shown in Table 3				
	V _H	C _H	V _L	C _L
	GGGGCCAAG GCACCAACCGT GACCGTCTCG AGC	ATCCGAGTCGAATGGGAATCGAAT GGCACGCCAGAAAACAACCTACAAG ACCACTCCCCGGTGCTCGACTCC GACCGTTCTTCTCCCTGACTCGA AGCTGACCGTGGACAAATCACGCT GGCACGCCAACGGAAACGTGTTAGCT GCAGCGTGTGATGCGATGAGCGCTGC ATAATCACTACACCCAGAAGTCAC CTCGCTCAGGCCAGGGAAAG	G	TCTCGTCCC CGGTGACCA AATCCCAA TAGAGGCGA ATGC
2.3	SEQ ID NO: 186	SEQ ID NO: 187	SEQ ID NO: 188	SEQ ID NO:
	CAAGTGCAGC TGGTGCAGAG CGGGGCCGA GGTGAAGAAG CCCGGCCAA GCGTGAAGGT GAGCTGCAG GCAAGCGGCT ACACCTTCAC CAACTACTGG ATGCAGTGGG TGAGACAAGC CCCCGGCCAA GGCCTGGAGT GGATCGGCGA GATCGACCCCT AGCGACAGCT ACACCAACTA CAATCAGAAG TTCCAAGGCA GAGTGACCCCT GACCGTGGAC ACAAGCACAA GCACCCCTTA CATGGAGCTG AGCAGCTGA GAAGCGAGGA CACCGCGTG TACTACTGCG CTAGAAGCCT GAGCGGCTAC GTGGACTACT GGGGCCAAG GCACCAACCGT GACCGTCTCG AGC	GCCAGCACCAAAGGTCCATCCGTG TTTCGCTCGCCCCGTCCTCAAGT CGACCTCCGGAGGCACTGCCGCC TGGGCTGCTTGTCAAGGACTATT CCCCGAACCTGTACCGGTCTCG GACAGCGGCCCT GAGCTGACCTGG GCAATCCAGCTTCTCCCGCT GTCATCCGTTGTGACTGTCCCGT CTTCCAGCTGG CATTGACAGTCGAATCACAAAC TCGAATACCAAGGTGATGAAAG TCGAGCGAAGTCATGCGACAAGA CTCACACCTGTCCGCCCT GTCAGCGCTGG CATTGACAGTCGA GAGCTGATGATG ATAATCACTACACCCAGAAGTCAC CTCGCTCAGGCCAGGGAAAG	GACATCGTAA TGACACAGAG CCCCGCGACC CTGAGCCTGT CCCCGGTGA GAGAGCTACC CTGAGCTGCA GAGCAAGCCA AGACATCAGC AACAGACTGA ACTGGTATCA GCAGAGGCC GGCAAGCCG TGAGACTGCT GATCAGCTAC CGGTGTTTTG GAGCTGACCC GAGAGCTAC TGCACAGCG CGTCCCGCT AGATTCAAGC GCAGCGGCC GGAGTAAATT GGTGAACCT GACGGGTGGA GAAGGACACT CACTCCAGGGT GGTCATGTT GGAGTAAATT GGAGGTGGA GAAGGACTCT TACAACCTCC CACTCTTACCG TTGGCTGAAC GACGGGTGGA AAAGCAGCT GCCGGGCTAT CACCGCGCT GGAGCGCAAG GCTTCGGGG GAATCAGGT GTGAAGGGATT ATCGCAGTC GGACAGCCAG ACCACTCCCC GACGGTTCTT AGCTGACCGT GGCAGCAGGG GCAGCGTGTG ATAATCACTAC CTCGCTCAGGCC	188 189 AGAACCTGTG GCCGCC GTCACTGTT TATCTCCCT CCATCGGAT GAACAGCTT AAAGTCCGC ACGGCGTCT GTGCTCTGC CTGCTCAAT AACTTTAC CTAGGGAAG CTAAAGTCC AATGGAAG TGGATAACG CCCTCGAGT CAGGAAACA GCCAGGAAT CGGTTACCG AACAGGACA GCAAGGACA GCACCTACT CCTTGTCTG CGACTCTTA CTCTGAGCA AGGCCGATT ACGAGAACG ACAAGGTCT ACGCCGCG AGGTACCC ATCAGGAC TCTCGTCCC CGGTGACCA AATCCCAA TAGAGGCGA ATGC
2.4	SEQ ID NO: 190	SEQ ID NO: 191	SEQ ID NO: 192	SEQ ID NO:
	CAAGTGCAGC TGGTGCAGAG CGGGGCCGA GGTGAAGAAG CCCGGCCAA GCGTGAAGGT GAGCTGCAAG GCAACGGGCT ACACCTTCAC CAACTACTGG ATGCAGTGGG TGAGACAAGC CCCCGGCCAA GGCCTGGAGT GGATCGGCGA GATCGACCCCT AGCGACAGCT ACACCAACTA CAATCAGAAG	GCCAGCACCAAAGGTCCATCCGTG TTTCGCTCGCCCCGTCCTCAAGT CGACCTCCGGAGGCACTGCCGCC TGGGCTGCTTGTCAAGGACTATT CCCCGAACCTGTACCGGTCTCG GACAGCGGCCCT AGTGCACACCT GCAATCCAGCG GTCATCCGTT GTCCAGCTGG CATTGACAGTC TCGAATACCA TCGAGCGCAAG CTCACACCTG GCCCAGAACT CGGTGTTTTG GGAGGACACT CACTCCAGCG GGTCGATGTT GGACAGGCC ACCACTCCCC GACGGTTCTT AGCTGACCGT GGCAGCAGGG GCAGCGTGTG ATAATCACTAC CTCGCTCAGGCC	GAGATCGTAA TGACACAGAG CCCCGCGACC CTGAGCCTGT CCCCGGTGA GAGAGCTACC CTGAGCTGCA GAGCAAGCCA AGACATCAGC AACAGACTGA ACTGGTATCA GCAGAGGCC GGCAAGCCG TGAGACTGCT GATCAGCTAC CGGTGTTTTG GAGGACACT GACACCCGG CATCCCGCT AGATTCAAGC G	192 193 AGAACCTGTG GCCGCC GTCACTGTT TATCTCCCT CCATCGGAT GAACAGCTT AAAGTCCGC ACGGCGTCT GTGCTCTGC CTGCTCAAT AACTTTAC CTAGGGAAG CTAAAGTCC AATGGAAG TGGATAACG CCCTCGAGT CAGGAAACA GCCAGGAAT

TABLE 4-continued

Nucleic acid sequences encoding antibodies of the invention as shown in Table 3				
	V _H	C _H	V _L	C _L
	TTCCAAGGCA GAGTGCACCT GACCCTGGAC ACAAGCACAA GCACCCCTA CATGGAGCTG AGCGCCTGA GAAGCGAGGA CACCGCGTG TACTACTCG CTAGAACCT GAGCGCTAC GTGGACTACT GGGGCAAG GCACCAACCGT GACCGTCTCG AGC	GGAAAGTGAATTCACAATGGTATGTC GACGGGGTGGAACTGCTATAATGCC AAGACAGGCCGGGGAGGAACAG TACAACTCCACCTACAGAGTGTGTT CAGTCTCTTACCGTCCATCAAGA TTGGCTAACCGGAAAGAGTACAA ATGTAAGGTGCGAACAAAGCGTT GCCGGCCCCATATGAAAGAACGATAT CAGCAAGGCCAAAGGACAGGCCGCG GGAGCGCAAGTGTACACCCCTCC GCCTTCGGGGACGAGCTGACCAA GAATCAGGTGCTCTTACTTGTGCTG GTGAAGGGATTCTACCCCTCGGAT ATGGCAGTGAATGGGAAATCGAAT CTGGCTAACGCCAGGGAAAG	GCAGCGGCAG CGGCACCGAC TACACCCCTGA CCATCAGCAG CCTGGAGCCT GAGGACTTCG CCGTGTACTA CTGTCAGCAA GGCAACAGCC TGCCCCCAC CTTCGGCGC GGCACCAAGC TCGAGATCAA G	CGGTACCG AACAGGACA GCAAGGACA GCACCTTACT CCTTGTCTG ACGAGCTCT GGTACCCCTC ATCAGGGAC TCTCTTCCC CGGTGACCA AATCCCTAA TAGAGGGCA ATG
2.9	SEQ ID NO: 194 CAAGTGCAGC TGGTGCAGAG CGGAGCGAG CTGAAGAACG CCGGCGCAAG CTGTAAAGGTG AGCTGCAAGG CAAGCGGCTA CACCTTCACC AAACTCTGGA TGCAGTGGGT GAGACAAGCC CCCGCCCAAG GCTTGGAGTG GATCGCGAG ATCGACCCCA GCGCAGCTAC CACCAACTAC AACAAAGGCT TCACCGGCAG ATTCTGTGCTG AGCGTGGACCA CAAGCGTGAG CACCGCCTAC CTGCAGATCA GCAGCGTGA GGCCGGAGAC ACCGCCGTGT ACTACTGC TAGAGGCTG AGCGCTACG TGGACTACT GGGCCAAGGC ACCAACCGTGA CCGTCAGAG C	SEQ ID NO: 195 GCCAGCACCAGGTCATCCGTG TTTCCGCTGCCCGTCCTCAAAGT CGACCTCCGGAGGCCTGCGCC TGGGCTGCTTGTCAAGGACTATT CCCCGAACCTGTACGGTGTCTCG GAACAGCGGCCCTGACTTCGG AGTGCACACCTTCCCGCGCTC GCAATCAGCGGCCGTGACTCACT GTCATCCGTGACTGTCCCGTC GTCAGCGGGTGGAAACCCAAACCTA CATTTGCAACGTGAAATCACAAA TCGAATACCAAGGTCGATAAGAAAG TCGAGCGGAAGTCATGGCACAAGA CTCACACCTGTCCGCTTGGCCAG CCCCAGAACGTCTGGCGCCCT CGGTGTTTTGTTTCCCGCGAAGCC GAAGGCAACTCTGTATGATCTCA CACTCCAGGGTACTGGTGTGGT GGTCGATGTTTCCACAGGAGGCC GGAAAGTGAATTCACAATGGTATGTC GACGGGGTGGAACTGCTATAATGCC AAGACAGGCCGGGGAGGAACAG TACAACTCCACCTACAGAGTGTGTT CAGTCCTTACCGTCCATCAAGA TTGGCTAACGCCAGGGAAAG ATGTAAGGTGCGAACAAAGCGTT GCCGGCCCCATATGAAAGAACGATAT CAGCAAGGCCAAAGGACAGGCCGCG GGAGCGCAAGTGTACACCCCTCC GCTTCCGGGGAGGACTGACCAA GAATCAGGTGCTCTTACTTGTGCTG GTGAAGGGATTCTACCCCTCGGAT ATCGCAGTGAATGGGAAATCGAAT GGCACAGGCCAAAGAACAAACTCAAG ACCAACTCCCGGTGCTGACTCC GACGGTTCTTCTCCCTGACTCGA AGCTGACCGTGGAAACATCACGCT GGCAGCGGGAAACGTTAGCT GCAGCGTGTGATGCTGAGGCGCTG ATAATCACTACACCCAGAAGTCACT CTGGCTAACGCCAGGGAAAG	SEQ ID NO: 196 GACATTCAGA TGACACAGAG CCCTAGCAGC CTGAGCGCAA GCCGGCG GCCTGGCGA CAGAGTGC ATCACCTGCA GAGCAAGCCA AGACATCAGC AACAGACTGA ACTGGTATCA GCAGAAGCCC GGCAAGGCC TGAAGTGT GATCACTAC GAGCAAGGCC TGAAGTGT GATCACTAC AACAGCAGAC TGCACAGCG CGTGCCTAGC AGATTAGCG GCAGCGGCAG CGGACCCGAC TACACCCCTGA CCATCAGCAG CCTGCAGCCT GAGGACTTCG CCACACTATT CTGTCAGCAA GGCACAGCC TGCCCCCAC CTTCGGCGC GGCACCAAGC TCGAGATCAA G	SEQ ID NO: 197 AGAAACTGTG GCCGGCCC GTCAGTGT TATCTCCCT CCATCGGAT GAACAGCTT AAGTCGGC ACGGCGCT GTGGTCTGC CTGCTCAAT AACTTTACC CTAGGGAAAG AACTTTACC CTAAAGTCC AATGGAAAG TGGATAACG CCCTCGAGT CAGGAAACA GCCAGGAAT CGGTTACCG AACAGGACA GCAAGGACA GCACCTTACT CTCTGAGCA AGGCCGATT GACAGCTG CCCTTGTCT ACGCGCTG AGGTACCC ATCAGGGAC TCTCGTCCC CGGTCACCA AATCCCTAA TAGAGGGCA ATG
2.11	SEQ ID NO: 198 CAAGTGCAGC TGGTGCAGAG CGGAGCGAG CTGAAGAACG CCGGCGCAAG CTGTAAAGGTG ACCAACCGTGA CCGTCAGAG C	SEQ ID NO: 199 GCCAGCACCAGGTCATCCGTG TTTCCGCTGCCCGTCCTCAAAGT CGACCTCCGGAGGCCTGCGCC TGGGCTGCTTGTCAAGGACTATT CCCCGAACCTGTACGGTGTCTCG GAACAGCGGCCGTGACTTCGG GAGAGCTTAC GACATCGTAA TGACACAGAG CCCCGGGACC CTGAGCCTGT CCCCGGTGA GAGAGCTACC	SEQ ID NO: 200 GACATCGTAA TGACACAGAG CCCCGGGACC CTGAGCCTGT CCCCGGTGA GAGAGCTACC	SEQ ID NO: 201 AGAAACTGTG GCCGGCCC GTCAGTGT TATCTCCCT CCATCGGAT

TABLE 4-continued

Nucleic acid sequences encoding antibodies of the invention as shown in Table 3				
V _H	C _H	V _L	C _L	
AGCTGCAAGG	AGTGCACACTCCCCGGCGTCCT	CTGAGCTGCA	GAACAGCTT	
CAAGCGGCTA	GCAATCAGCGCCGTACTCACT	GAGCAAGCCA	AAGTCCGGC	
CACCTTCACC	GTCATCGGTGACTGTCCCCTC	AGACATCAGC	ACGGCGTCT	
AACTACTGGA	GTCAGCGCTGGAACCCAAACCTA	AACAGACTGA	GTGTCCTGC	
TGCAGTGGGT	CATTGCAACGTAATCACAAACCA	ACTGGTATCA	CTGCTCAAT	
GAGACAAGCC	TCGAATACCAAGGTGATAAGAAC	GCAGAGGCC	AACTTTTAC	
CCCGGCAAG	TCGAGCGAAGTCATGCGACAAGA	GGCAAGCCG	CTAGGGAAG	
GCCTGGAGTG	CTCACACCTGTCGCCCTTGCGCCAG	TGAGACTGCT	CTAAAGTCC	
GATCGGGAG	CCCCAGAACTGTCGGCGGCCCTT	GATCGCTAC	AATGGAAAG	
ATCGACCCCTA	CGGTGTTTTGTTCTCGCGGAAGCC	AGAACGACT	TGGATAACG	
GCGCAGCTA	GAAGGACACTCTGATGATCTACCG	TGCACAGCGG	CCCTGCAGT	
CACCAACTAC	CACTCCAGAGGTGACTTCGCGTGT	CGTCCCCTG	CAGGAAACA	
AAACAAGGCT	GGTCGATGTTTCGCGCAGGAGG	AGATTCAAGC	GCCAGGAAT	
TCACCGGCG	GGAGACTTAAATCACTGGTATGTC	GCAGCGCAG	CGGTTACCG	
ATTCTGCTG	GACGGGGTGGAAAGTCATAATGCC	CGGCACCGAC	AAACAGGACA	
AGCGTGTGACA	AAAGCAGGCCAGGGAGGAAAGCAG	TACACCTGTA	GCAAGGACA	
CAAGCGTGTG	TACAACTCCACCTACAGAGTGT	CCATCAGCAG	GCACACTACT	
CACCGCTTAC	CACTCCCTTACCGTCCTCATCAAGA	CCTGGAGCCT	CCTCTGCGT	
CTGCAGATCA	TTGGCTGAACGAAAGAGGTACAA	GAGGACTTCG	CGACTCTTA	
GCAGCCTGAA	ATGTAAGGTGTCGAACAAAGCGTT	CCGTCTACTT	CTCTGAGCA	
GGCCGAGGAC	GCCGGGGCTATCGAAAGGACTAT	CTGTCAGCAA	AGGCCGATT	
ACCGCGGTGT	CACCAAGGCCAAAGGACAGCCCG	GGCACAGCC	ACGAGAACG	
ACTACTGCGC	GGAGCCGAAGTGTACACCCCTCC	TGCCCCCAC	ACAAGGTCT	
TAGAACGCTG	GCCTTCGCGGGACAGCTGACCAA	CTTCGGCGG	ACGCCCTGCG	
AGCGCTACTG	GAATCAGGTGCTCTTACTTGTGCTG	GGCACCAAGC	AGGTCAACC	
TGGAACTACTG	GTGAAGGGATTCTACCCCTCGGAT	TCGAGATCAA	ATCAGGGAC	
GGGCAAGGC	ATCGCAGTCGAATGGGAATCGAAT	G	TCTCTGCCC	
ACCACCGTGA	GGACAGCCAGAAAACAACATACAAG		CGGTGACCA	
CCGTCTCGAG	ACCAACTCCCCCGTGTGACTCTCC		AACTCCCAA	
C	GACGGTCTTCTTCTCTGTACTCGA		TAGAGGCGA	
	AGCTGACCGTGTGACCAATCACCGCT		ATGC	
	GGCAGCAGGGAAACGTGTTAGCT			
	GCAGCGTGTGATGCGATGAGGGCGTGC			
	ATAATCACTACACCCAGAAGTCAC			
	CTCGCTCAGCCCCAGGGAAAG			
2.12	SEQ ID NO: 202	SEQ ID NO: 203	SEQ ID NO: 204	SEQ ID NO:
CAAGTGCAGC	GCCAGCACCAAAGGTCATCCCGTG	GAGATCGTAA	205	AGAACATGTG
TGGTGCAGAG	TTTCGCTCGCCCCGTCTCAAAAGT	TGACACAGAG		GCCCGGCC
CGGCAGCGAG	CGACCTCCGGAGGCCTGCGCCCG	CCCCCGCACC		GTCACTGTG
CTGAAAGAAGC	TGGGCTGCTTGTCAAGGACTATT	CTGAGCTGT		TATCTCCCT
CCGGCGCAAG	CCCCGAACCTGTACCGGTCTCG	CCCCCGGTGA		CCATCGGAT
CGTGAAGGTG	GAACAGCGGCCCTGACTTCGGG	GAGACTTAC		GAACAGCTT
AGCTGCAAGG	AGTGCACACCTTCCCCGGCGTCCT	CTGAGCTGCA		AAAGTCCGC
CAAGCGGCTA	GCAATCAGCGCCGTACTCACT	GAGCAAGCCA		ACGGCGTCT
CACCTTCACC	GTCATCGGTGACTGTCCCCTG	AGACATCAGC		GTGTCCTGC
AACTACTGGA	GTCCAGGCTGGAACCCAAACCTA	AACAGACTGA		CTGCTCAAT
TGCAGTGGGT	CATTGCAACGTAATCACAAACCA	ACTGGTATCA		
GAGACAAGCC	TCGAATACCAAGGTGATAAGAAAG	GCAGAAGCCC		AACTTTTAC
CCCGGCCAAG	TCGAGCGAACGTCATGCCAACGA	GGCAAGCCG		CTAGGGAAG
GCCTGGAGTG	CTCACACCTGTCGCCCTTGCCCCAG	TGAGACTGCT		CTAAAGTCC
GATCGGGAG	CCCCAGAACTGTCGGCGCCCTT	GATCGCTAC		AAATGGAAAG
ATCGACCCCTA	CGGTGTTTTGTTCTCGCGAAGCC	AGAACGAGAA		TGGATAACG
GCGCAGCTA	GAAGGACACTCTGATGATCTACG	GACACCCCG		CCCTGCAGT
CACCAACTAC	CACTCCAGAGGTGACTTCGCGTGT	CATCCCCGCT		CAGGAAACA
AAACAAGGCT	GGTCGATGTTTCGCAAGGAGGCC	AGATTCAAGC		GCCAGGAAT
TCACCGGCG	GGAAAGTAAATCACTGGTATGTC	GCAGCGCG		CGGTTACCG
ATTCTGCTG	GACGGGGTGGAAAGTCATAATGCC	CGGCACCGAC		AAACAGGACA
AGCGTGTGACA	AAAGCAGGCCAGGGAGGAAACAG	TACACCTGTA		GCAAGGACA
CAAGCGTGTG	TACAACTCCACCTACAGAGTGT	CCATCAGCAG		GCACACTACT
CACCGCTTAC	CACTCCCTTACCGTCCTCCATCAAGA	CCTGGAGCCT		CCTCTGCGT
CTGCAGATCA	TTGGCTGAACGAAAGAGGTACAA	GAGGACTTCG		CGACTCTTA
GCAGCGTGA	ATGTAAGGTGTCGAACAAAGCGTT	CCGTGTACTA		CTCTGAGCA
GGCCGAGGAC	GCCGGCCCCATCGAAAAGACTAT	CTGTCAGCAA		AGGCCGATT
ACCGCGGTGT	CAGCAAGGCCAAAGGACAGCCCG	GGCAACAGCC		ACGAGAACG
ACTACTGCGC	GGAGCCGCAAGTGTACACCCCTCC	TGCCCCCAC		ACAAGGTCT
TAGAACGCTG	GCCTTCGCGGGACAGCTGACCAA	CTTCGGCGG		ACGCCCTGCG
AGCGCTACTG	GAATCAGGTGCTCTTACTTGTGCTG	GGCACCAAGC		AGGTCAACC
TGGACTACTG	GTGAAGGGATTCTACCCCTCGGAT	TCGAGATCAA		ATCAGGGAC
GGGCAAGGC	ATCGCAGTCGAATGGGAATCGAAT	G		TCTCTGCCC
ACCACCGTGA	GGACAGCGAACAAACAACATACAAG			CGGTGACCA
CCGTCTCGAG	ACCAACTCCCCGGTGTGACTCTCC			AAATCCCAA
C	GACGGTTCTTCTCTCTGTACTCGA			TAGAGGCGA

TABLE 4-continued

Nucleic acid sequences encoding antibodies of the invention as shown in Table 3				
	V _H	C _H	V _L	C _L
		AGCTGACCGTGGACAAATCACGCT GGCAGCAGGGAAACGTGTTAGCT GCAGCGTGATGATGAGGCCGCTGC ATAATCACTACACCCAGAAGTCACT CTCGCTCAGCCAGGGAAAG		ATGC
2.16	SEQ ID NO: 206	SEQ ID NO: 207	SEQ ID NO: 208	SEQ ID NO:
	CAAGTGCAGC	GCCAGCACAAAGGTCATCCGTG	GAGATCGTAA	209
	TGGTCCAGAG	TTTCCGCTCGCCGCTCTCAAAGT	TGACACAGAG	AGAACTGTG
	CGGCAGCAG	CGACCTCGGAGGCACTGCCGCC	CCCGCGAAC	GCCCGGCC
	CTGAAGAACG	TGGGCTGCTTGTCAAGGACTATT	CTGAGGCTGT	GTCAGTGT
	CCGGCGCAAG	CCCCGAACCTGTACCGGTCTG	CCCCGGGTGA	TATCTCCCT
	CGTGAAGGTG	GAACAGCGGCCCTGACTTCCGG	GAGAGCTACC	CCATCGGAT
	AGCTGCAAGG	AGTGCACACCTTCCCCTCCGCTCT	CTGAGCTGCA	GAACAGCTT
	CAAGCGGCTA	GCAATCCAGCGGCTGTACTACT	GAGAACGCA	AAGTCGGC
	CACCTTCACC	GTACATCCGTTGACTGTCCCGTC	AGACATCAGC	ACGGCGTCT
	AACTACTGGA	GTCCAGCCTGGAAACCCAACCTA	AACAGACTGA	GTGGTCTGC
	TGAATGTTG	CATTGCAACGTGAATCACAAACCA	ACTGGTATCA	CTGCTCAAT
	GAGACAAGCC	TCGAATACCAAGGTCGATAAGAAAG	GCAGAACGCC	AACTTTAAC
	CCCGGCAAG	TCGAGCGGAAGTCATGCGACAAGA	GGCCAAGCCG	CTAGGGAAAG
	GCCCTGGAGTG	CTCACACCTGTCCGCCTTGCCCG	TGAGACTGCT	CTAAAGTCC
	GATGGCGAG	CCCCAGAACGTGCTCGGGCCCTT	GATCAGCTAC	AATGGAAAAG
	ATCGACCTA	CGGTTTTTGTTCGCCGAAGCC	AGAACAGGAA	TGGATAACG
	GCAGCAGCTA	GAAGGACACTCTGATGATCTACG	GACACACCGG	CCCTGCAGT
	CACCAACTAC	CACTCCAGAGGTGACTTGCCTGTT	CATCCCCGCT	CAGGAAACA
	AACCAAGGCT	GGTCGATGTTCCGACAGGACCC	AGATTCAAGC	GCCAGGAAT
	TCACCCGGCAG	GGAAAGTGAATTAACACTGTTATGTC	GCAGCGGCAG	CGGTACCG
	ATTCTGTTCA	GACGGGGTGGAAAGTGCATAATGCC	CGGCACCGAC	AACAGGACA
	GCCTGGACAC	AAGACGAAGCCGAGGGAGGAACAG	TACACCTGAA	GCAAGGACA
	AAGCGTGGAC	TACAATCCACCTACAGAGTGGTTT	CCATCAGCAG	GCACTTACT
	ACCGCTTACCC	CAGTCCTTACCGTCTCCATCAAGA	CCTGGAGCCT	CCTTGTGCGT
	TGCAGATCAG	TTGGCTGAACGGAAAGGAGTACAA	GAGGAACCTCG	CGACTCTTA
	CAGCCTGAAG	ATGTAAGGTGTCGAACAAAGCGTT	CCGTGTACTA	CTCTGAGCA
	GCCGAGGACA	GCCGGCCCTATGAAAGACTAT	CTGTCAGCAA	AGGCCGATT
	CCGGCGTGA	CAGCAAGGCAAAAGGACAGCCCG	GGCAACAGCC	ACGAGAAC
	CTACTGCGCT	GGAGCCCGAAGTGTACACCCCTCC	TGCCCCCAC	ACAAGGTCT
	AGAACGCTGA	GCCTTCGCGGGACGAGCTGACCAA	CTTCGGCGC	ACGCCTGCG
	GCGCTCATGT	GAATCAGGTGTCCTACTGCGCTG	GGCACCAAGC	AGGTCAACC
	GGACTACTGG	GTGAAGGGATTCTACCCCTCGGA	TCGAGATCAA	ATCAGGGAC
	GGCCAAGGCA	ATCGCAGTCGAATGGGAATCGAAT	G	TCTCGTCCC
	CCACCGTGAC	GGACAGCCAGAAAACAATACAAG		CGGTGACCA
	CGTCTCGAGC	ACCAACTCCCGGTGCTGACTCC		AATCCTTCAA
		GACGGTTCTCTCTCGTACTCGA		TAGAGGCCA
		AGCTGACCGTGGACAAATCACGCT		ATGC
		GGCAGCAGGGAAACGTGTTAGCT		
		GCAGCGTGATGATGAGGCCGCTGC		
		ATAATCACTACACCCAGAAGTCACT		
		CTCGCTCAGCCAGGGAAAG		

[0298] In one embodiment, the nucleic acid sequence has at least 60%, 70%, 80%, 90%, 95% or more sequence homology to one of the sequences selected from Table 4. In one embodiment, said sequence homology is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0299] A nucleic acid according to the present invention may comprise DNA or RNA and may be wholly or partially synthetic or recombinantly produced. Reference to a nucleotide sequence as set out herein encompasses a DNA molecule with the specified sequence and encompasses an RNA molecule with the specified sequence in which U is substituted for T, unless context requires otherwise.

[0300] Furthermore, the invention relates to a nucleic acid construct comprising at least one nucleic acid as defined

above. The construct may be in the form of a plasmid, vector, transcription or expression cassette.

[0301] The invention also relates to an isolated recombinant host cell comprising one or more nucleic acid constructs as described above. The host cell may be a bacterial, viral, mammalian or other suitable host cell. In one embodiment, the cell is an *E. coli* cell. In another embodiment, the cell is a yeast cell. In another embodiment, the cell is a Chinese Hamster Ovary (CHO) cell.

[0302] The invention also provides a method of producing an antibody as described herein, wherein the method comprises culturing the host cell under conditions suitable for expression of the polynucleotide encoding the antibody and isolating the antibody.

[0303] In one embodiment, the antibodies of the invention are conjugated to a toxin, enzyme, radioisotope, label, therapeutic agent or other chemical moiety.

[0304] In embodiments, the antibodies are conjugated to (or labelled with) a detectable or functional label. A label can be any molecule that produces or can be induced to produce a signal, including but not limited to fluorophores, fluorescers, radiolabels, enzymes, chemiluminescers, a nuclear magnetic resonance active label or photosensitizers. Thus, the binding may be detected and/or measured by detecting fluorescence or luminescence, radioactivity, enzyme activity or light absorbance.

[0305] The invention provides an immunoconjugate comprising an antibody of the invention conjugated to at least one therapeutic and/or diagnostic agent.

[0306] In embodiments, the therapeutic agent may be a toxin, enzyme, radioisotope or other chemical moiety. In one embodiment, the therapeutic agent comprises a toxin, for example a cytotoxic radionuclide, chemical toxin or protein toxin.

[0307] The present invention thus relates to an antibody-drug conjugate (ADC) comprising (i) the antibody or antigen-binding fragment thereof as described herein, (ii) a payload, such as a toxin with cytostatic activity capable of killing a cell, and (iii) a payload-antibody linker moiety which is covalently bound to the antibody or antigen-binding fragment thereof. Linker groups for attaching biologically active moieties are well-known in the art.

[0308] The payload may be a cytotoxin. In another embodiment, the payload may be an immune-modulating molecule, e.g. a TLR8 or TLR7 agonist or a STING agonist (Gingrich J. How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy—J. ADC. Apr. 7, 2020).

[0309] Examples of toxins which may be conjugated to the antibody are well known in the art and include, for example auristatins, for example monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF), or duocarmycins, calicheamicins, pyrrolobenzodiazepines and SN-38. In embodiments, the immunoconjugate comprises an antibody linked to MMAE.

[0310] MMAE is a synthetic antimitotic antineoplastic agent. MMAE is 100-1000 times more potent than doxorubicin but its toxicity is such that it cannot be used as a drug itself. However, it has been used as part of an antibody-drug conjugate (ADC) where MMAE is linked to an antibody that recognises a specific marker expressed in cancer cells and directs MMAE to the cancer cell.

[0311] The structure linking the antibody to MMAE may comprise an attachment group (maleimide (aml) and caproic acid (cap)), a spacer (paraaminobenzoic acid) and a cathepsin-cleavable linker (amino acids valine (Val) and citrulline (Cit)). The structure that connects MMAE to the antibody may be cleaved by cathepsin once the ADC has bound to the targeted cancer cell antigen and entered the cancer cell, after which the ADC releases the toxic MMAE and activates the potent anti-mitotic mechanism. ADCs reduce adverse systemic effects of highly potent cytotoxic agents.

[0312] MMAF is a synthetic antineoplastic agent which is used in some experimental anti-cancer ADCs as the toxic entity. The structure linking the antibody to MMAF may comprise maleimide and caproic acid.

[0313] Monomethyl auristatin E (MMAE, desmethyl-auristatin E) is a synthetic antimitotic, antineoplastic agent. The IUPAC name for MMAE is (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-

3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide.

[0314] Monomethyl auristatin E or MMAE is 100-1000 times more potent than doxorubicin, but its toxicity is such that cannot be used as a drug itself. However, it has been used as part of an antibody-drug conjugate or ADC, wherein MMAE is linked to a monoclonal antibody (mAb) that recognizes a specific marker expressed in cancer cells and directs MMAE to the cancer cell.

[0315] As MMAE is toxic, it has been used as a therapeutic only when conjugated to a monoclonal antibody (mAb) to target the MMAE to cancer cells. In the International Nonproprietary Names for MMAE-mAb-conjugates, the name "vedotin" denotes MMAE plus its linking structure to the antibody. The structure linking the targeting mAb to MMAE may comprise an attachment group (maleimide (mal) and caproic acid (cap)), a spacer (paraaminobenzoic acid) and a cathepsin-cleavable linker (amino acids valine (Val) and citrulline (Cit)).

[0316] The tether that connects MMAE to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the antibody-drug-conjugate has bound to the targeted cancer cell antigen and entered the cancer cell, after which the ADC releases the toxic MMAE and activates the potent anti-mitotic mechanism. Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of highly potent cytotoxic agents.

[0317] Monomethyl auristatin F (MMAF, desmethyl-auristatin F) is a synthetic antineoplastic agent. The IUPAC name for MMAF is (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid. MMAF is the toxic payload used in some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. The attachment group may consist of maleimide and caproic acid.

[0318] Auristatins and their use as components of ADC are reviewed by Madera and Leverett in "Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates"; Mol. Pharmaceutics, 2015, 12 (6), pp 1798-1812 Mendelsohn et al., "Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates". Bioconjugate Chem., Article ASAP DOI: 10.1021/acs.bioconjchem.6b00530, Publication Date (Web): Jan. 6, 2017 describe derivatives of the natural product dolastatin 10 containing pyridines and other basic amines, which were examined to assess more hydrophilic auristatin derivatives would be sufficiently potent for use in ADC. A pyridine derivative, monomethyl auristatin PYE, showed the greatest potency when tested in vivo.

[0319] MMAE may be conjugated to the antigen-binding moiety via a valine-citrulline (vc) linker (vc-MMAE). MMAF is conjugated to the antigen-binding moiety via a maleimidocaprolyl linker (mc-MMAF) using HiPEG™ technology (WO 2009/047500). Thus, in one embodiment, D is MMAE or a derivative thereof conjugated to the antigen-binding moiety via a valine-citrulline (vc) linker (vc-MMAE). In another embodiment D is MMAF or a derivative thereof conjugated to the antigen-binding moiety via a

maleimidocaproyl linker (mc-MMAF). In another embodiment L-D is vedotin or mafodotin.

[0320] The immunoconjugate, compositions and methods of the invention may feature an auristatin which is either monomethylaunstatin E (MMAE) or monomethylaunstatin F (MMAF) or a derivative thereof.

[0321] Immunoconjugates in which the antibody is conjugated to a toxin can be used to mediate specific cell killing of LGR5 expressing cancer cells without systemic toxicity.

[0322] A diagnostic agent may be a detectable or functional label, as described above.

[0323] In another aspect of the present invention, there is provided a pharmaceutical composition comprising an antibody according to the present invention or an immunoconjugate according to the invention and, optionally, a pharmaceutically acceptable carrier.

[0324] An antibody, immunoconjugate, or pharmaceutical composition of the invention can be administered by any convenient route, including but not limited to oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intranasal, pulmonary, intradermal, intravital, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin or by inhalation.

[0325] Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical or subcutaneous administration. Preferably, the compositions are administered parenterally.

[0326] The pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form. The term "carrier" refers to a diluent, adjuvant or excipient, with which a drug antibody conjugate of the present invention is administered. Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. In one embodiment, when administered to an animal, the antibody of the present invention or compositions and pharmaceutically acceptable carriers are sterile. Water is a preferred carrier when the drug antibody conjugates of the present invention are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

[0327] The pharmaceutical composition of the invention can be in the form of a liquid, e.g., a solution, emulsion or suspension. The liquid can be useful for delivery by injection, infusion (e.g., IV infusion) or subcutaneously.

[0328] When intended for oral administration, the composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.

[0329] As a solid composition for oral administration, the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition typically contains one or more inert diluents. In addition, one or more of the following can be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrans, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent. When the composition is in the form of a capsule (e.g. a gelatin capsule), it can contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol, cyclodextrin or a fatty oil.

[0330] The composition can be in the form of a liquid, e.g. an elixir, syrup, solution, emulsion or suspension. The liquid can be useful for oral administration or for delivery by injection. When intended for oral administration, a composition can comprise one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.

[0331] Compositions can take the form of one or more dosage units.

[0332] In specific embodiments, it can be desirable to administer the composition locally to the area in need of treatment, or by intravenous injection or infusion.

[0333] The amount of the antibody of the present invention that is effective/active in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account.

[0334] Typically, the amount is at least about 0.01% of an antibody of the present invention by weight of the composition. When intended for oral administration, this amount can be varied to range from about 0.1% to about 80% by weight of the composition. Preferred oral compositions can comprise from about 4% to about 50% of the antibody of the present invention by weight of the composition.

[0335] Preferred compositions of the present invention are prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the antibody of the present invention.

[0336] For administration by injection, the composition can comprise from about typically about 0.1 mg/kg to about 250 mg/kg of the animal's body weight, preferably, between about 0.1 mg/kg and about 20 mg/kg of the animal's body weight, and more preferably about 1 mg/kg to about 10 mg/kg of the animal's body weight. In one embodiment, the composition is administered at a dose of about 1 to 30

mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks.

[0337] The invention provides methods of treating or diagnosing disease, for example cancer, in a subject, e.g., a mammal (e.g. human patient), comprising administering an effective amount of an antibody, immunoconjugate or pharmaceutical composition of the present invention to the subject. The invention provides methods of diagnosing disease, for example cancer, by assessing LGR5 expression, e.g. in a target tissue. The method is described in detail herein.

[0338] As used herein, "treat", "treating" or "treatment" means inhibiting or relieving a disease or disorder. For example, treatment can include a postponement of development of the symptoms associated with a disease or disorder, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease. The terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms. Thus, the terms denote that a beneficial result is being conferred on at least some of the subjects, e.g., human patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment.

[0339] The term "subject" or "patient" refers to an animal which is the object of treatment, observation, or experiment. By way of example only, a subject includes, but is not limited to, a mammal, including, but not limited to, a human or a non-human mammal, such as a non-human primate, murine, bovine, equine, canine, ovine, or feline.

[0340] As used herein, the term "effective amount" means an amount of an antibody, that when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective to achieve the desired therapeutic or prophylactic effect under the conditions of administration.

[0341] The invention also relates to an antibody, immunoconjugate or pharmaceutical composition of the invention for use in the treatment or prevention of a disease.

[0342] In another aspect, the invention relates to an antibody, immunoconjugate or pharmaceutical composition of the invention for use in the treatment or prevention of cancer.

[0343] In another aspect, the invention relates to the use of an antibody, immunoconjugate or pharmaceutical composition of the invention in the manufacture of a medicament for the treatment or prevention of a disease.

[0344] In another aspect, the invention relates to the use of an antibody, immunoconjugate or pharmaceutical composition of the invention in the manufacture of a medicament for the treatment or prevention of cancer.

[0345] In an aspect of the invention the antibodies may be used as part of a CAR-T cell for the treatment of cancer. The CAR-T cell may comprise a chimeric antigen receptors (CAR) which comprises an antibody of the invention i.e. an antibody or fragment thereof which binds to LGR5.

[0346] Adoptive cellular therapy (ACT) has received much attention as a technique for cancer treatment. One therapeutic approach of ACT involves genetic engineering of T cells to express chimeric antigen receptors (CARs) on the surface of T cells to enable targeting of specific tumours. Once the CAR is expressed in T cells, the CAR modified T

cell (CAR-T or CAR- T cell) acquires properties that include antigen-specific recognition, activation and proliferation and the cells thus act as "living drugs". The purpose of expressing a CAR in a T cell is therefore to redirect immune reactivity of the cell to a chosen target. Furthermore, CARs with different strength and signalling can also modulate T cell expansion as well as alter the strength of T cell activation.

[0347] CARs are synthetic receptors typically consisting of a targeting/binding moiety that is associated with one or more signaling domains in a single fusion molecule. The binding moiety of a CAR typically consists of an antigen-binding domain of a single-chain antibody (scFv) comprising paired antibody light chain and heavy chain variable domains (V_L and V_H) that are fused into a single polypeptide chain via a short flexible linker. The scFv retains the same specificity and a similar affinity as the full antibody from which it was derived and is capable of binding to the specific target of interest. In addition to an extracellular antigen-binding domain CARs also comprise a transmembrane domain and signaling molecules such as costimulatory endodomains and CD3(chain).

[0348] CARs combine antigen-specificity and T cell activating properties in a single fusion molecule. First generation CARs typically included the cytoplasmic region of the CD3zeta or Fc receptor γ chain as their signalling domain. First generation CARs have been tested in phase I clinical studies in patients with ovarian cancer, renal cancer, lymphoma, and neuroblastoma, where they have induced modest responses (reviewed in Sadelain et al., Curr Opin Immunol, 21 (2): 215-223, 2009). Second generation CARs, which contain the signalling domains of both CD28 and CD3zeta, provide dual signalling to direct combined activating and co-stimulatory signals. Third generation CARs are more complex with three or more signalling domains.

[0349] The terms "Chimeric antigen receptor" or "CAR" or "CARs" as used herein refer to engineered receptors, which graft an antigen specificity onto cells (for example T cells such as naive T cells, central memory T cells, effector memory T cells or combination thereof) thus combining the antigen binding properties of the antigen binding domain with the lytic capacity and self renewal of T cells. CARs are also known as artificial T cell receptors, chimeric T cell receptors or chimeric immunoreceptors. The term "antigen binding domain" or "antigen-specific targeting domain" as used herein refers to the region of the CAR which targets and binds to specific antigens as explained above. When a CAR is expressed in a host cell, this domain forms the extracellular domain (ectodomain).

[0350] A skilled person would know that a CAR may comprise additional elements.

[0351] A skilled person would also know that such elements of a CAR (other than antigen-specific targeting domain described herein) are well known in the art. Thus, the invention is not limited to specific domains of the CAR in addition to the antigen-specific targeting domain described herein.

[0352] As mentioned above, the first generation CARs have been tested in various phase I clinical studies in patients with cancer. Second generation CARs and third generation CARs have also been described are more complex with three or more signalling domains (reviewed in Sadelain et al., Curr Opin Immunol, 21 (2): 215-223, 2009, Sterner, R. C., Sterner, R. M. CAR-T cell therapy: current

limitations and potential strategies. Blood Cancer J. 11, 69, 2021). CARs are also described in US2004043401, WO2019200007 and WO2021108613, all incorporated herein by reference.

[0353] For example, the CAR of the invention may comprise a molecule of the general formula: LGR5 binding scFv—transmembrane domain- Intracellular signaling domain. Exemplary domains transmembrane domains and intracellular signaling domains are listed below and are known in the art.

[0354] The present invention may therefore also provide a chimeric antigen receptor comprising an antibody or fragment thereof, e.g. a scFv, of the invention. In one embodiment, the CAR may be labelled. In one embodiment, the CAR comprises a scFv as shown in SEQ ID NO: 211 or a sequence with 70%, 80 or 90% sequence identity thereto as encoded by SEQ ID NO: 218 or a sequence with 70%, 80 or 90% sequence identity thereto. In one embodiment, the CAR comprises a scFv that comprises the CDRs of clone 2.4, also numbered herein as SEQ ID NO. 212, 213 and 214 and the heavy chain CDRs of 215, 216 and 217. In one embodiment, the CAR comprises a scFv that comprises the VH and VL of clone 2.4 or a sequence with at least 90% sequence identity thereto.

[0355] The invention also relates to a cell expressing a CAR of the invention, for example an immune cell, for example wherein the immune cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), tumor infiltrating lymphocyte (TIL), TCR-expressing cell, dendritic cell, or NK-T cell and a regulatory T cell. The cell may be an autologous T cell or an allogeneic T cell.

[0356] The invention also relates to a cell or population of cells comprising a CAR as described herein. The invention also relates to a population of cells comprising a CAR as described herein for use in adaptive immunotherapy, e.g. to treat cancer. The invention also relates to a method for treating, e.g. for adoptive adaptive immunotherapy for treating a cancer comprising administering a population of cells comprising a CAR as described herein.

[0357] The invention also relates to a method for stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, the method comprising administering to the subject an effective amount of a cell or cell population comprising a CAR as described herein.

[0358] The invention also relates to an ex vivo method for generating a population of cells for use in adaptive immunotherapy comprising transforming said cell with a nucleic acid encoding a CAR, e.g. SEQ ID NO. 218 or a sequence with 70%, 80 or 90% sequence identity thereto.

[0359] The invention also relates to method of making a population expressing a CAR, the method comprising:

[0360] (i) contacting a population of cells (for example, T cells, for example, T cells isolated from a frozen or fresh leukapheresis product) with an agent that stimulates a CD3/TCR complex and/or an agent that stimulates a costimulatory molecule on the surface of the cells; (ii) contacting the population of cells (for example, T cells) with the nucleic acid molecule of SEQ ID NO. 218 or a sequence with 70%, 80 or 90% sequence identity thereto, thereby providing a population of cells (for example, T cells) comprising the nucleic acid molecule, and (iii) harvesting the population of cells (for example, T cells) for storage (for

example, reformulating the population of cells in cryo-preservation media) or administration.

[0361] As will be appreciated by the skilled person, the term “chimeric antigen receptor” or “CAR” refers to a recombinant molecule containing an extracellular recognition domain, a transmembrane region and an intracellular signaling domain.

[0362] The extracellular domain comprises a ligand specific for a target tumour antigen, for example an antibody or fragment thereof which binds to LGR5, as described herein.

[0363] The extracellular domain is tethered to a transmembrane region. The transmembrane region may be selected from the transmembrane region(s) of the alpha, beta or zeta chain of the T-cell receptor, PD-1, 4-1BB, OX40, ICOS, CTLA-4, LAG3, 2B4, BTLA4, TIM-3, TIGIT, SIRPA, CD28, CD3 epsilon, CD3zeta, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 or CD154, for example.

[0364] The intracellular (cytoplasmic) domain of the CAR can provide activation of at least one of the normal effector functions of the immune cell. The CAR of the invention may thus further comprise an intracellular signaling domain. An “intracellular signaling domain”, “cytoplasmic domain” or “endodomain” is the domain that transmits activation signals to T cells and directs the cell to perform its specialized function.

[0365] An “intracellular signaling domain,” as the term is used herein, refers to an intracellular portion of a molecule. The intracellular signaling domain generates a signal that promotes an immune effector function of the CAR containing cell, e.g., a CART cell or CAR-expressing NK cell.

[0366] Examples of immune effector function, e.g., in a CART cell or CAR-expressing NK cell, include cytolytic activity and helper activity, including the secretion of cytokines.

[0367] In an embodiment, the intracellular signaling domain can comprise a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include those derived from the molecules responsible for primary stimulation, or antigen dependent stimulation. In an embodiment, the intracellular signaling domain can comprise a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include those derived from molecules responsible for costimulatory signals, or antigen independent stimulation. For example, in the case of a CART, a primary intracellular signaling domain can comprise a cytoplasmic sequence of a T cell receptor, and a costimulatory intracellular signaling domain can comprise cytoplasmic sequence from co-receptor or costimulatory molecule.

[0368] The intracellular signaling domain contains a signaling domain, for example CD28, OX40 and/or CD3zeta. The intracellular signaling domain may comprise a costimulatory domain the costimulatory domain is a signaling region of CD28, CD8, OX40, 4-1BB, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell co-stimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1 (CD1 la/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor,

ICAM11, B7-H3, CDS, ICAM-I, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1 Id, ITGAE, CD 103, ITGAL, CD1 la, LFA-I, ITGAM, CD1 lb, ITGAX, CD1 lc, ITGB1, CD29, ITGB2, CD 18, LFA-I, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSLGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD 150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof.

[0369] In an aspect of the invention the antibodies may be used as part of a Bispecific T-cell Engager (BiTE) for the treatment of cancer. The BiTE may comprise an antibody of the invention, i.e. an antibody or fragment thereof which binds to LGR5.

[0370] The present invention may therefore also provide a BiTE comprising an antibody of the invention.

[0371] As will be appreciated by the skilled person, the term "Bispecific T-cell Engager" or "BiTE" As refers to fusion proteins including two scFvs of different antibodies wherein one of the scFvs binds to T cells via the CD3 receptor, and the other to a tumor cell via a tumor specific molecule (e.g. an antibody or fragment thereof which binds to LGR5). The CD3 molecule non-covalently associates with a T cell receptor (TCR) and participates in antigen-specific signal transduction which activates T cells and initiates redirected lysis of the tumour cell by the T cell.

[0372] In one embodiment, the BiTE comprises a scFv as shown in SEQ ID NO: 211 or a sequence with 70%, 80 or 90% sequence identity thereto or one or more CDR of SEQ ID NO: 211.

[0373] The cancer may be a solid or non-solid tumor. For example, the cancer may be selected from cancer of the head or neck, uterine cancer, colorectal cancer, stomach cancer, carcinoma of the endometrium, cancer of the esophagus, leukemia, such as acute lymphoblastic leukemia (ALL), liver cancer, such as hepatocellular carcinoma or pancreatic cancer.

[0374] In one embodiment, the tumour is a solid tumour. Solid tumours which may be treated include colorectal carcinoma, for example. Some examples of such tumours include epidermoid tumours, squamous tumours, such as head and neck tumours, colorectal tumours.

[0375] In one embodiment, the tumour is a non-solid tumour. Examples of non-solid tumours include leukemia.

[0376] In one embodiment, the cancer is selected from colorectal cancer (CRC), hepatocellular carcinoma (HCC), and pre-B ALL.

[0377] In one embodiment, the cancer is identified as a LGR5 positive cancer. The term "LGR5 positive cancer" as used herein, means a cancer whose cells express LGR5. The antibody and pharmaceutical compositions of the present invention are particularly useful for the treatment of cancers that express abnormally high levels of LGR5, for example cancers which overexpress LGR5. The term "overexpress" as used herein means that the cells express more LGR5 than that observed in normal, non-cancerous cells. The cancer

cells may express 5, 10, 20, 30, 40, 50, 60, 70, 80, 90% more LGR5 than that observed in normal, non-cancerous cells.

[0378] The skilled person will be well aware how to assess whether a cancer is LGR5 positive and/or overexpresses LGR5. Methods include for example, using fluorescence in-situ hybridization, immunohistochemistry approaches, flow cytometry, RT-PCR.

[0379] The present inventors have found that by utilising the antibodies of the present invention, a toxic payload, in the form of an antibody drug conjugate (ADC) can be delivered to LGR5-expressing cancer cells to kill those cells without systemic toxicity.

[0380] In one embodiment, the cancer is locally advanced, unresectable, metastatic, or recurrent cancer.

[0381] In one embodiment, the cancer has progressed after another treatment, for example chemotherapy.

[0382] The antibody, immunoconjugate or pharmaceutical composition of the invention may be administered as the sole active ingredient or in combination with one or more other therapeutic agents. A therapeutic agent is a compound or molecule which is useful in the treatment of a disease. Examples of therapeutic agents include antibodies, antibody fragments, drugs, toxins, nucleases, hormones, immuno-modulators, pro-apoptotic agents, anti-angiogenic agents, boron compounds, photoactive agents or dyes and radioisotopes. An antibody molecule includes a full antibody or fragment thereof (e.g., a Fab, F(ab')², Fv, a single chain Fv fragment (scFv) or a single domain antibody, for example a V_H domain) or antibody mimetic protein.

[0383] In one embodiment, the treatment is used in combination with an existing therapy or therapeutic agent, for example an existing anti-cancer therapy. Thus, in another aspect, the invention also relates to a combination therapy comprising administration of an antibody, immunoconjugate or pharmaceutical composition of the invention and an anti-cancer therapy.

[0384] The anti-cancer therapy may include a therapeutic agent or radiation therapy and includes gene therapy, viral therapy, RNA therapy bone marrow transplantation, nano-therapy, targeted anti-cancer therapies or oncolytic drugs. Examples of other therapeutic agents include other checkpoint inhibitors, antineoplastic agents, immunogenic agents, attenuated cancerous cells, tumor antigens, antigen presenting cells such as dendritic cells pulsed with tumor-derived antigen or nucleic acids, immune stimulating cytokines (e.g., IL-2, IFNa2, GM-CSF), targeted small molecules and biological molecules (such as components of signal transduction pathways, e.g. modulators of tyrosine kinases and inhibitors of receptor tyrosine kinases, and agents that bind to tumor- specific antigens, including E G F R antagonists), an anti-inflammatory agent, a cytotoxic agent, a radiotoxic agent, or an immunosuppressive agent and cells transfected with a gene encoding an immune stimulating cytokine (e.g., GM-CSF), chemotherapy. In one embodiment, the antibody is used in combination with surgery.

[0385] In a specific embodiment of the present invention, the composition is administered concurrently with a chemotherapeutic agent or with radiation therapy. In another specific embodiment, the chemotherapeutic agent or radiation therapy is administered prior or subsequent to administration of the composition of the present invention, preferably at least an hour, five hours, 12 hours, a day, a week, a month,

more preferably several months (e. g. up to three months), prior or subsequent to administration of composition of the present invention.

[0386] In some embodiments, the antibody, immunoconjugate or pharmaceutical composition of the invention may be administered with two or more therapeutic agents.

[0387] The antibody, immunoconjugate or pharmaceutical composition of the invention may be administered at the same time or at a different time as the other therapy or therapeutic compound or therapy, e.g., simultaneously, separately or sequentially.

[0388] In another aspect, the invention relates to an antibody, immunoconjugate or pharmaceutical composition of the invention for use in the treatment or prevention of inflammatory disease.

[0389] In another aspect, the invention relates to the use of an antibody, immunoconjugate or pharmaceutical composition of the invention in the manufacture of a medicament for the treatment or prevention of inflammatory disease.

[0390] In another aspect, the invention relates to a method for treating an inflammatory disease comprising administering a therapeutically effective amount of an antibody as described herein, an immunoconjugate as described herein or a pharmaceutical composition as described herein.

[0391] As will be appreciated by the skilled person the term "inflammatory disease" refers to a disease in which tissues are inflamed, with, for example, increased recruitment of white blood cells to a tissue, which may cause swelling, pain and loss of function. Inflammatory diseases include, for example, arthritis, asthma, Crohn's disease, colitis, dermatitis, irritable bowel syndrome.

[0392] Notably, chronic inflammation is often a precursor to cancer. Inflammatory diseases also include autoimmune diseases and other inflammatory disorders such as myositis, ankylosing spondylitis, vasculitis.

[0393] In embodiments, the inflammatory disease is an inflammatory disease that expresses abnormally high levels of LGR5, for example inflammatory disease which overexpress LGR5.

[0394] The term "overexpress" as used herein means that the cells express more LGR5 than that observed in normal cells not suffering from inflammatory disease. The cells may express 5, 10, 20, 30, 40, 50, 60, 70, 80, 90% more LGR5 than that observed in normal cells. The skilled person will be well aware how to assess whether an inflammatory disease overexpresses LGR5. Methods include for example, using fluorescence in-situ hybridization, immunohistochemistry approaches, flow cytometry, RT-PCR.

[0395] Without wish to be bound by theory, the inventors hypothesize that chronically inflamed tissues result in the upregulation of stem cell pathways and overexpression of LGR5. By targeting LGR5, using the antibodies of the present invention, the inventors can therefore target cells affected by inflammatory disease.

[0396] The present inventors have found that by utilising the antibodies of the present invention, a toxic payload, in the form of an antibody drug conjugate (ADC) can be delivered to LGR5-expressing cells to kill those cells without systemic toxicity.

[0397] In another aspect, the invention provides a kit comprising an antibody, immunoconjugate or a pharmaceutical composition as described herein.

[0398] In another aspect, the invention provides a kit for the treatment or prevention of a disease and/or for detecting

LGR5 for diagnosis, prognosis or monitoring disease comprising an antibody or immunoconjugate of the invention. Such a kit may contain other components, packaging, instructions, or material to aid in the detection of LGR5 protein. The kit may include a labeled antibody of the invention as described above and one or more compounds for detecting the label.

[0399] The invention in another aspect provides an antibody of the invention packaged in lyophilized form or packaged in an aqueous medium.

[0400] The invention also relates to an antibody as described herein with reference to the figures and examples.

[0401] In another aspect, antibodies of the invention are used for non-therapeutic purposes, such as diagnostic tests and assays. A method for detecting the presence of LGR5 in a biological sample comprises contacting said sample with an antibody according to the invention under conditions permissive for binding of the antibody to LGR5, and detecting whether a complex is formed between the antibody and LGR5.

[0402] The inventors have shown that the antibodies of the present invention bind with high affinity and specificity to cancer cells expressing LGR5. Therefore, the antibodies of the present invention may be used in a method of detecting cancer is a sample from a subject.

[0403] The invention therefore provides a method of detecting cancer in a biological sample from a subject, the method comprising contacting the sample with an antibody according to the invention under conditions permissive for binding of the antibody to LGR5, and detecting whether a complex is formed between the antibody and LGR5. The method is particularly useful in detecting a cancer which is positive for LGR5 or overexpresses LGR5.

[0404] The invention therefore also provides a method of detecting inflammatory disease in a biological sample from a subject, the method comprising contacting the sample with an antibody according to the invention under conditions permissive for binding of the antibody to LGR5, and detecting whether a complex is formed between the antibody and LGR5. The method is particularly useful in detecting an inflammatory disease which overexpresses LGR5.

[0405] The methods may be carried out in vivo, in vitro or ex vivo.

[0406] Modifications of antibodies for diagnostic purposes are well known in the art. For example, antibodies may be modified with a ligand group such as biotin, or a detectable marker group such as a fluorescent group, a radioisotope, or an enzyme. Compounds of the invention can be labelled using conventional techniques. Suitable detectable labels include but are not limited to fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands having specific binding partners.

[0407] The biological sample, may include, for example, a tissue sample, blood and blood components (e.g. serum), mucus, saliva, urine, vomit, faeces, sweat, semen, vaginal secretion, tears, pus, sputum or pleural fluid. Preferably the biological sample is a blood sample or tissue sample. As will be appreciated by the skilled person, the method of detecting cancer may therefore be in vitro method for detecting cancer in a subject, the method being carried out on a sample provided from a subject.

[0408] There is also provided a method of detecting cancer in a biological sample from a subject, the method comprising contacting the sample with an antibody according to the

invention under conditions permissive for binding of the antibody to LGR5, and detecting whether a complex is formed between the antibody and LGR5. The method is particularly useful in detecting a cancer which is positive for LGR5 or overexpresses LGR5. If a complex is formed between the antibody and LGR5 this may be indicative that cancer is present in the subject. In such cases, the method may further comprise administering to the subject a cancer treatment. In embodiments, the treatment may comprise administering the antibody, immunoconjugate or pharmaceutical composition of the invention, particularly immunoconjugates or pharmaceutical compositions wherein the antibody is conjugated to a therapeutic agent such as a toxin, enzyme, radioisotope or other chemical moiety (as described above).

[0409] There is also provided a method of detecting inflammatory disease in a biological sample from a subject, the method comprising contacting the sample with an antibody according to the invention under conditions permissive for binding of the antibody to LGR5, and detecting whether a complex is formed between the antibody and LGR5. The method is particularly useful in detecting an inflammatory disease which overexpresses LGR5. If a complex is formed between the antibody and LGR5 this may be indicative that inflammatory disease may be present in the subject. In such cases, the method may further comprise administering to the subject a treatment. In embodiments, the treatment may comprise administering the antibody, immunoconjugate or pharmaceutical composition of the invention, particularly immunoconjugates or pharmaceutical compositions wherein the antibody is conjugated to a therapeutic agent such as a toxin, enzyme, radioisotope or other chemical moiety (as described above).

[0410] In a preferred embodiment, the present invention relates to an *in vitro* method of detecting an epitope of the invention in a sample, wherein the method comprises incubating an antigen binding protein of the invention with a sample of interest, and determining binding of the antigen-binding protein to an epitope of the invention present in the sample, wherein binding of the antigen-binding protein indicates the presence of an epitope of the invention in the sample. Methods for detecting binding of an antigen-binding protein to its target antigen are known in the art and include ELISA, ICC, IHC, immunofluorescence, western blot, IP, SPR and flow cytometry. The sample of interest may be a sample obtained from an individual. The individual may be human. Samples include, but are not limited to, tissue such as brain tissue, cerebro-spinal fluid (CSF), primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph fluid, synovial fluid, follicular fluid, seminal fluid, amniotic fluid, milk, whole blood, plasma, serum, blood-derived cells, urine, saliva, sputum, tears, perspiration, mucus, tumour lysates, and tissue culture medium, tissue extracts such as homogenized tissue, tumour tissue, cellular extracts, and combinations thereof.

[0411] Following incubation, antigen-binding protein to antigen binding, e.g., antibody to antigen binding, is detected using an appropriate detection system. The method of detection can be direct or indirect, and may generate a fluorescent or chromogenic signal. Direct detection involves the use of primary antibodies that are directly conjugated to a label. Indirect detection methods employ a labelled secondary antibody raised against the primary antigen-binding

protein, e.g., antibody, host species. Indirect methods may include amplification steps to increase signal intensity. Commonly used labels for the visualization (i.e., detection) of antigen-binding protein—antigen (e.g., antibody—epitope) interactions include fluorophores and enzymes that convert soluble substrates into insoluble, chromogenic end products. [0412] The term “detecting” is used herein in the broadest sense to include both qualitative and quantitative measurements of a target molecule. Detecting includes identifying the mere presence of the target molecule in a sample as well as determining whether the target molecule is present in the sample at detectable levels. Detecting may be direct or indirect.

[0413] Suitable detectable labels which may be conjugated to antigen-binding proteins, such as antibodies are known in the art and include radioisotopes such as iodine-125, iodine-131, yttrium-90, indium-111 and technetium-99; fluorochromes, such as fluorescein, rhodamine, phycoerythrin, Texas Red and cyanine dye derivatives for example, Cy7, Alexa750 and Alexa Fluor 647; chromogenic dyes, such as diaminobenzidine; latex beads; enzyme labels such as horseradish peroxidase; phospho or laser/fluorescent dyes with spectrally isolated absorption or emission characteristics; electro-chemiluminescent labels, such as SULFO-TAG which may be detected via stimulation with electricity in an appropriate chemical environment; and chemical moieties, such as biotin, which may be detected via binding to a specific cognate detectable moiety, e.g. labelled avidin or streptavidin.

[0414] In another aspect, the invention relates to an isolated synthetic or recombinant peptide comprising an epitope, the peptide consisting of residues 22 to 37 of SEQ ID NO: 1. This may be used in method for immunization to identify and select antibodies. Thus, methods of immunization using the fragment are also contemplated.

[0415] Further, the invention relates to the use of LGR5 expression as a prognostic marker.

[0416] Thus, the invention relates to a method of diagnosing or assessing progression of cancer comprising assessing expression of LGR5 and/or protein levels of LGR5. Assessing expression includes measuring expression using routine methods. Proteins levels can be assessed using the antibodies of the invention.

[0417] In one embodiment, the method may further comprise comparing the level of expression to a threshold level.

[0418] In one embodiment, the threshold level is the level of expression in normal tissue.

[0419] In one embodiment, the method may further comprise selecting a treatment if the level of expression is above the threshold.

[0420] In one embodiment, the method may further comprise administering said treatment.

[0421] In one embodiment, the treatment is an antibody or antibody fragment as described herein.

[0422] In one embodiment, the cancer is CRC, HCC and pre-B ALL.

[0423] In one embodiment, the cancer is HCC and the method may further comprise assessing the presence of mutations in β -catenin.

[0424] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. While the foregoing disclosure provides a general description of the subject

matter encompassed within the scope of the present invention, including methods, as well as the best mode thereof, of making and using this invention, the following examples are provided to further enable those skilled in the art to practice this invention and to provide a complete written description thereof. However, those skilled in the art will appreciate that the specifics of these examples should not be read as limiting on the invention, the scope of which should be apprehended from the claims and equivalents thereof appended to this disclosure. Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure.

[0425] All documents mentioned in this specification are incorporated herein by reference in their entirety, including references to gene accession numbers and references to patent publications.

[0426] "and/or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example "A and/or B" is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein. Unless context dictates otherwise, the descriptions and definitions of the features set out above are not limited to any particular aspect or embodiment of the invention and apply equally to all aspects and embodiments which are described.

[0427] The invention is further described in the non-limiting examples.

EXAMPLES

[0428] The present inventors undertook significant experimentation to develop the antibodies of the present invention and in doing so have established antibodies with high binding affinity and specificity which may be used as both a research tool and for therapeutic purposes.

Materials and Methods

Plasmid Constructs

[0429] The plasmid for hLGR5-eGFP expression plasmid has been previously described. All other LGR transgenes used in the study were constructed by direct replacement of the LGR5 coding sequence with PCR amplicons from the corresponding LGR -family coding sequence by either Gibson assembly (New England Biolabs) or restriction enzyme cloning. LGR-family coding sequences were sourced as follows: hLGR4 (HG15689), Sino Biological; mLGR5 (MR219497) Origene; mLGR5 (MR219702) Origene; and hLGR6(LGR6_OHu16329D) GenScript.

[0430] Sequencing of antibody hybridoma clones and generation of plasmids encoding heavy and light chains of the humanised α -LGR5 antibodies (α -LGR5v4 and α -LGR5v6) and the scFv fragment were obtained from Absolute Antibody.

Preparation of Proteins from Bacterial Expression

[0431] The coding sequence for the N-terminal 100 amino acids of human LGR5 lacking the signal peptide was inserted into the pGEX-4T1 bacterial expression vector and expressed in *E. coli* XL1 blue. The expressed GST-fusion protein was absorbed to glutathione-Sepharose 4B (Sigma-Aldrich) followed by extensive washing of the column with phosphate buffered saline (PBS) and elution with 20 mM glutathione. The eluate was digested, overnight with 2 U of

thrombin protease (Sigma) and the LGR5 N-terminal fragment was resolved in PBS on a Superdex 75 10/300 gel filtration column on an AKTA pure system.

[0432] Bacterial expression plasmids for RAD display of LGR5 N-terminal fragments were generated by Gibson assembly, expressed in bacteria and purified by heat denaturation and Ni-Sepharose affinity chromatography as previously described (Rossmann et al).

Mammalian Cell Lines

[0433] Cell lines were purchased from the European Collection of Cell Cultures and have been authenticated by short tandem repeat (STR) DNA profiling. Upon receipt, cell lines were frozen, and individual aliquots were taken into culture, typically for analysis within <10 passages. Cells were grown in a humidified incubator at 37° C. and 5% CO₂ and tested *mycoplasma* negative (MycoProbe® *Mycoplasma* Detection Kit, R&D systems). HEK293T cells, and the colorectal cancer cell lines LoVo, SW480, HT29, HCT116, CaCo and DLD1, were maintained in DMEM medium supplemented with 10% heat-inactivated FCS (Gibco) and 100 U/ml penicillin/streptomycin (Gibco). pre-B ALL cell lines NALM6, REH, 697, RS4-11, HAL-01, NALM16, SupB15 KOP N8, and MHH-CALL2 were maintained in RPMI-1640 (Gibco) medium supplemented with 10% heat-inactivated FCS (Gibco) and 100 U/ml penicillin/streptomycin (Gibco).

Cellular Assays and Manipulation

[0434] Indirect immunofluorescence, western blot analysis, flow cytometry and TopFlash assays have been previously described. For immunofluorescence, detection was carried out by confocal spinning disc microscopy using an Andor Dragonfly 500 (Oxford Instruments). Images were processed using Imaris software (Bitplane/Oxford Instruments). Flow cytometry was carried out with a BD LSR Fortessa or BD LSR Symphony cell analyzer using the BD FACSDiva software (BD Biosciences Inc.). Quantitative real-time PCR (qRT-PCR) has been previously described and used Taqman probes specific for human LGR5 (Life Technology, Hs00969422_m1) and for TBP (Life Technology, Hs00427620_m1) as control housekeeping gene. The Prism software package was used to graph data sets from TopFlash assays and qRT-PCR experiments and for statistical analysis using two-tailed Students t-test.

[0435] For overexpression of LGR family proteins, HEK 293T cells were transfected with the corresponding plasmids using lipofectamine 2000 (Life Technology) according to manufacturer's recommendations. Cells were transfected overnight and recovered in culture media for an additional 16 hours prior to immunofluorescence, western blot or flow cytometry.

[0436] Generation of a-LGR5v4 and a-LGR5v6 was carried out by transfection of HEK293T 4×T175 flasks with 15 µg of each encoding plasmid (Absolute Antibody). Media containing antibodies was collected at 2- and 4-days post-transfection and subject to Protein G purification. The fluorescent versions of a-LGR5 (Fl-a-LGR5), a-LGR5v4 (Fl-a-LGR5v4) and a-LGR5v6 (Fl-a-LGR5v6) were generated using the Dylight TM650 Antibody labelling kit (Thermo Fisher Scientific). Fluorescent Trastuzumab (Fl-a-HER2) was generated using the Dylight TM550 Antibody labelling kit, respectively. In some controls for flow cytometry and immunofluorescence, Fl-a-LGR5 was pre-incubated with

supra-stoichiometric amounts of RAD-displayed Frag1A or Frag1B, or the Frag1A peptide (Cambridge Peptides) at a molar ratio of 10:1.

[0437] Antibody internalisation assays were carried out by incubation of cells with 20 µg/ml of FI- α -LGR5 or FI- α -HER2 for various timepoints, followed by fixation in 4% paraformaldehyde and immunofluorescence. Images derived from z-stacks of cells were analysed for FI- α -LGR5v4 and fluorescent signals from antibodies against various cellular markers, fluorescent phalloidin to visualise cortical actin, and Hoechst 33342 to visualise nuclei. Images were processed and analysed using Arivis Vision 4D software. Image segmentation to delineate fluorescent features: whole cells, delineated by cortical F-actin, nuclei and puncta) in 3D was carried out using Blob Finder. The Arivis Vision 4D software was then used to classify puncta associated with the cell membrane or within the cells and to determine the degree of co-localisation between LGR5 and compartment-specific markers—co-localisation is defined as >50% overlap with LGR5 puncta.

[0438] For the internalisation kinetics experiments, images were analysed using Arivis Vision 4D software, combined with a deep-learning segmentation using Cellpose. Two regions were defined: cell outer membrane, and cell cytoplasm. Segmented dotted signal corresponding to FI- α -LGR5 or FI- α -LGR5v4, as well as segments-like signal corresponding to FI- \square -HER2, were classified according to their location within these two regions. Ratiometric analysis was performed to quantify the internalisation of both markers at the various time points.

TCGA Data Mining for LGR5 Expression in Cancers

[0439] Publicly available gene expression data (RNAseq V2) from The Cancer Genome Atlas (TCGA; <https://www.cancer.gov/about-nci/organization/cancer-research/structural-genomics/tcga>) were downloaded using FireBrowse (<http://firebrowse.org/>). Gene-level read counts were quantile normalised using Voom and (log 2 median-centred) LGR5 gene expression was determined for each sample. Tumour subtypes for which more than 70% of samples had higher than pan-cancer median LGR5 expression were triaged as “high LGR5 tumours”.

Generation of a-LGR5 Antibodies

[0440] The fusion was made from splenocytes of NMRI mice or S P R D rats (Taconic), which were SC immunized twice at a 14-day interval with 30 mg of the LGR5 N-terminal fragment glutaraldehyde coupled to diphtheria toxoid. The antigen was administered with the GERBU Pa adjuvant according to the manufacturer's recommendations. Four days prior to the fusion, the animals received an IV injection boost of 15 mg antigen administered with adrenaline.

[0441] Fusions and screenings were essentially performed as described before with the mouse SP2 myeloma cell line as the fusion partner.

[0442] Purification of immunoglobulin fractions was carried out by absorption of 1 L of the hybridoma supernatants to 3 ml packed volume of Protein G fast flow Sepharose equilibrated in PBS.

[0443] After extensive washing of the column with PBS, the immunoglobulin fraction was eluted with 100 mM glycine, pH 2.7 and immediately neutralization with 200 mM Tris pH 8.0.

Western Blotting

[0444] Western blots of HEK293t, LoVo and NALM6 lysates was carried out with 40 µg of protein. Western blots of RAD displayed peptides were carried out with 2.5, 12 and 60 ng of purified protein.

Wnt Signaling Reporter Assay

[0445] TopFlash assays were performed as previously reported (de la Roche et al).

DNA Sequencing of the CDR3 Region of Anti-LGR5 Mouse Monoclonal Antibodies

[0446] Outsourced to Absolute Antibody.

Humanisation of Anti-LGR5 Mouse Monoclonal Antibodies

[0447] Outsourced to Absolute Antibody.

Cell Culture

[0448] All cells were grown in a humidified incubator at 37° C. and 5% CO₂. Colorectal cancer cell lines, LoVo, SW480, HT29, HCT116, CaCo and DLD1 were maintained in DMEM medium supplemented with 10% heat-inactivated FCS (Gibco) and 100 U/ml penicillin/streptomycin (Gibco). HEK 293T were maintained in DMEM medium supplemented with 10% heat-inactivated FCS (Gibco) without 100 U/ml penicillin/streptomycin (Gibco). Colo205 colorectal cancer cell line and pre-B-ALL cell lines, NALM6, REH and 697, were maintained in resuspended in RPM I-1640 (Gibco) medium supplemented with 10% heat-inactivated FCS (Gibco) and 100 U/ml penicillin/streptomycin (Gibco). Quantification of LGR5 Expression at mRNA Level

[0449] Cells harvested for RNA extraction were washed twice in ice-cold PBS and snap-freeze as dry pellets for storage at -80° C. freezer. Total RNA was extracted following manufacturer's instructions using Single cell RNA Purification kit (Genewflow) or PureLink RNA Mini kit (Life Tech) according to the number of cells acquired. Quantitative RT-PCR (qRT-PCR) was carried out using the One-Step qRT-PCR Kit (Thermo Fisher SuperScript III Platinum) with Taqman probes specific for human LGR5 (Life Technology, Hs00969422_ml) and for TBP (Life Technology, Hs00427620_ml) as control housekeeping gene. Each experiment included a non-template water control for the assurance of clean reaction background. The non-RT control substituting SuperScript Platinum III RT with Platinum Taq DNA Polymerase (Life Technology, cat no. 10966018) was performed to control for non-specificity of RT amplifying genomic DNA. Expression level of gene transcript was calculated by the ΔCt method. The cycle threshold (Ct) value from the gene of interest was subtracted from the housekeeping gene and transformed with a factor of 2^(~ΔCt) to give the fold expression relative to the housekeeping gene.

Patient Samples and Immunofluorescence Detection of LGR5 and f-Catenin

[0450] All human tissue biopsies used in the study were paraformaldehyde-fixed paraffin embedded and probed with α-LGR5 and an antibody to β-catenin and visualised by fluorescent secondary antibodies to mouse labelled with Alexa 488 and rabbit labelled with Alexa 555. All immune stained samples were imaged using the PhenolImager HT™ Automated Quantitative Pathology Imaging System (Akoya

Biosciences). Scoring of all human biopsies for simultaneous LGR5 and β -catenin expression was performed by an individual blind to the provenance of the samples and graded from no expression—0 to high expression—3 for all sample sets. The Prism software package was used for plotting of LGR5 or β -catenin expression levels for all biopsy sample sets and for determining statistical differences using two-tailed students t-test. Unless otherwise notes, all relevant legal and ethical guidelines of the Addenbrooke's Hospital (Cambridge, UK) were followed for collection of samples and provision for the present study. Informed consent for research application was obtained from all subjects.

[0451] LGR5 expression in individual colorectal cancer cases and adjacent healthy tissue were determined for biopsies provided by Dr Olivier Giger(OG; (IRAS: 162057). Within these tissue samples, regions were annotated as normal, dysplastic or invasive tissue from consecutive H&E sections. LGR5 and β -catenin protein levels were additionally determined in CRC by immunofluorescence using the Bern CRC sample set, provided by Dr Inti Zlobec. The Bern CRC sample set is a highly annotated tumour microarray (TMA) consisting of 160 individual cases in duplicate with determined phenotypic feature—gender, age, tumour stage, therapeutic intervention, and MSI status. Biopsies used in the construction of the TMA were collected under ethics 2020-00498 granted by the Ethical Committee of the Canton of Bern, Switzerland. All relevant guidelines of the Institute of Pathology, University of Bern, Canton of Bern, Switzerland were followed for construction of the TMA.

[0452] The Cambridge HCC TMA consists of 104 human liver samples and was collected by Drs Sarah Aitken and Matthew Hoare with informed consent from Addenbrooke's Hospital, Cambridge, UK, according to procedures approved by the East of England Local Research Ethics Committee (16/NI/0196 and 20/EE/0109). Liver samples classified as healthy were obtained from resections from females with inflammatory adenoma of the liver (2 individuals) or focal nodular hyperplasia (2 individuals) or from a male with an HNF1 α -inactivated adenoma. All biopsies of healthy liver tissue were taken from patients between the ages of 25 and 36.

[0453] High grade serous ovarian carcinoma (HGSOC) samples comprising the Cambridge ovarian cancer TMA were provided by Prof James Brenton. Tumour samples were obtained from patients enrolled in the Cambridge Translational Cancer Research Ovarian Study 04 (CT-CROV04, short OV04) study approved by the Institutional Ethics Committee (REC08/H0306/61). Samples were processed following standardised operating protocols as outlined in the OV04 study design. Tissue quality was assessed using haematoxylin and eosin (H&E) sections, and high purity regions were selected for tissue microarray (TMA) generation (using 0.1 cm cores). The TMA consisted of healthy fallopian tube (FT; 27 samples), 28 ovarian cancer cases (OvC) and 14 omentum cancer cases (OmC).

[0454] The Cambridge brain cancer TMA consists of 5 samples of healthy brain tissue, 5 from low grade glioma and 5 from glioblastoma that were collected via the ICARUS biorepository, Addenbrooke's Hospital, according to approved local research ethics (LREC 18/EE/0172).

[0455] Sections of PDAC and healthy pancreas were provided by Dr Eva Serrao and were obtained from the Cambridge University Hospital Human Tissue bank, Cambridge, UK, according to procedures approved by the Cambridge

South Research Ethics Committee (REC18/EE/0227). Primary haematological malignancy samples used in this study were provided by Blood Cancer UK Childhood Leukaemia Cell Bank (LREC 16/SW/0219) and Cambridge Blood and Stem Cell Biobank (LREC 18/EE/0199) as well as the Blood Cancer UK Biobank (REC16/SW/0219) according to procedures approved by the South West-Central Bristol Research Ethics Committee.

[0456] Buffy Coats from healthy donors were acquired from NHS Blood and Transplant (Cambridge) under appropriate ethics (Research into Altered Lymphocyte Function in Health and Disease, REC reference: 17/YH/0304). PBMCs were isolated using SepMate PBMC Isolation Tubes (Stem-cell Technologies) and B cells and CD8+ T cells were isolated from these using the human CD19 Microbeads (Miltenyi Biotec) or the human CD8+ isolation kit (Miltenyi Biotec).

ADC Generation and in Vitro Killing Assays.

[0457] All antibodies and IgG1 (Sigma-Aldrich) were coupled to MMAE through a divinyl pyrimidine bridging linker inserted within the heavy chain-light chain disulphide linkages for precise drug-to-antibody ratio of 4. F or in vitro killing assays, LoVo target cells were seeded into opaque 96-well plate for overnight, allowing settlement before treatment using ADCs with cleavable linker or non-cleavable control linker at doses of 30, 10, 3, 1, 0.3, and 0.1 nM for 3 days. NALM 6 and REH target cells were seeded into opaque 96-well plate and treated directly by ADCs with cleavable linker or non-cleavable control linker at doses of 30, 10, 3, 1, 0.3, and 0.1 nM for 3 days. On day 3, cell viability was evaluated by CellTiter-Glo 2.0 Cell Viability Assay (Promega) according to manufacturer's instructions. Bioluminescence was measured using a CLARIOStar(BMG Labtech).

[0458] The efficacy of α -LGR5-ADC in targeting CRC was tested in CRC organoid models from the de la Roche laboratory biobank. For killing assays, organoid models 1 and 2 were treated with a concentration range of α -LGR5-ADC from 1 to 100 nM. Organoid killing was evaluated after 24 hours by the percentage of cleaved caspase 3 (CC3) expressing cells.

Flow Cytometric Analysis for Internalisation of LGR5

[0459] Cells were blocked with Human TruStain fcX (Biolegend) for 15 mins and then incubated with FITC-labeled a-LGR5 mAbs with or without blocking by epitope peptides (synthesised by Cambridge Peptides) at a ratio of 10:1 (peptide:mAb). Incubation was performed at 37°C. (surface and internalised LGR5) or 4°C. (surface LGR5). For cell surface staining, cells were washed twice with ice-cold PBS and incubated for 10 mins light protected at room temperature with Fixable Viability dye eFlour780 (eBioscience). Cells were then washed once with FACS buffer, made with PBS (Gibco), 3% FCS (Biosera), 0.05% Sodium Azide (Sigma), and 2 mM EDTA (Sigma). Cells were then incubated with fluorophore-conjugated antibodies at the appropriate dilution in the presence of Human TruStain fcX (Biolegend) for 30 mins at 4°C. protected from light. Cells were washed twice with FACS buffer and flow cytometric analyses were conducted on a BD Fortessa or Symphony cell analyser, and data was analysed with FlowJo software (Tree Star Inc., version 10.4).

Immunofluorescence (IF) Microscopy

[0460] For the overexpression of different LGRs from different species (human, mouse and macaque), HEK 293T cells were cultured on top of glass coverslip and grown in culture for overnight before transfection with various expression vectors (FIG. 2B) using lipofectamine 2000 (Life Technology) according to manufacturer's instructions. Transfected cells were further incubated for overnight to allow transgenes to be expressed before subjected to IF staining and microscopy.

[0461] LoVo cells were seeded on top of glass coverslip and grown in culture for 2 days before being stained for IF Microscopy. NALM6 cells were washed with RPMI medium without FCS twice, resuspended and seeded on top of glass slides for 8 minutes at 37° C. in incubator, allowing firm adherence for further IF staining and microscopy.

[0462] To visualise internalisation, NALM6 cells were incubated in full medium in a 37° C. incubator with FI-conjugated anti-LGR5 mAbs or FI-conjugated anti-LGR5 mAbs blocked by epitope peptides as negative control for 5, 15, 30 and 60 minutes. Then NALM6 cells were washed with RPMI medium without FCS twice, resuspended and seeded on top of glass slides for 8 minutes at 37° C. in an incubator. For LoVo, cells were seeded on top of glass coverslip and grown in culture for 2 days, then incubated in full medium in a 37° C. incubator with FI-conjugated anti-LGR5 mAbs or FI-conjugated anti-LGR5 mAbs blocked by epitope peptides as negative control for 5, 15, 30 and 60 minutes for further IF staining and microscopy.

[0463] Cells were washed twice with PBS then fixed with 4% PFA (CN Technical Services) for 10 mins at room temperature. Slides were washed 5 times with PBS and blocked with blocking buffer including 1% bovine serum albumin (BSA, Sigma) and 0.1% TritonX-100 (Alfa Aesar) in PBS for 30 mins at room temperature. Blocking buffer was aspirated and slides were stained with primary Abs in blocking buffer for 1 hours at room temperature and then washed 5 times with blocking buffer. Secondary antibodies (anti-mouse Alexa488 (Thermo) and Alexa647 AffiniPure Donkey Anti-Human IgG (H+L) (Jackson ImmunoResearch)) with or without FI-conjugated Phalloidin (Alexa488 or Alexa555, Thermo) in blocking buffer were added onto slides for 30-minutes at room temperature. After incubation, slides were washed 5 times with blocking buffer and stained with Hoechst33342(Invitrogen) prepared in blocking buffer for 5 mins, light protected at room temperature. Slides were washed 5 times with blocking buffer and mounted with ProLong Diamond Antifade Mountant (Fisher). Excess mounting fluid was wiped off and slides were allowed to set at room temperature and light protected overnight before imaging. Confocal spinning disc microscopy was performed on an Andor Dragonfly 500 (Oxford Instruments). Images were processed using Imaris software (Bitplane/Oxford Instruments).

Generation of ADCs

[0464] All antibodies and IgG 1 were coupled to MMAE using a previously reported protocol (Walsh et al).

Cytotoxicity of ADCs Against CRC and preB ALL Cell Lines in Vitro

[0465] LoVo target cells were seeded into opaque 96-well plate for overnight, allowing settlement before treatment using ADCs with cleavable linker or non-cleavable control

linker at doses of 30, 10, 3, 1, 0.3, and 0.1 nM for 3 days. NALM6 and REH cells were seeded into opaque 96-well plate and treated directly by ADCs with cleavable linker or non-cleavable control linker at doses of 30, 10, 3, 1, 0.3, and 0.1 nM for 3 days. On day 3, cell viability was evaluated by CellTiter-Glo® 2.0 Cell Viability Assay (Promega) according to manufacturer's instructions. Bioluminescence was measured by CLARIOStar (BMG Labtech).

In Vivo Therapeutic Efficacy of Mouse and Humanised ADCs Against Human NALM6 preB ALL Cells in an Immunodeficient NSG Mouse Model

[0466] NSG mice (NOD scid gamma; strain NOD.Cg-Prkdc^{scid} Il2rg^{tm1wjl/Szj}) were purchased from Charles River UK Ltd (Margate, UK) and housed under specific pathogen-free conditions at the University of Cambridge, CRUK Cambridge Institute in accordance with UK Home Office regulations. NALM6 cells were transduced to stably expressing LucEYFP reporter.

[0467] Immunodeficient NSG mice were engrafted with NALM6 cells by intravenous (i.v) injection and monitored for weight loss and imaged using IVIS imaging in a 2-3 day interval. (FIGS. 11A and 13A). For IVIS imaging, mice were given D-luciferin at dose of 150 mg/kg by i.p 10 minutes prior to imaging by IVIS2000 under general anaesthesia with isoflurane. Mice were randomised into control and treatment groups according to the bioluminescence signal detected on day 5 after engraftment. Treatment with mIgG-ADC or α-LGR5-ADC at 5 mg/kg was carried out by i.v injection starting on day 6 for 4 times every other day. Treatment with a-LGR5v6-ADC (control) or α-LGR5v4-ADC at 5 mg/kg was carried out by i.v injection on days 6 and 7. At the experimental endpoint on day 20, all animals were euthanised in accordance with Schedule 1 of the Animals (Scientific Procedures) Act 1986. Spleen, blood, heart, kidney, lung, liver, small intestine, femur and tibia were collected at the experimental endpoint for histology and/or FACS.

[0468] Single cell suspensions prepared from spleen, blood, and bone marrow of femur and tibia were stained with eflour780 fixable live/dead, followed by fluorescence-conjugated antibody against human CD19 for identification of NALM6 cells (CD19+EYFP+) by FACS analysis. Absolute number of NALM6 cells was quantified by the use of AccuCheck Counting Beads (Thermo).

[0469] Whole heart, kidney, lung, liver, small intestine, and part of spleen were fixed with paraformaldehyde, dehydrated by 70% ethanol, then embedded in paraffin blocks. Tissue sections were stained by hematoxylin and eosin (H&E) for evaluating general cellular structures of different tissues. Small intestine sections were stained by fluorescence-conjugated antibody against Ki67 and β-catenin.

Engineering of LoVo and NALM6 Cell Lines

[0470] The LGR5 and LGR4 genes were targeted by CRISP R-Cas9 using the following guide RNAs (gRNAs) targeting the first exon of both gene-LGR5-5'-GCTGCTGCAGCTGGCGACCGG-3'; (SEQ ID No. 219) LGR4-5'-GCGCGGCCGCCCTCTGCG-3'. (SEQ ID No. 220)

[0471] The DNA sequence corresponding to the gRNAs were integrated into the pSpCas9(BB)-2A-GFP (Addgene plasmid 48138). LoVo and NALM6 cell lines were transfected with the gRNA-bearing pSpCas9(BB)-2A-GFP plasmids and the next day, single GFP expressing cells were

seeding into wells of a 96-well plate. Clonal targeted cells lines were confirmed by PCR amplification of the targeted region and sequencing.

[0472] The luciferase transgene was introduced into LoVo and NALM6 cell lines by transduction with the lentiviral vector lenti-luc.

Patient Samples

[0473] CRC patient sections—CRC tumour samples were obtained under ethics. Sections of the tumour were assessed by a histopathologist (O.T.G.) to identify areas of normal colon epithelia, dysplastic epithelial growth and cancer.

[0474] Bern TMA—All relevant guidelines of the Institute of Pathology, University of Bern, Canton of Bern, Switzerland were followed for the study. The informed consent was obtained from all subjects or, if subjects are under 18, from a parent and/or legal guardian. At the time of ngTMA construction, similar tissue types, i.e. normal epithelium, tumor epithelium or tumor stroma, were pooled onto the same TMA recipient block, therefore prior knowledge with regard to the expected content of the tissue punch was available.

Binding Affinity Determination

[0475] Binding affinities were determined by bio-layer interferometry measurements using the Octet platform. For scFv- α -LGR5, Kd values were derived for scFv- α -LGR5 absorbed to Ni-NTA biosensors from changes in interference measurements with the addition of the α -LGR5 epitope peptide N-SSPRSGVLLRGCPTHCHC-C(SEQ ID NO: 210).

Preparation of scFv- α -LGR5

[0476] An expression plasmid containing the 6xHis-tagged scFv- α -LGR5 transgene was transfected into HEK293T cells and the protein purified from the conditioned media using Ni-NTA-Sepharose. Purified protein was dialyzed in phosphate-buffered saline (pH 7.2).

Cambridge Liver Cancer TMA

[0477] Liver and liver cancer samples ethic are under Rec—20/NI/0109 to M.H.

Bite Production, T Cell Activation and Killing Assay

[0478] Expression plasmids containing the coding region for transgenic BiTE versions of α -LGR5^{scFv} fused to the

neered to include an N-terminal signal sequence and FLAG epitope tag. Both BiTEs were purified from conditioned media of transfected HEK293T cells using HiTrap Protein L column (Cytiva) chromatography.

[0479] T cell activation assays were initiated by adding 3.7 nM CL or LC BiTEs or a-LGR5scFv as a negative control to a mixture of 10⁶ PBMCs and 10⁶ NALM6 cells. After 24-hour incubation, cells were stained with eFlour780 fixable live/dead dye, followed by fluorescence-conjugated antibodies against CD4, CD8, CD25 and CD69. Flow cytometry was used to assess expression of the T cell activation markers CD25 and CD69 on CD4+ and CD8+ T cells.

[0480] BiTE-mediated killing assays were carried out using cytotoxic CD8+ T cells. For this, CD8+ T cells were isolated from PBMCs as described and stimulated for 72 h with 25 μ L/mL ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator (STEMCELL). CD8+ T cells were cultured in TexMACS media (Miltenyi Biotec) supplemented with 100 U/ml human IL-2 (Miltenyi Biotec) and 100 U/ml Penicillin/Streptomycin (Gibco). Cells were restimulated at 1 \times 10⁶ cells/mL concentration for 48 h on day 8-10 with 1 μ g/mL plate-bound anti-CD3E antibody (clone UCHT1, Biologend). BiTE-mediated killing assays were carried out on day 14-16 of culture. NALM6 target cells were labelled with CellVue membrane dye (CellVue Claret Far Red Fluorescent Cell Linker Kit protocol; Sigma-Aldrich) and 6.25 \times 10⁴ or 1.25 \times 10⁵ cytotoxic CD8+ T cells were used at indicated effector to target ratios. After 6 hours of co-culture at 37° C., cells were labelled with eFluor780 fixable live/dead dye (ThermoFisher) and NALM6 cells were analysed for viability by flow cytometry.

α -LGR5 CAR-NK92 and CAR-T Cell Production

[0481] The α -CD19-CAR lentiviral plasmid was a kind gift from Dr John James (University of Warwick) and contained the coding region for the α -CD19 scFv domain (clone FM363) fused to the CD8 stalk and transmembrane regions, a 4-1BB or CD28 intracellular costimulatory domain, respectively, and mScarlet. The humanized a-LGR5 scFv fragment (Absolute Antibody) was used to replace the α -CD19 scFv domain in the α -CD19-CAR lentiviral plasmid (PHR-SIN) using restriction digest and Gibson Assembly. PHR-SIN backbone was cut with BamHI and MluI and the following PCR primers were used:

TABLE 6

Forward Primer to amplify LGR5 scFv: LGR5scFv_F1	Gacagactgagtcgcggccggacgcgtcccaccatgccgtgc (SEQ ID NO. 221)
Reverse Primer to amplify LGR5 scFv: LGR5scFv_R1	Gcgctgtggtgctgtcacggtcacgg (SEQ ID NO. 222)
Forward Primer to amplify CAR: CAR_F1	Cgtgagcagcaccacgacgcgcgc (SEQ ID NO. 223)
Reverse Primer to amplify CAR: CAR_R1	Caccatggtggcgaccgggtggatcccgaggggggcagggc (SEQ ID NO. 224)

scFv antibody fragment of CD3E were constructed in both orientations: either with LGR5scFv at the N-terminus, LGR5^{scFv}-CD3e^{scFv} (LC BiTE), or with CD3e^{scFv} at the N-terminus (CL BiTE). The CL and LC BiTEs were engi-

[0482] Lentiviruses were produced using HEK293T cells. For the transfection, 1.5 mL of OptiMEM (Gibco, cat no. 31985070) were mixed with 30 μ L of 1 mM HEPES (in-house) and 42 μ L of TransIT-293 Transfection Reagent

(Geneflow, cat no. E7-0026) and incubated at RT for 5 mins. In parallel, 6 µg of the desired lentiviral plasmid, was mixed with 4pg of the lentiviral packaging plasmid pCMV8.91 and 4pg of the lentiviral envelope plasmid pMDG. Next, the OptiMEM/TransIT solution was gently added and mixed with the lentiviral plasmids. After 15 min incubation at RT, 13 ml of pre-warmed complete DMEM was added and the mixture added to HEK293T cells.

[0483] After 48 h and 72 h, respectively, the viral supernatant was harvested, centrifuged at 250 g for 5 min, before being filtered through a 0.45 µm filter into 30 ml conical ultracentrifuge tubes. Viral supernatant was ultracentrifuged using a SW-28 rotor (Beckmann) at 25000 g for 90 min at 4° C. After the spin the supernatant was discarded, and the virus pellet was gently resuspended in 200-300 µl PBS containing 1% heat-inactivated FCS by pipetting several times over the pellet without creating air bubbles or dislodging the pellet. Resuspended, concentrated virus was stored in aliquots at -80° C.

[0484] NK92 cells were transduced with an MOI of 10. For this, the virus stock was mixed with 6 µg/ml protamine sulfate and added to NK92 cells, that had been washed and seeded at 0.2x10⁶ cells the previous day. Spinfection was carried out at 1800 rpm for 15 min at 32° C. mScarlet expression was assessed after 48-72 h and NK92 cells were sorted from Scarlet. >95% Scarlet-positive NK92 cells were used for all in vitro and in vivo assays.

[0485] CD8+ T cells were isolated from PBMCs as described above and stimulated with 25 µL/mL ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator (STEMCELL). CD8+ T cells were cultured in TexMACS media (Miltenyi Biotec) supplemented with 100 U/ml human IL-2 (Miltenyi Biotec) and 100 U/ml Penicillin/Streptomycin (Gibco). 24 h later CD8 T cells were transduced with an MOI of 5 and used between day 15-20 post stimulation. α-LGR5-CAR+CD8 T cells were sorted for in vitro killing assays with purities routinely >90%.

a-LGR 5 CAR-NK and CAR-T Cell Killing Assays

[0486] NALM6, REH or HEK293T cells overexpressing hLGR5-eGFP, mLGR5-eGFP or cLGR5-eGFP were used as target cells in the VITAL killing assay and were pre-loaded with CellVue membrane dye (CellVue Claret Far Red Fluorescent Cell Linker Kit protocol; Sigma-Aldrich). a-LGR5 CAR-NK and CAR-T cells or respective untransduced control cells were added at indicated effector to target ratios. At designated timepoints percent target cell killing was assessed by flow cytometry.

[0487] LoVo and HepG2 cells were used as target cells in incucyte killing assays. For this, tumour cells were pre-seeded 24 h prior to the assay in a 96-well plate. α-LGR5 CAR-NK and CAR-T cells or respective untransduced control cells were added at indicated effector to target ratios. Cell death was assessed using Apotracker Green (Biolegend, 1:200) and monitored over 15h using the Incucyte SX5 (Sartorius).

Results

Generation and Validation of Antibodies Against LGR5

[0488] For monoclonal antibody production the inventors immunized mice with the N-terminal 100 amino acids of the human LGR5 extracellular domain (FIG. 2A). Coupling of the antigen to diphtheria toxin was necessary to initiate effective immune responses. Fusion reactions led to the

generation of 18 hybridoma clones. To functionally test the clones the inventors generated transgenic versions of human and murine LGR family members: all human and murine LGR4-6 transgenes contain a common N-terminal influenza hemagglutinin (HA) epitope tag and a C-terminal extension consisting of the fusion to the vasopressin V2 receptor C-terminal tail for enhanced protein stability that is in turn fused to eGFP (FIG. 2B). The inventors also created a version of human LGR5 with Gly1Ser and Val8Ala substitutions to match the corresponding cynomolgus LGR5 N-terminus (cynoLGR5). The N-terminal 100 amino acid residues of cynoLGR5 are otherwise identical to the human protein. Western blot analysis of lysates derived from HEK293T cells expressing the various LGR transgenes demonstrated specific immunoreactivity of hybridoma clones 1, 2, 3, and 4 towards human and cynomolgus LGR5 (FIG. 1A, FIG. 2C). None of the hybridoma clones were reactive towards murine LGR5 protein, nor the human or murine LGR4 and LGR6 proteins. Moreover, the inventors did not observe any specific immunoreactivity of the hybridoma clones towards HEK293T cells, as these cells do not express endogenous LGR5 in the absence of pathway activity.

All a-LGR5 Antibodies Bind a Common Epitope at the LGR5 N-Terminus

[0489] Upon sequencing, the inventors found that the complementary determining regions (CDRs) of the light and heavy chains of the four a-LGR5 antibodies were highly conserved, displaying only four variable amino acid positions (FIG. 2D). To determine whether the a-LGR5 clones bind to a common epitope, the inventors designed four overlapping fragments of approximately 35 amino acids in length of the 100 amino acid antigen (Fragment 1-4) whose sequences were unique to the human but not murine LGR5 protein (FIG. 2A). The inventors expressed the individual fragments as RAD-display fusion constructs and purified them from expressing bacteria using standard protocols. Western blot analysis indicated that all four a-LGR5 clones bound specifically to Fragment 1 (FIG. 1B; FIG. 2E). The inventors further narrowed down the epitope to Fragment 1A, a 15 amino acid sequence at the N-terminus of the LGR5 protein that was bound by all four a-LGR5 clones (FIG. 1B, FIG. 2E). None of the clones bound to the adjacent LGR5-fragment 1B that contains 5 overlapping amino acid residues. Notably, the sequence of the Fragment 1A epitope diverges substantially in sequence from the corresponding region in human LGR4/6 and mouse LGR4/5 and by two residues in the corresponding cynoLGR5 sequence (FIG. 2F) explaining why all of the hybridoma clones are specific to the human and cyno LGR5.

[0490] Binding affinities between the a-LGR5 clones and the RAD-Fragment 1 fusion were determined by bio-layer interferometry measurements using the Octet platform. Owing to the bidentate binding of the two arms of the antibodies and high binding affinities displayed by the LGR5 antibodies, accurate determination of the Kd values required inclusion of 10 µM of the Fragment 1 peptide. The inventors observed high affinity binding between the captured Fragment 1A and the original murine clones 1 and 2 with Kd values of 0.76 and 1.1 nM, respectively (Table 5). No detectable binding was observed between all LGR5 antibodies and captured Fragment 1B.

TABLE 5

Antibody	Kd (nM)	
	Fragment 1A	Fragment 1B
α -LGR 5 clone 1	0.76 ± 0.006	ND
α -LGR 5 clone 2	1.1 ± 0.005	ND
α -LGR 5 clone 3	1.0 ± 0.005	ND
α -LGR 5 clone 4	1.4 ± 0.007	ND
IgG2	ND	ND
α -LGR 5 humanized	3.4 ± 0.019	ND
α -LGR 5 variant 4	2.0 ± 0.017	ND
α -LGR 5 variant 6	ND	ND
α -LGR 5 variant 12	2.0 ± 0.017	ND
IgG2-ADC	ND	ND
α -LGR 5 clone 2-ADC	2.7 ± 0.028	ND
α -LGR 5 variant 4-ADC	2.0 ± 0.017	ND
α -LGR 5 variant 6-ADC	ND	ND
scFv fragment	0.77 ± 0.029	ND

ND - not detectable; below the differential light pathlength threshold value of the 1 nm used for the interference measurements

[0491] The humanised variant 4 corresponds to clone 2.4 as in Tables 1 and 2. The α -LGR5 humanised is the direct transposition of the murine clone 2 variable domain sequences into the human IgG scaffold. The variable domain protein sequences of this humanised clone match the murine clone 2.

[0492] Humanized variant 6 (α -LGR5v6) is an antibody also generated by the inventors, but this has lost all reactivity and did not bind to either human or cyno LGR5 proteins (FIG. 14A) or the LGR5 epitope. This variant was used as a negative control for the experiments.

[0493] Clones 1, 2, 3 and 4 in table 5 are the murine antibodies 1, 2, 3 and 4 as in Tables 1 and 2.

[0494] Because of the proximity of the α -LGR5 epitope on LGR5 to the binding site for its R-spondin family ligands, the inventors sought to determine whether antibody binding interfered with the ability of R-spondin1 to potentiate Wnt pathway activity using the TopFlash assay. The inventors treated HEK293T cells expressing LGR5-eGFP or eGFP controls with Wnt and R-spondin1, in the presence of greater than 10-fold molar excess (relative to R-spondin1) of either murine IgG1 or α -LGR5 (FIG. 2G). No significant differences in Wnt/R-spondin1 potentiated activity between IgG 1 or α -LGR5 treated cells were observed indicating antibody binding to LGR5 does not interfere with R-spondin1 binding.

[0495] Taken together, the α -LGR5 antibody binds with high affinity to the N-terminus of human and cynomolgus LGR5 at a site that does not interfere with binding of R-spondin ligands.

α -LGR5 Antibodies Discriminate Cells Expressing Human LGR5 but not Other LGR Family Members

[0496] To determine antibody specificity in detecting cellular LGR5 expression, the inventors overexpressed the LGR transgenes in HEK293T cells and probed expression with murine a-LGR5 clone 2 (α -LGR5) coupled to the Alexa647 fluorophore (FI-a-LGR5) by immune fluorescence. HEK293T cells do not express endogenous LGR5 at steady state and thus the inventors did not observe fluorescence signal from FI-a-LGR5 in the absence of transgenic expression. The inventors observed complete co-localisation

of FI-a-LGR5 and overexpressed human LGR5-GFP with the signal from the antibody abrogated by pre-incubation with the Fragment 1A peptide (FIG. 1C). While FI-a-LGR5 was able to detect the overexpressed cynoLGR5 transgene (FIG. 1C), there was no signal in HEK293T cells over-expressing human LGR4 or LGR6 transgenes or the murine LGRs (FIG. 1C; FIG. 2H).

[0497] To determine whether fluorescent a-LGR5 specifically detects native LGR5 expressed at the cell surface, we carried out flow cytometric analysis of live HEK293T cells overexpressing human, murine, and cyno LGR versions. Cells expressing either human or cynoLGR5-eGFP were detected with the fluorescent a-LGR5 antibody. By contrast, HEK293T cells over-expressing human LGR4-eGFP, LGR6-eGFP or any of the murine LGRs were not detected by flow cytometry using FI-a-LGR5 (FIG. 1D). Importantly, the fluorescent signal observed in LGR5-eGFP-expressing cells was attenuated by pre-incubation with supra-stoichiometric levels of the Fragment 1A or the blocking peptide based on this sequence (10:1; FIG. 1E).

Census of LGR5 Expression Levels in Healthy Tissues and Cancers

[0498] Previous studies have quantified LGR5 transcript levels in a number of cancer types and have established increased LGR5 mRNA expression some cancers relative to matched normal tissues. This work raises the intriguing possibility of discriminating and targeting cancer cells using a-LGR5-based therapeutic strategies. To investigate this in more detail the inventors carried out a comprehensive census of LGR5 transcript levels across 33 cancer types using datasets extracted from the TCGA database. Read counts were quantile normalized across the genome for direct comparison amongst cancer subtypes and sample sets and median expression levels for extracted LGR5 data determined across the entire dataset (FIG. 4A). The inventors triaged 12 of the cancer types as ‘high LGR5 expressors’ where greater than 70% of the component cases harboured LGR5 expression levels greater than the median. Brain cancer, ovarian cancer and uterine carcinosarcoma were excluded from this analysis since no normal tissue samples were available. For these high LGR5 expressing cancers the inventors compared LGR5 expression to matched healthy tissue. In all cases median LGR5 mRNA expression was higher in the cancer compared to matched healthy tissue with the exception of cancers of the adrenal gland. Highly significant increases in LGR5 expression was observed in head and neck, uterine endometrial, stomach, colon and rectal cancers (FIG. 4B).

[0499] Human expression data was also analysed by the inventors, see Hung-Chang Chen, et al, LGR5 targeting molecules as therapeutic agents for multiple cancer types Preprint, BioRxiv, <https://doi.org/10.1101/2022.09.01.506182>.

[0500] The transcription data ranked ovarian cancer as one of the highest LGR5 expressing cancers. However, owing to lack of transcriptomic data for fallopian tubes in the TCGA database, the presumptive tissue of origin for ovarian cancer, we were unable to determine whether this represents malignancy-specific LGR5 overexpression. The inventors therefore probed 24 fallopian tube biopsies with a-LGR5 and a-b-catenin alongside a TMA containing 28 ovarian cancer and 14 omentum cancer cases. b-catenin was expressed at the cortex of all epithelial cells; however, in all cancer cases

the inventors did not detect appreciable LGR5 protein levels in the b-catenin positive fallopian tube epithelia except in very rare instances where we observed individual cells expressing LGR5 localized to intracellular puncta (less than <0.1% cells; FIG. 4C). Comparing LGR5 expression between fallopian tube samples and the ovarian and omentum cancer cases, the inventors did not observe a significant increase in protein levels (FIG. 3A), nor did the inventors observe significant differences in b-catenin protein expression (FIG. 4D).

[0501] The inventors next used a-LGR5 to determine whether LGR5 was upregulated in brain cancers (glioblastoma and low-grade glioma; LGG) using a TMA containing malignant and normal resected brain biopsies. No LGR5 expression was detected in healthy brain tissue and amongst the cancer cases we investigated, there was no significant upregulation of LGR5 protein levels compared to resected non-malignant brain controls (FIG. 3B; FIG. 4H) Finally, the inventors examined LGR5 protein expression in immune cells from healthy donors.

[0502] Flow cytometric analysis of human peripheral blood mononuclear cells (PBMCs) with FI- α -LGR5 did not detect any B cells, CD4+ T cells or CD8+ T cells expressing LGR5 protein (FIG. 4F). In line with a previous study, the inventors determined whether LGR5 transcript levels in tumour cells from acute lymphoblastic leukaemias (ALL) patients was upregulated relative to non-malignant controls. For further human expression data and analysis by the inventors, see Hung-Chang Chen et al, LGR5 targeting molecules as therapeutic agents for multiple cancer types Preprint, BioRxiv, <https://doi.org/10.1101/2022.09.01.506182>

[0503] The transcript and protein data sets obtained establish that: (i) LGR5 overexpression is endemic to a number of cancer types, and (ii) there is a substantial therapeutic window of LGR5 expression between normal tissues and cancers. Together, the data supports therapeutic intervention in CRC, HCC and acute lymphoblastic leukaemia by strategies that target cellular LGR5 overexpression.

α -LGR5 Detects Endogenous Expression of LGR5

[0504] Based on the inventors' LGR5 expression data with CRC and ALL tumours, they sought to determine whether endogenous cellular LGR5 expression could be detected in cell line models of the disease. The LoVo colon cancer cell line has previously been shown to express sufficient levels of LGR5 for antibody detection and indeed, the inventors found that amongst a panel of five colorectal cancer cell lines, LoVo cells expressed at least 10-fold higher LGR5 transcript compared to the SW480 cell line (FIG. 5A). The inventors were also able to detect high LGR5 protein levels in lysates of LoVo, HCT116 and DLD1 cells, but low levels of the protein in lysates from SW480 and CaCo cells (FIG. 5B).

[0505] Cell surface expressed LGR5 was detected on LoVo cells using FI- α -LGR5 which could be abrogated by pre-incubation of the antibody with the Fragment1A peptide (FIG. 5C). No LGR5 was detected on SW480 cells by flow cytometry.

[0506] The inventors further investigated LGR5 protein expression in pre-B-ALL cell lines and identified NALM6 cells as expressing highest transcript levels of LGR5, followed by intermediate levels in REH cells, and lowest levels in 697 cells (FIG. 5D). LGR5 transcript levels in the

pre-B-ALL cell lines are consistent with the relative levels of LGR5 protein detected by western blot (FIG. 5E) and flow cytometry (FIG. 5F).

Lgr5 Associates with a Unique Intracellular Compartment [0507] Endogenous LGR5 expression in NALM6 and LoVo cells allowed the inventors to determine its cellular localization using FI- α -LGR5. Consistent with the localization pattern of overexpressed transgenic LGR5-eGFP, the vast majority of endogenous LGR5 localizes to internal puncta (FIG. 6A). Previous work using transgenic LGR5 over-expression in HEK293T determined the association of LGR5 puncta with the LAMP 1 positive compartment and the inventors tested whether the endogenous protein behaved accordingly in LoVo cells. In both cases, antibodies to LAMP1 and LGR5 proteins detected puncta; however, these were never co-incident, indicating localisation to distinct cellular compartment. (FIG. 6B).

Rapid Internalization of a-LGR5 Antibodies by LGR5-Overexpressing Cell Lines

[0508] The inventors next sought to determine whether they could target exogenous cargo such as FL- α -LGR5 to the LGR5 decorated intracellular puncta. Treatment of HEK293T cells overexpressing LGR5-eGFP with FL- α -LGR5 at 37° C. led to specific internalization of the antibody (FIG. 7A). The kinetics of internalization were rapid; within 5 minutes FI-a-LGR5 was internalised, localising to puncta juxtaposed to the cell surface that ultimately associated entirely with the intracellular LGR5-eGFP puncta over the course of 45 minutes. HEK293T cells that were transfected with LGR4-eGFP failed to bind or internalize FL- α -LGR5 (FIG. 7A).

[0509] To determine whether endogenous LGR5 expression could support FI- α -LGR5 internalisation, the inventors repeated the internalisation assay using NALM6 cells. Similar to HEK293T cells overexpressing hLGR5, NALM6 cells rapidly internalised FI- α -LGR5, within 15 minutes, but not when the antibody was pre- incubated with the Fragment 1A peptide (FIG. 7B).

[0510] To distinguish between cell surface binding of FI- α -LGR5 and its internalisation in NALM6 cells, the inventors carried out the assay at 4° C. and 37° C. respectively. While the inventors detected antibody binding to only a small proportion of NALM6 cells (approx. 1%), the cells uniformly internalised FI- α -LGR5 after 30 minutes of incubation (FIG. 7C).

[0511] LoVo cells also rapidly internalised FI- α -LGR5, within 5 minutes, unless the antibody was pre-incubated with the Fragment 1A peptide (FIG. 7D).

[0512] To examine specific LGR5 internalisation by FI- α -LGR5 uptake in LoVo cells, the inventors generated a control line in which they inactivated LGR5 by targeting the first exon of the LGR5 gene using CRISPR/Cas9. Interestingly, some of the targeted clonal lines harboured lesions in both LGR5 alleles that code for a protein lacking the 7 amino acids of the signal sequence (Suppl. FIG. 5). The mutant protein was expressed at in the targeted cell line at comparable levels to the parental line (FIG. 5E); however, flow cytometry analysis using FI- α -LGR5 to probe for cell surface LGR5 did not detect the mutant protein in the LGR5-targeted line (FIG. 5F). The data suggests that the mutant LGR5 protein lacking a complete signal peptide is not translated into the endoplasmic reticulum for incorporation into the secretory pathway and cell surface expression.

[0513] Together, the internalization data indicates that α -LGR5 binds to and is rapidly internalized by cells with low and transient levels of cell-surface LGR5.

Validation of α -LGR5 Antibody-Drug Conjugates

[0514] The inventors next engineered versions of α -LGR5 fused to the microtubule poison MMAE through a divinyl pyrimidine disulfide bridging linker inserted within the heavy chain-light chain disulfide linkages for precise 4:1 stoichiometry (FIG. 10). Two versions of the α -LGR5-MMAE conjugate were generated for in vitro studies: a sulphatase cleavable version (α -LGR5-ADC; (Walsh et al; Bargh et al)) and a non-cleavable version (a-LGR5-ADCNC; FIG. 10). The inventors also generated the control IgG1 conjugated to MMAE via the cleavable linker. Importantly, the α -LGR5-ADC demonstrated similar epitope binding affinities to the parental antibody (Table 5).

[0515] Single dose treatment of NALM6 cells with α -LGR5-ADC showed effective cell killing over three days with an EC₅₀ of 4 nM (FIG. 9A). α -LGR5-ADC was slightly less effective against the REH pre-B-All cell line that expresses lower LGR5 levels with an EC₅₀ of 10 nM. The inventors found no effect when treating NALM6 cells with α -LGR5-ADCNC consistent with a previous study that found a non-cleavable version of an LGR5 antibody-based ADC was ineffective at cell killing. In vitro killing assays using LoVo cells showed similar results with effective cell killing at an EC₅₀ value of 9 nM.

Targeting NALM6 Tumours in Vivo

[0516] To test in vivo efficacy of the α -LGR5-ADC the inventors implanted NALM6 cells constitutively expressing the luciferase transgene into NSG mice. On day 5 post-implantation IVIS imaging was performed and mice were stratified into two groups with identical overall tumour burden. On day 6, 8, 10, and 12 post implantation mice were treated with 5 mg/kg α -LGR5-ADC via tail vein injection (FIG. 11A). The control cohort of mice received injections of 5 mg/kg IgG1-ADC control on these days. Tumour burden was monitored at 2-3 day intervals by IVIS imaging. While NALM6 tumours treated with IgG1-ADC grew at a logarithmic rate, the inventors observed tumour regression within 4 days of the initial day 6 α -LGR5-ADC treatment (FIG. 11A). Tumour regression persisted throughout the course of treatment at which tumour growth resumed, with a four-day latency period, on day 16 p.i. At experimental endpoint on day 20, the a-LGR5-ADC treatment group had less than 0.5% of the tumour burden of control mice (FIG. 11A, B). The inventors also noted a marked reduction in splenic mass (approximately 2-fold) and residual NALM6 cells (approximately 100-fold; (FIG. 11C) as well as absolute numbers of NALM6 cells in the blood (100-fold) and bone marrow (50-fold) of α -LGR5-ADC treated mice (FIG. 11D, E). No tissue toxicity was observed and proliferation of stem cells in the intestinal crypts was unaffected by α -LGR5-ADC treatment (FIG. 12).

Targeting NALM6 Tumours with a Humanized ADC Version of α -LGR5

[0517] In order to generate an ADC product for potential clinical use, the inventors humanised a-LGR5 antibody leading to the generation of 16 variants based on the human IgG scaffold. The inventors proceeded with one of the humanized clones, variant 4 (α -LGR5v4) that displayed

specific immune reactivity towards expressed human or cynoLGR5 (FIG. 14A) and high-affinity binding to the LGR5 epitope, Kd=2 nM, comparable to the parental murine antibody (Table 5). As a negative control for the experiments, the inventors used humanized variant 6 (a-LGR5v6) which lost all reactivity and did not bind to either human or cyno LGR5 proteins (FIG. 14A) or the LGR5 epitope (Table 5). Moreover, we observed essentially the same specificities as α -LGR5 when using a-LGR5v4 as an immune fluorescent probe; detection of the human and cyno over-expressed transgenic LGR5 proteins but none of the other LGR proteins (FIG. 14B).

[0518] The inventors generated ADC versions of α -LGR5v4 and the α -LGR5v6 control for treatment of NALM6 tumour bearing mice with a two-dose treatment regime on days 6 and 8 p.i. Consistent with the previous in vivo trial, the inventors observed a significant reduction in tumour growth after a four-day latency period from the first treatment day and persistence of the reduction in tumour growth for at least two days after the last α -LGR5v4 treatment (FIG. 13A). Overall NALM tumour burden, measured by IVIS imaging, was about half of control values at experimental endpoint (FIG. 13A, B). As with treatment with the α -LGR5-ADC, the inventors noted a reduction in splenic mass (3-fold) and residual NALM6 cells (approximately 50-fold) as well as an approximately 10-fold reduction NALM6 cells in the blood. Interestingly, this treatment regime saw the maintenance of the NALM6 tumour burden within the bone marrow where there were no significant differences in total tumour cell number. No tissue toxicity was observed and proliferation of stem cells in the intestinal crypts was unaffected by α -LGR5-ADC treatment (FIG. 14).

[0519] Together, the in vivo trial data obtained by the inventors indicates that the α -LGR5 ADCs are effective at suppressing tumour growth but require persistent treatment for durable response.

Binding Affinity Constant of scFv- α -LGR5

[0520] The inventors next sought to develop an LGR5 antibody fragment and determine whether such fragments exhibited binding activity equivalent to the α -LGR5 clones. The inventors prepared a single chain variable chain fragment (scFv) by transfecting an expression plasmid containing the 6xHis-tagged scFv- α -LGR5 transgene into HEK293T cells and purifying the protein from the conditioned media. Binding affinity was determined by biolayer interferometry on the Octet platform. The inventors observed extremely high affinity binding between the scFv- α -LGR5 and the peptide with a Kd value 770 μ M (table 5).

Generation of CARs and BiTEs

[0521] The inventors next developed a chimeric antigen receptor (CAR) and bispecific T-cell engager (BiTE) using the antibodies of the present invention.

[0522] A humanized scFv fragment of the LGR5 antibody (scFv- α -LGR5) was engineered for use as a Bispecific T cell Engager(BiTE). The α -LGR5-BiTEs are composed of the polypeptide chain of scFv- α -LGR5 fused to the scFv fragment of an antibody binding to the CD3 ϵ subunit of the T cell receptor (TCR). The two BiTE formats are either scFv- α -LGR5 or scFv- α -CD3 ϵ as the N-terminal moiety and are compatible with either bacterial expression or expression in mammalian cell lines prior to purification and use as a BiTE.

[0523] A scFv- α -LGR5 was engineered for use as a chimeric antigen receptor (CAR). The α -LGR5-CAR was expressed from lentivirally-transduced cells as a single polypeptide chain consisting of the scFv- α -LGR5 fused to a CD8alpha stalk and transmembrane domain followed by either a CD28 or a 4-1BB costimulatory domain and ending with the CD3zeta signalling domain.

[0524] The α -LGR5-CAR is compatible for expression in T cells, NK cells and other immune cells.

[0525] As shown in FIG. 15, α -LGR5-CAR NK cells are efficient killers with favorable killing kinetics. 2nd generation CAR constructs were generated using the humanized α -LGR5 scFv. CAR constructs were stably introduced into NK92 cells by lentiviral delivery. (A,B) HEK293 cells were transfected with human (A) and cynomolgus (B) LGR5 and served as target cells in killing assays. α -LGR5 CAR NK92 cells were co-cultured with modified HEK target cells at the indicated effector to target ratios for 5 and 9 hours, respectively. (C) a-LGR5 CAR NK92 cells were incubated for 50 min with NALM6 target cells labelled with blue cell dye and immunological synapse formation was assessed by confocal microscopy showing that a-LGR5 CAR NK92 cells form productive synapses with tumour target cells. (D) a-LGR5 CAR NK92 cells were incubated with Acute Lymphoblastic Leukemia (ALL) human tumour cell lines at the indicated effector to target ratios and specific tumour cell killing was assessed after 12 hours.

[0526] As shown in FIG. 16, α -LGR5 Bispecific T cell engagers (BiTEs) are activating T cells and lead to efficient tumour cell destruction. BiTE constructs were generated using the humanized a-LGR5 scFv and a humanized a-CD3 scFv in both directions (LC and CL, respectively). (A) PBMCs were isolated from healthy donors and incubated with NALM6 tumour cells in the presence of α -LGR5 scFv control, α -LGR5LC or CL BiTE, respectively. CD4+ and CD8+ T cell activation was determined by flow cytometric analysis of CD69 and CD25 expression after 24 hours. (B) NALM6 tumour cells were co-cultured with cytotoxic CD8+ T cells generated from healthy donor PBMC in the presence of α -LGR5 scFv control, α -LGR5LC or CL BiTE, respectively. Tumour cell killing was assessed at an effector to target ratio of 5 to 1 after 5 hours.

[0527] Sequences used are shown below:

[0528] α -LGR5 scFv fragment used in the experiments relating to CAR and BiTE constructs, see FIGS. 15 to 27:

[0529] The human variant 4 (clone 2.4 as shown in Tables 1 and 2) was used to make the scFv fragment and therefore is incorporated in the CAR and BiTE constructs. Thus, the CAR and BiTE referred to in FIGS. 17 to 27 use the human variant 4 (clone 2.4, see also sequences in Tables 2 and 3).

peptide:

SEQ ID NO: 211

```
MPLLLLPLWAGALAEIVMTQSPATLSLSPGERATLSCRASQDISNRL
NWYQQKPGQAVRLLISYRSRRHTGIPARFSGSGSGTDYTLTISSLEPED
FAVYYCQQGNSLPPTFGGGTKLEIKGGGGSGGGSGGGSGGGSQVQL
VQSGAEVKKPGASVKVSCKASGYTFTNYWMQVRQAPGQGLEWIGEIDP
SDSYTNYNQKFQGRVTLTVDTSTSTAYMELSSLRSEDTAVYYCARSLSG
YVDYWGQGTTVTVSS
```

[0530] The CDRs of the light and heavy chains are underlined and are as follows (see also sequences in Table 2):

CDR1 light chain	SEQ ID NO: 212
RASQDISNRLN	
CDR2 light chain	SEQ ID NO: 213
YRSRRHT	
CDR3 light chain	SEQ ID NO: 214
QQGNSLPPT	
CDR1 heavy chain	SEQ ID NO: 215
NYWMQ	
CDR2 heavy chain	SEQ ID NO: 216
EIDPSDSYTNYNQKFQG	
CDR3 heavy chain	SEQ ID NO: 217
SLSGYVDY	
nucleic acid:	SEQ ID NO: 218
ATGCCGCTGCTACTGCTGCCCTGCTGTGGCAGGGCGCTAGCTG	
AGATCGTGTACTCAAAGCCCCGCCAACACTGAGCCTATCTCCGGCA	
GAGAGCCACGCTGAGCTGTAGAGCAAGCCAAGACATCAGCAACAGACTG	
AACTGGTATCAGCAGAACGCCCCGCCAACCCGTGAGACTGCTGATCAGCT	
ACAGAACGAGAACACACCCGCATCCCGCTAGATTCAAGCCGAGCGG	
CAGCGGACCGACTACACCCTGACCACATCAGCAGCCTGGAGCCTGAGGAC	
TTCGCTGTATACTACTGCCAACAAAGGCAACAGCCTGCCGCCAACCTCG	
GAGGCGGACGAAGCTGGAGATCAAGGGCGGTGGATCGGGCGGG	
GGGCAGCGGGGTGGTGGTCTGGTGAGGGGCTCACAAAGTGCAGCTG	
GTGCAGAGCGGGCGCGAGGTGAAGAACGCCGGCGAACGCTGAAGGTGA	
GCTGCAAGGCAAGCGGTACACCTCACCAACTACTGGATGCAGTGGGT	
GAGACAAGCCCCGGCCAAGGCCCTGGATCGGGAGATCGACCC	
AGCGACAGCTACACCAACTACAATCAGAAGTCCAAGGCAGACTGACCC	
TGACCGTGGACACAAGCACAAGCACCGCCTACATGGAGCTGAGCAGCCT	
GAGAACGAGGACACCGCGTTACTACTGCGCTAGAACGCTGAGCGGC	
TACGTGGACTACTGGGCCAACGCCACCGTGACCGTGAGCGAGC	

SUMMARY

[0531] Our census of human cancers revealed preB-ALL, CRC and HCC as indicator diseases for our portfolio of a-LGR5 therapeutics (FIG. 3).

[0532] Human preB-ALL cells (NALM6), CRC cells (LoVo), and HCC cells (HepG2) express high levels of LGR5 transcript and protein (FIG. 5, 17).

[0533] The a-LGR5 ADC shows high efficacy in vitro targeting NALM, REH and LoVo cells (FIG. 9) and importantly preferentially kills LGR5HIGH patient-derived CRC organoids (FIG. 18). Murine and humanised α -LGR5 ADC show pre-clinical efficacy in an NSG model of ALL (NALM6) (FIG. 11).

[0534] The α-LGR5 BiTE efficiently activated human CD4+ and CD8+ T cells and importantly efficiently leads to specific tumour cell death (NALM6) when incubated in the presence of tumour and human CD8+ cytotoxic T cells (FIG. 19).

[0535] α-LGR5-CAR NK92 cells efficiently and specifically target HEK293T cells overexpressing human and cynomolgus LGR5 but not HEK293T cells overexpressing human LGR4, human LGR6, and to a much lesser extent mouse Lgr5 (FIGS. 20 and 26). α-LGR5-CAR NK92 cells also specifically target LGR5HIGH NALM6 cells and to a much lesser extent LGR5LOW R E H cells in vitro (FIG. 20). Taken together, these experiments indicate exquisite specificity of the α-LGR5-CAR and a favourable therapeutic window by not targeting LGR5 low-expressing cells (potential stem cells). Furthermore, α-LGR5-CAR NK92 cells efficiently kill HepG2 cells (FIG. 21) and show moderate pre-clinical efficacy in an NSG model of ALL (NALM6) in vivo (FIG. 27).

[0536] α-LGR5-CART cells efficiently kill NALM6 (FIG. 23), HepG2 (FIG. 24), and LoVo tumour cells (PP FIG. 13) in vitro. Strikingly, our α-LGR5-CART cells show exquisite pre-clinical efficacy in an NSG model of ALL (NALM6) in vivo (FIG. 25).

Discussion

[0537] The inventors have carried out extensive validation and characterisation of a novel antibody against the extracellular domain of LGR5 with a view to establishing it as a research tool and for determining its potential therapeutic applications. α-LGR5 is distinct from previously reported anti-LGR5 therapeutic antibodies owing to its target epitope on the LGR5 protein, unique variable heavy and light chains, and particularly high binding affinity to its epitope.

[0538] LGR5 has been established as a marker of stem cells in a number of epithelial tissues through extensive expression analysis with genetically engineered mouse models (GEMMs). Moreover, it has received a great deal of attention as a marker of certain malignancies through functional studies in GEMMs as well as detailed transcriptional analysis of cancer patient datasets.

[0539] The inventors have shown that the α-LGR5 antibodies developed are sensitive and specific tools for determining cellular levels and localisation of LGR5 protein in healthy and malignant tissue. The inventors used transcriptomic analysis of LGR5 expression and characterised LGR5 protein expression in a wide range of clinical samples from various cancers and matched healthy tissues. The inventors thereby established elevated LGR5 expression as a characteristic of various cancers including CRC, HCC and pre-B-ALL. Importantly, the tissue census, both transcriptional and at the level of LGR5 protein indicates that normal tissues, in general, harbour very low LGR5 levels, paving the way for therapeutic targeting of malignancies that overexpress the protein.

[0540] The inventors observed differences between the results from their and previous transcript analyses in relation to the LGR5 protein levels in brain and ovarian cancers; both malignancies consistently score high for LGR5 transcript levels yet the inventors were only able to detect very low LGR5 protein levels in few cells in less than 10% of the tumours tested. While this disparity may, in part, be due to different case samples used in the generation of the datasets,

it highlights the need for establishing LGR5 protein levels as a prognostic indicator targeting of cancers based LGR5 overexpression.

[0541] The antibodies developed by the present inventors specifically recognise native LGR5 on the plasma membrane but also faithfully detect LGR5 expression under various fixation conditions.

[0542] This makes the antibodies developed by the inventors an excellent research tool and the inventors have used α-LGR5 to characterise the subcellular localisation of endogenous LGR5.

[0543] All detectable LGR5 protein in NALM6 and LoVo cells as well as in colon epithelial, CRC tumours, HCC and some of the ovarian cancer cases examined is localised to intracellular puncta. The ability to access the LGR5 positive intracellular puncta through rapid internalisation of FI-α-LGR5 supports dynamic shuttling between highly transitory population of LGR5 at the cell surface and an LGR5-associated vesicular compartment. Indeed, this hypothesis is corroborated by the inventors' comparative studies of LoVo cells and the LGR5-targeted in which LGR5 protein, lacking the signal peptide was not trafficked to the plasma membrane along the secretory pathway; these cells do not internalise LGR5.

[0544] Overexpression of LGR5 protein by some cancers and the highly dynamic nature of its internalisation makes LGR5 an ideal cellular target for ADC-based therapeutics. The inventors used a recently developed protocol for linking the MMAE payload to α-LGR5 resulting in an ADC displaying little change in Kd values for epitope binding indicating no loss in binding affinity. In vitro validation showed low nanomolar EC50 values, on par with Kd values for epitope binding, in targeting LGR5-expressing NALM6 and LoVo cells.

[0545] In vivo experiments targeting NALM6 tumours with α-LGR5-ADC are consistent with previous studies targeting LoVo tumours; after a two-day refractory period, the inventors observed tumour attrition that persisted during the course of treatment. Withdrawal of αLGR5-ADC restored tumour growth indicating the possibility that during the course of treatment, NALM6 cells may localise, reversibly, to niches that are less accessible to the drug. This notion is reinforced with the trial using the humanized versions of α-LGR5-ADC—while treatment over four days effectively targeted the NALM6 tumour, tumour growth was eventually restored. In this instance, the bone marrow was one of the compartments examined that contained substantial levels of NALM6 cells that were not eliminated by the low dose targeting regime.

[0546] Importantly, no detectable off-target toxicities of the α-LGR5-ADC was observed in the treated mice paving the way for future in vivo trials with increased treatment doses of α-LGR5-ADC that may provide increased efficacy in targeting potential tumour cell niches.

[0547] The present inventors have developed and validated novel antibodies and antibody fragments against human and cynoLGR5. The antibodies are highly specific, with high affinity and are taken up rapidly by LGR5 expressing cancer cells. They represent excellent research tools but also show great efficacy when used as ADCs in a model of ALL in vivo and so represent therapeutic tools which could be used to treat cancer, particularly cancers in which LGR5 is overexpressed. For example, the present inventors have designed and developed a chimeric antigen receptor (CAR)

and bispecific T-cell engager (BiTE) using the antibodies of the present invention which could be used in the treatment of cancer, for example.

REFERENCES

- [0548] M. Rossmann, S. J. Greive, T. Moschetti, M. Dinan, M. Hyvönen, Development of a multipurpose scaffold for the display of peptide loops. *Protein Eng. Des. Sel.* 30, 419-430 (2017).
- [0549] S. J. Walsh, et al., A general approach for the site-selective modification of native proteins, enabling the

generation of stable and functional antibody-drug conjugates. *Chem. Sci.* 10, 694-700 (2019).

- [0550] J. D. Bargh, et al., Sulfatase-cleavable linkers for antibody-drug conjugates. *Chem. Sci.* 11, 2375-2380 (2020).

- [0551] W. C. Peng, et al., Structure of Stem Cell Growth Factor R-spondin 1 in Complex with the Ectodomain of Its Receptor LGR5. *Cell Rep.* 3, 1885-1892 (2013).

- [0552] M. De La Roche, A. E. K. Ibrahim, J. Miesczanek, M. Bienz, LEF1 and B9L shield b-catenin from inactivation by axin, desensitizing colorectal cancer cells to tankyrase inhibitors. *Cancer Res.* 74, 1495-1505 (2014).

SEQUENCE LISTING

```

Sequence total quantity: 224
SEQ ID NO: 1      moltype = AA length = 907
FEATURE          Location/Qualifiers
source           1..907
mol_type = protein
organism = Homo sapiens
SEQUENCE: 1
MTDSRLGVLL SLPVLLQLAT GGSSPRSGVL LRGCPTHCHC EPDGRMLLRV DCSDLGLSEL 60
PSNLSVFTSY LDLSMNNISQ LLNPPLPSLR FLEELRLAGN ALTYIPKGAF TGLYSLKVL 120
LQNNQLRHVP TEALQNLRSI QSLRLDANHI SYVPPSCFSG LHSLRHWLW DNALTEIPVQ 180
AFRSLSLAQI MTLALNKHII IPDYAFCGMLS SLVVLHLHNN RIHSLGKKCF DGLHSLETLD 240
LNYYNNLDEFP TAIRTLSNLK ELGFPHSNNI RIPEKAFVGNN PSLTITHFYD NPPIQFVGRSA 300
FQHLPELRTL TLNGASQITE FPDLTGTA NL ESLTLLTGAQI SSLPQTCVCNQ LPNLQVLDLS 360
YNLLEDLPSF SVCOKLQKID LRHNEIYEIK VDTFQQLLSSL RSLNLAWNKI AIIPHNAFST 420
LPSLKLDSL SNLSSSPTI GLHGLTHKL TGNHALQSLI SSENFPELK V IEMPYAYQCC 480
AFGVCEENAYK ISNQWNKGDN SSMDDLHKKD AGMFQAQDEF DLEDFLLDFE EDLKALHSVQ 540
CSPSPGPFPKP CEHLLDGWL RIGWVTIAVL ALTCNALVTS TVFRSPLYIS PIKLLIGVIA 600
AVNMLTVGSS AVLAVGDRAFT FGSPARHGAW WENGVGCHVI GFLSIFASES SVFLLTIAAL 660
ERGFSVKYSA KFETKAPFSS LKVIIILCAL LALTMAAVPL LGGSKYGASP LCLPLPFGEPE 720
STMGYMVALI LLNSLCFLMM TIAYTKLYCN LDKGDLENLI DCMSVKHIAL LLFTNCILNC 780
PVAFLSFSSL INLTFISPEV IKFILLVVVP LPACLNPLLY ILFNPHFKED LVSLRKQTYV 840
WTRSKHPHSLM SINSDDVEKQ SCDSIQALVT FTSSSITYDL PPSSVPSPAY PVTESCHLSS 900
VAFVPC          907

SEQ ID NO: 2      moltype = AA length = 5
FEATURE          Location/Qualifiers
REGION          1..5
source           note = VH CDR1
                1..5
mol_type = protein
organism = synthetic construct
SEQUENCE: 2
SYWMQ          5

SEQ ID NO: 3      moltype = AA length = 17
FEATURE          Location/Qualifiers
REGION          1..17
source           note = VH CDR2
                1..17
mol_type = protein
organism = synthetic construct
SEQUENCE: 3
EIDPSDYYTN YNQKFKG          17

SEQ ID NO: 4      moltype = AA length = 8
FEATURE          Location/Qualifiers
REGION          1..8
source           note = VH CDR3
                1..8
mol_type = protein
organism = synthetic construct
SEQUENCE: 4
SLSGYVDY          8

SEQ ID NO: 5      moltype = AA length = 11
FEATURE          Location/Qualifiers
REGION          1..11
source           note = VL CDR1
                1..11

```

-continued

SEQUENCE: 5 RASQDIRNRL N	mol_type = protein organism = synthetic construct	
		11
SEQ ID NO: 6 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = VL CDR2	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 6 YRSRLQS		7
SEQ ID NO: 7 FEATURE REGION	moltype = AA length = 9 Location/Qualifiers 1..9 note = VL CDR3	
source	1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 7 QQGNTLPPT		9
SEQ ID NO: 8 FEATURE REGION	moltype = AA length = 5 Location/Qualifiers 1..5 note = VH CDR1	
source	1..5 mol_type = protein organism = synthetic construct	
SEQUENCE: 8 NYWMQ		5
SEQ ID NO: 9 FEATURE REGION	moltype = AA length = 17 Location/Qualifiers 1..17 note = VH CDR2	
source	1..17 mol_type = protein organism = synthetic construct	
SEQUENCE: 9 EIDPSDSYTN YNQKFKG		17
SEQ ID NO: 10 FEATURE REGION	moltype = AA length = 8 Location/Qualifiers 1..8 note = VH CDR3	
source	1..8 mol_type = protein organism = synthetic construct	
SEQUENCE: 10 SLSGYVVDY		8
SEQ ID NO: 11 FEATURE REGION	moltype = AA length = 11 Location/Qualifiers 1..11 note = VL CDR1	
source	1..11 mol_type = protein organism = synthetic construct	
SEQUENCE: 11 RASQDISNRL N		11
SEQ ID NO: 12 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = VL CDR2	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 12 YRSRLHS		7
SEQ ID NO: 13	moltype = AA length = 9	

-continued

FEATURE	Location/Qualifiers
REGION	1..9
source	note = VL CDR3
	1..9
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 13	
QQGNNSLPPT	9
SEQ ID NO: 14	moltype = AA length = 5
FEATURE	Location/Qualifiers
REGION	1..5
source	note = VH CDR1
	1..5
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 14	
SYWMQ	5
SEQ ID NO: 15	moltype = AA length = 17
FEATURE	Location/Qualifiers
REGION	1..17
source	note = VH CDR2
	1..17
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 15	
EIDPSDSYSN YNQKFKG	17
SEQ ID NO: 16	moltype = AA length = 8
FEATURE	Location/Qualifiers
REGION	1..8
source	note = VH CDR3
	1..8
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 16	
SLSGYVVDY	8
SEQ ID NO: 17	moltype = AA length = 11
FEATURE	Location/Qualifiers
REGION	1..11
source	note = VL CDR1
	1..11
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 17	
RASQDISNRL N	11
SEQ ID NO: 18	moltype = AA length = 7
FEATURE	Location/Qualifiers
REGION	1..7
source	note = VL CDR2
	1..7
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 18	
YRSRLQS	7
SEQ ID NO: 19	moltype = AA length = 9
FEATURE	Location/Qualifiers
REGION	1..9
source	note = VL CDR3
	1..9
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 19	
QQGNTLPPT	9
SEQ ID NO: 20	moltype = AA length = 5
FEATURE	Location/Qualifiers
REGION	1..5
source	note = VH CDR1
	1..5
	mol_type = protein
	organism = synthetic construct

-continued

SEQUENCE: 20		
DYWMQ		5
SEQ ID NO: 21	moltype = AA length = 17	
FEATURE	Location/Qualifiers	
REGION	1..17	
source	note = VH CDR2	
	1..17	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 21		
EIDPSDSYTN YNQKFQG		17
SEQ ID NO: 22	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = VH CDR3	
	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 22		
SLSGSVDY		8
SEQ ID NO: 23	moltype = AA length = 11	
FEATURE	Location/Qualifiers	
REGION	1..11	
source	note = VL CDR1	
	1..11	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 23		
RASQDISNRL N		11
SEQ ID NO: 24	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = VL CDR2	
	1..7	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 24		
YRSRLQS		7
SEQ ID NO: 25	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = VL CDR3	
	1..9	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 25		
QQGNTLPPT		9
SEQ ID NO: 26	moltype = AA length = 5	
FEATURE	Location/Qualifiers	
REGION	1..5	
source	note = VH CDR1	
	1..5	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 26		
DYYMN		5
SEQ ID NO: 27	moltype = AA length = 17	
FEATURE	Location/Qualifiers	
REGION	1..17	
source	note = VH CDR2	
	1..17	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 27		
DINPNNGGTI YNQKFKG		17
SEQ ID NO: 28	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
REGION	1..6	

-continued

source	note = VH CDR3 1..6 mol_type = protein organism = synthetic construct	
SEQUENCE: 28		6
GYLFDFY		
SEQ ID NO: 29	moltype = AA length = 17 Location/Qualifiers	
FEATURE	1..17	
REGION	note = VL CDR1	
source	1..17 mol_type = protein organism = synthetic construct	
SEQUENCE: 29		
KSSQSQLNNS NQKNYLA		17
SEQ ID NO: 30	moltype = AA length = 7 Location/Qualifiers	
FEATURE	1..7	
REGION	note = VL CDR2	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 30		
FASTRES		7
SEQ ID NO: 31	moltype = AA length = 9 Location/Qualifiers	
FEATURE	1..9	
REGION	note = VL CDR3	
source	1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 31		
QQHYSTPLT		9
SEQ ID NO: 32	moltype = AA length = 5 Location/Qualifiers	
FEATURE	1..5	
REGION	note = VH CDR1	
source	1..5 mol_type = protein organism = synthetic construct	
SEQUENCE: 32		
NYWMQ		5
SEQ ID NO: 33	moltype = AA length = 17 Location/Qualifiers	
FEATURE	1..17	
REGION	note = VH CDR2	
source	1..17 mol_type = protein organism = synthetic construct	
SEQUENCE: 33		
EIDPDSYTN YNQKFQG		17
SEQ ID NO: 34	moltype = AA length = 8 Location/Qualifiers	
FEATURE	1..8	
REGION	note = VH CDR3	
source	1..8 mol_type = protein organism = synthetic construct	
SEQUENCE: 34		
SLSGYVVDY		8
SEQ ID NO: 35	moltype = AA length = 11 Location/Qualifiers	
FEATURE	1..11	
REGION	note = VL CDR1	
source	1..11 mol_type = protein organism = synthetic construct	
SEQUENCE: 35		
RASQDISNRL N		11

-continued

SEQ ID NO: 36	moltype = AA length = 7
FEATURE	Location/Qualifiers
REGION	1..7
source	note = VL CDR2
	1..7
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 36	
YRSRLHS	7
SEQ ID NO: 37	moltype = AA length = 9
FEATURE	Location/Qualifiers
REGION	1..9
source	note = VL CDR3
	1..9
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 37	
QQGNNSLPPT	9
SEQ ID NO: 38	moltype = AA length = 5
FEATURE	Location/Qualifiers
REGION	1..5
source	note = VH CDR1
	1..5
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 38	
NYWMQ	5
SEQ ID NO: 39	moltype = AA length = 17
FEATURE	Location/Qualifiers
REGION	1..17
source	note = VH CDR2
	1..17
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 39	
EIDPSDSYTN YNQKFQG	17
SEQ ID NO: 40	moltype = AA length = 8
FEATURE	Location/Qualifiers
REGION	1..8
source	note = VH CDR3
	1..8
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 40	
SLSGYVVDY	8
SEQ ID NO: 41	moltype = AA length = 11
FEATURE	Location/Qualifiers
REGION	1..11
source	note = VL CDR1
	1..11
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 41	
RASQDISNRL N	11
SEQ ID NO: 42	moltype = AA length = 7
FEATURE	Location/Qualifiers
REGION	1..7
source	note = VL CDR2
	1..7
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 42	
YRSRLHS	7
SEQ ID NO: 43	moltype = AA length = 9
FEATURE	Location/Qualifiers
REGION	1..9
source	note = VL CDR3
	1..9

-continued

SEQUENCE: 43 QQGNNSLPPT	mol_type = protein organism = synthetic construct	
		9
SEQ ID NO: 44 FEATURE REGION	moltype = AA length = 5 Location/Qualifiers 1..5 note = VH CDR1	
source	1..5 mol_type = protein organism = synthetic construct	
SEQUENCE: 44 NYWMQ		5
SEQ ID NO: 45 FEATURE REGION	moltype = AA length = 17 Location/Qualifiers 1..17 note = VH CDR2	
source	1..17 mol_type = protein organism = synthetic construct	
SEQUENCE: 45 EIDPSDSYTN YNQKFQG		17
SEQ ID NO: 46 FEATURE REGION	moltype = AA length = 8 Location/Qualifiers 1..8 note = VH CDR3	
source	1..8 mol_type = protein organism = synthetic construct	
SEQUENCE: 46 SLSGYVVDY		8
SEQ ID NO: 47 FEATURE REGION	moltype = AA length = 11 Location/Qualifiers 1..11 note = VL CDR1	
source	1..11 mol_type = protein organism = synthetic construct	
SEQUENCE: 47 RASQDISNRL N		11
SEQ ID NO: 48 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7 note = VL CDR2	
source	1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 48 YRSRLHS		7
SEQ ID NO: 49 FEATURE REGION	moltype = AA length = 9 Location/Qualifiers 1..9 note = VL CDR3	
source	1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 49 QQGNNSLPPT		9
SEQ ID NO: 50 FEATURE REGION	moltype = AA length = 5 Location/Qualifiers 1..5 note = VH CDR1	
source	1..5 mol_type = protein organism = synthetic construct	
SEQUENCE: 50 NYWMQ		5
SEQ ID NO: 51	moltype = AA length = 17	

-continued

FEATURE	Location/Qualifiers
REGION	1..17
source	note = VH CDR2
	1..17
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 51	
EIDPSDSYTN YNQKFQG	17
SEQ ID NO: 52	moltype = AA length = 8
FEATURE	Location/Qualifiers
REGION	1..8
source	note = VH CDR3
	1..8
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 52	
SLSGYVVDY	8
SEQ ID NO: 53	moltype = AA length = 11
FEATURE	Location/Qualifiers
REGION	1..11
source	note = VL CDR1
	1..11
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 53	
RASQDISNRL N	11
SEQ ID NO: 54	moltype = AA length = 7
FEATURE	Location/Qualifiers
REGION	1..7
source	note = VL CDR2
	1..7
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 54	
YRSRRHT	7
SEQ ID NO: 55	moltype = AA length = 9
FEATURE	Location/Qualifiers
REGION	1..9
source	note = VL CDR3
	1..9
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 55	
QQGNNSLPPT	9
SEQ ID NO: 56	moltype = AA length = 5
FEATURE	Location/Qualifiers
REGION	1..5
source	note = VH CDR1
	1..5
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 56	
NYWMQ	5
SEQ ID NO: 57	moltype = AA length = 17
FEATURE	Location/Qualifiers
REGION	1..17
source	note = VH CDR2
	1..17
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 57	
EIDPSDSYTN YNQGFTG	17
SEQ ID NO: 58	moltype = AA length = 8
FEATURE	Location/Qualifiers
REGION	1..8
source	note = VH CDR3
	1..8
	mol_type = protein
	organism = synthetic construct

-continued

SEQUENCE: 58 SLSGYVVDY		8
SEQ ID NO: 59 FEATURE REGION source	moltype = AA length = 11 Location/Qualifiers 1..11 note = VL CDR1 1..11 mol_type = protein organism = synthetic construct	
SEQUENCE: 59 RASQDISNRL N		11
SEQ ID NO: 60 FEATURE REGION source	moltype = AA length = 7 Location/Qualifiers 1..7 note = VL CDR2 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 60 YRSRLHS		7
SEQ ID NO: 61 FEATURE REGION source	moltype = AA length = 9 Location/Qualifiers 1..9 note = VL CDR3 1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 61 QQGNNSLPPT		9
SEQ ID NO: 62 FEATURE REGION source	moltype = AA length = 5 Location/Qualifiers 1..5 note = VH CDR1 1..5 mol_type = protein organism = synthetic construct	
SEQUENCE: 62 NYWMQ		5
SEQ ID NO: 63 FEATURE REGION source	moltype = AA length = 17 Location/Qualifiers 1..17 note = VH CDR2 1..17 mol_type = protein organism = synthetic construct	
SEQUENCE: 63 EIDPSDSYTN YNQGFTG		17
SEQ ID NO: 64 FEATURE REGION source	moltype = AA length = 8 Location/Qualifiers 1..8 note = VH CDR3 1..8 mol_type = protein organism = synthetic construct	
SEQUENCE: 64 SLSGYVVDY		8
SEQ ID NO: 65 FEATURE REGION source	moltype = AA length = 11 Location/Qualifiers 1..11 note = VL CDR1 1..11 mol_type = protein organism = synthetic construct	
SEQUENCE: 65 RASQDISNRL N		11
SEQ ID NO: 66 FEATURE REGION	moltype = AA length = 7 Location/Qualifiers 1..7	

-continued

source	note = VL CDR2 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 66	YRSRLHS	7
SEQ ID NO: 67	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = VL CDR3 1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 67	QQQNSLPPPT	9
SEQ ID NO: 68	moltype = AA length = 5	
FEATURE	Location/Qualifiers	
REGION	1..5	
source	note = VH CDR1 1..5 mol_type = protein organism = synthetic construct	
SEQUENCE: 68	NYWMQ	5
SEQ ID NO: 69	moltype = AA length = 17	
FEATURE	Location/Qualifiers	
REGION	1..17	
source	note = VH CDR2 1..17 mol_type = protein organism = synthetic construct	
SEQUENCE: 69	EIDPSDSYTN YNQGFTG	17
SEQ ID NO: 70	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
REGION	1..8	
source	note = VH CDR3 1..8 mol_type = protein organism = synthetic construct	
SEQUENCE: 70	SLSGYVVDY	8
SEQ ID NO: 71	moltype = AA length = 11	
FEATURE	Location/Qualifiers	
REGION	1..11	
source	note = VL CDR1 1..11 mol_type = protein organism = synthetic construct	
SEQUENCE: 71	RASQDISNRL N	11
SEQ ID NO: 72	moltype = AA length = 7	
FEATURE	Location/Qualifiers	
REGION	1..7	
source	note = VL CDR2 1..7 mol_type = protein organism = synthetic construct	
SEQUENCE: 72	YRSRRHT	7
SEQ ID NO: 73	moltype = AA length = 9	
FEATURE	Location/Qualifiers	
REGION	1..9	
source	note = VL CDR3 1..9 mol_type = protein organism = synthetic construct	
SEQUENCE: 73	QQQNSLPPPT	9

-continued

SEQ ID NO: 74	moltype = AA length = 5
FEATURE	Location/Qualifiers
REGION	1..5
source	note = VH CDR1
	1..5
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 74	
NWMMN	5
SEQ ID NO: 75	moltype = AA length = 17
FEATURE	Location/Qualifiers
REGION	1..17
source	note = VH CDR2
	1..17
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 75	
EIDPSDSYTN YNQGFTG	17
SEQ ID NO: 76	moltype = AA length = 8
FEATURE	Location/Qualifiers
REGION	1..8
source	note = VH CDR3
	1..8
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 76	
SLSGYVVDY	8
SEQ ID NO: 77	moltype = AA length = 11
FEATURE	Location/Qualifiers
REGION	1..11
source	note = VL CDR1
	1..11
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 77	
RASQDISNRL N	11
SEQ ID NO: 78	moltype = AA length = 7
FEATURE	Location/Qualifiers
REGION	1..7
source	note = VL CDR2
	1..7
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 78	
YRSRRHT	7
SEQ ID NO: 79	moltype = AA length = 9
FEATURE	Location/Qualifiers
REGION	1..9
source	note = VL CDR3
	1..9
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 79	
QQGNNSLPPT	9
SEQ ID NO: 80	moltype = AA length = 117
FEATURE	Location/Qualifiers
REGION	1..117
source	note = VH
	1..117
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 80	
QVQLQQPGAE LVKPGASVKL SCKASGYTFT SYWMQWVKQR PGQGLEWIGE IDPSDYYTNY	60
NQKFKKGATL TVDTSSSTAY MQLSSLTSED SAVYYCARSL SGYVDYWGQG TTLTVSS	117
SEQ ID NO: 81	moltype = AA length = 107
FEATURE	Location/Qualifiers
REGION	1..107
	note = VL

-continued

```

source          1..107
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 81
DIQMTQSTSS LSASLGDRV T ISCRASQDIR NRLNWYQQKP DGTVKLLISY RSRLQSGVPS 60
RFSGSGSGTE YSLTISNLEQ EDIATYFCQQ GNTLPPTFGG GTKLEVR             107

SEQ ID NO: 82      moltype = AA  length = 117
FEATURE           Location/Qualifiers
REGION            1..117
note = VL
source             1..117
mol_type = protein
organism = synthetic construct
SEQUENCE: 82
QVOLQQPGAE LVKPGASVKL SCKASGYTFT NYWMQWVKQR PGQGLEWIGE IDPSDSYTNY 60
NQKFKKGATL TVDTSSSTAY MQLSSLTSED SAVYYCARSL SGYVDYWGQG TTLTVSS     117

SEQ ID NO: 83      moltype = AA  length = 107
FEATURE           Location/Qualifiers
REGION            1..107
note = VL
source             1..107
mol_type = protein
organism = synthetic construct
SEQUENCE: 83
DIQMTQTSS LSASLGDRV T ISCRASQDIS NRLNWYQQKP DGTVKLLISY RSRLHSGVPS 60
RFSGSGSGTD YSLTISNLEQ EDIATYFCQQ GNSLPPTFGG GTKLEVR             107

SEQ ID NO: 84      moltype = AA  length = 117
FEATURE           Location/Qualifiers
REGION            1..117
note = VH
source             1..117
mol_type = protein
organism = synthetic construct
SEQUENCE: 84
QVQLQQPGAE LVKPGASVKL SCKASGYTFT SYWMQWVKQR PGQGLEWIGE IDPSDSYSNY 60
NQKFKKGATL TVDTSSSTAY MQLSSLTSED SAVYYCARSL SGYVDYWGQG TTLTVSS     117

SEQ ID NO: 85      moltype = AA  length = 107
FEATURE           Location/Qualifiers
REGION            1..107
note = VL
source             1..107
mol_type = protein
organism = synthetic construct
SEQUENCE: 85
DIQMTQTSS LSASLGDRV T ISCRASQDIS NRLNWYQQKP DGTVKLLISY RSRLQSGVPS 60
RFSGSGSGTD YSLTISNLEE EDIATYFCQQ GNTLPPTFGG GTKLEVR             107

SEQ ID NO: 86      moltype = AA  length = 117
FEATURE           Location/Qualifiers
REGION            1..117
note = VH
source             1..117
mol_type = protein
organism = synthetic construct
SEQUENCE: 86
QVQLQQPGAE LVKPGASVKL SCKASGYTFT DYWMQWVKQR PGQGLEWIGE IDPSDSYTNY 60
NQKFKQKGATL TVDTSSSTAY IQLSSLTSDD SAVYYCARSL SGYVDYWGQG TTLTVSS     117

SEQ ID NO: 87      moltype = AA  length = 107
FEATURE           Location/Qualifiers
REGION            1..107
note = VL
source             1..107
mol_type = protein
organism = synthetic construct
SEQUENCE: 87
DIQMTQTSS LSASLGDRV T ISCRASQDIS NRLNWYQQKP DGTVKLLISY RSRLQSGVPS 60
RFSGSGSGTD YSLTITNLEQ EDIATYFCQQ GNTLPPTFGG GTKLEVR             107

SEQ ID NO: 88      moltype = AA  length = 115
FEATURE           Location/Qualifiers
REGION            1..115

```

-continued

```

source          note = VH
               1..115
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 88
EVQLQQSGPE LVKPGASVKI SCKASGYTFT DYYMMNWVKQS HGKSLEWIGD INPNNGGTIY 60
NQKFQGRVTL TVDKSSSTAY MELRSLTSED SAVYYCASGY LFDYWGPGTT LTVSS      115

SEQ ID NO: 89      moltype = AA length = 113
FEATURE          Location/Qualifiers
REGION           1..113
note = VL
source          1..113
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 89
DIVMTQSPSS LAMSVGQKV SCKASGYTFT NSSNQKNYLA WYQQKPGQSP KLLVYFASTR 60
ESGVVPDRFIG SGSGTDFTLT ISSVQAEDLA AYFCQQHYST PLTFGAGTKL ELK      113

SEQ ID NO: 90      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION           1..117
note = VH
source          1..117
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 90
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQKFQGRVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTVTVSS      117

SEQ ID NO: 91      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = VL
source          1..107
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 91
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NRLNWYQQKP GKAVKLLISY RSRLHSGVPS 60
RFGSGSGSTD YTTLISSLQP EDFATYFCQQ GNSLPPTFGG GTKLEIK      107

SEQ ID NO: 92      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION           1..117
note = VH
source          1..117
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 92
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQKFQGRVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTVTVSS      117

SEQ ID NO: 93      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = VL
source          1..107
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 93
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NRLNWYQQKP GKAVKLLISY RSRLHSGVPS 60
RFGSGSGSTD YTTLISSLQP EDFATYYCQQ GNSLPPTFGG GTKLEIK      107

SEQ ID NO: 94      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION           1..117
note = VH
source          1..117
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 94
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQKFQGRVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTVTVSS      117

SEQ ID NO: 95      moltype = AA length = 107
FEATURE          Location/Qualifiers

```

-continued

```

REGION          1..107
source          note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 95
D1VMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRLHSGVPA 60
RFSGSGSGTD YTTLISSLQ  EDFAVYFCQQ GNSLPPTFGG GTKLEIK           107

SEQ ID NO: 96      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION          1..117
source          note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 96
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQKFTGRFVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTGTVSS     117

SEQ ID NO: 97      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source          note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 97
E1VMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRRHTGIPA 60
RFSGSGSGTD YTTLISSLQ  EDFAVYYCQQ GNSLPPTFGG GTKLEIK           107

SEQ ID NO: 98      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION          1..117
source          note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 98
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQGFTGRFVTL SVDTSTVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTGTVSS     117

SEQ ID NO: 99      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source          note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 99
D1QMTQSPSS LSASVGDRVT ITCRASQDIS NRLNWYQQKP GKAVKLLISY RSRLHSGVPS 60
RFSGSGSGTD YTTLISSLQ  EDFATYFCQQ GNSLPPTFGG GTKLEIK           107

SEQ ID NO: 100     moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION          1..117
source          note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 100
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQGFTGRFVTL SVDTSTVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTGTVSS     117

SEQ ID NO: 101     moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source          note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 101
D1QMTQSPSS LSASVGDRVT ITCRASQDIS NRLNWYQQKP GKAVKLLISY RSRLHSGVPS 60
RFSGSGSGTD YTTLISSLQ  EDFATYYCQQ GNSLPPTFGG GTKLEIK           107

SEQ ID NO: 102     moltype = AA length = 117

```

-continued

```

FEATURE          Location/Qualifiers
REGION          1..117
source           note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 102
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQGFTGRFVL SVDTSVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTDTVSS    117

SEQ ID NO: 103      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source           note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 103
DIVMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRLHSGVPA 60
RFSGSGSGTD YTTLISSLPE EDFAVYFCQQ GNSLPPTFGG GTKLEIK             107

SEQ ID NO: 104      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION          1..117
source           note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 104
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYWMNWRQQA PGQGLEWMGE IDPSDSYTNY 60
NQGFTGRFVF SVDTSVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTDTVSS    117

SEQ ID NO: 105      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source           note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 105
EIVMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRRHTGIPA 60
RFSGSGSGTD YTTLISSLPE EDFAVYYCQQ GNSLPPTFGG GTKLEIK             107

SEQ ID NO: 106      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION          1..117
source           note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 106
QVQLQQGAE LVKPGASVKL SCKASGYTFT SYWMQWVKQR PGQGLEWIGE IDPSDYYTNY 60
NQKFKKGATL TVDTSSSTAY MQLSSLTSED SAVYYCARSL SGYVDYWGQG TTLTVSS    117

SEQ ID NO: 107      moltype = AA length = 324
FEATURE          Location/Qualifiers
REGION          1..324
source           note = CH
                1..324
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 107
AKTTPPSVYP LAPGSAAQTN SMVTLGCLVK GYFPEPVTVT WNSGSLSSGV HTFPAVLQSD 60
LYTLSSSVT PSSTWPSQTV TCNVAPASS TKVDKKIVPR DCGCKPCICT VPEVSSVFIF 120
PPPKDKVLTI TLTPKVCVV VDISKDDPEV QFSWFVDDVE VHATAQTKPRE EQINSTFRSV 180
SELPIMHQDW LNGKEFKCRV NSAAFPAPIE KTISKTKGRP KAPQVYTIIPP PKEQMAKDKV 240
SLTCMITNFF PEDITVEWQW NGQPAENYKN TQPIMD TDGS YFVYSKLNQ KSNWEAGNTF 300
TCSVLHEGLH NHHTEKSLSH SPGK                                         324

SEQ ID NO: 108      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source           note = VL
                1..107
                mol_type = protein
                organism = synthetic construct

```

-continued

```

SEQUENCE: 108
DIQMTQSTSS LSASLGDRV T INCRASQDIR NRLNWYQQKP DGTVKLLISY RSRLQSGVPS 60
RFSGSGSGTE YSLTISNLEQ EDIATYFCQQ GNTLPPTFGG GTKLEVR 107

SEQ ID NO: 109      moltype = AA length = 107
FEATURE           Location/Qualifiers
REGION            1..107
note = CL
source             1..107
mol_type = protein
organism = synthetic construct

SEQUENCE: 109
RADAAPTSI FPPSSEQLTS GGAVVCFLN NFYPKDINVK WKIDGSERQN GVLNSWTQDQ 60
SKDSTYSMSS TLTLTKDEYE RHNSYTCEAT HKTSTSPIVK SFNRNEC 107

SEQ ID NO: 110      moltype = AA length = 117
FEATURE           Location/Qualifiers
REGION            1..117
note = VH
source             1..117
mol_type = protein
organism = synthetic construct

SEQUENCE: 110
QVQLQQPGAE LVKPGASVKL SCKASGYTFT NYWMQWVQKR PGQGLEWIGE IDPSDSYTNY 60
NQKFKGKATL TVDTSSSTAY MQLSSLTSED SAVYYCARSL SGYVDYWGQG TTLTVSS 117

SEQ ID NO: 111      moltype = AA length = 336
FEATURE           Location/Qualifiers
REGION            1..336
note = CH
source             1..336
mol_type = protein
organism = synthetic construct

SEQUENCE: 111
AKTPPPSVY LAPGCGDTTG SSVTLGCLVK GYFPESVTW WNSGSLSSSV HTFPALLQSG 60
LYPMSSSVTV PSSTWPSQTV TCSVAHPASS TTVDKKLEPS GPISTINPCP PCKECHKCPA 120
PNLEGGPSVF IFPPNIKDVL MISLTPKVTC VVVDVSEDDP DVRISWFVN VEVHTAQQT 180
HREDYNSTIR VVSALPIQHQ DWMSGKEFKC KVNWKDLPSP IERTISKIKG LVRAPQVYL 240
PPPAEQLSRK DVSLTCLVVG FNPGDISVWE TSNGHTEENY KDTAPVLDSD GSYFIYSKLD 300
IKTSKWEKTD SFSCNVRHEG LKNYYLKKTI SRSPKG 336

SEQ ID NO: 112      moltype = AA length = 107
FEATURE           Location/Qualifiers
REGION            1..107
note = VL
source             1..107
mol_type = protein
organism = synthetic construct

SEQUENCE: 112
DIQMTQTTSS LSASLGDRV T ISCRASQDIS NRLNWYQQKP DGTVKLLISY RSRLHSGVPS 60
RFSGSGSGTD YSLTISNLEQ EDIATYFCQQ GNSLPPTFGG GTKLEVR 107

SEQ ID NO: 113      moltype = AA length = 107
FEATURE           Location/Qualifiers
REGION            1..107
note = CL
source             1..107
mol_type = protein
organism = synthetic construct

SEQUENCE: 113
RADAAPTSI FPPSSEQLTS GGAVVCFLN NFYPKDINVK WKIDGSERQN GVLNSWTQDQ 60
SKDSTYSMSS TLTLTKDEYE RHNSYTCEAT HKTSTSPIVK SFNRNEC 107

SEQ ID NO: 114      moltype = AA length = 117
FEATURE           Location/Qualifiers
REGION            1..117
note = VH
source             1..117
mol_type = protein
organism = synthetic construct

SEQUENCE: 114
QVQLQQPGAE LVKPGASVKL SCKASGYTFT SYWMQWVQKR PGQGLEWIGE IDPSDSYSNY 60
NQKFKGKATL TVDTSSSTAY MQLSSLTSED SAVYYCARSL SGYVDYWGQG TTLTVSS 117

SEQ ID NO: 115      moltype = AA length = 324
FEATURE           Location/Qualifiers

```

-continued

```

REGION          1..324
source          note = CH
                1..324
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 115
AKTTPPSVYP LAPGSAAQTN SMVTLGCLVK GYFPEPVTVT WNSGSLSSGV HTFPAVLQSD 60
LYTLSSSVTV PSSTWPSQTV TCNVAHPASS TKVDKKIVPR DCGCKPCICT VPEVSSVFIF 120
PPPKPKDVLTI TLTPKVTCVV VDISKDDPEV QFSWFVDDVE VHTAQTKPRE EQINSTFRSV 180
SELPIMHQDW LNGKEPKCRV NSAAFPAPIE KTISKTKGRP KAPQVYTIPP PKEQMAKDKV 240
SITCMITNFF PEDITVEWQW NGQPAENYKN TQPIMDTDGs YFVYSKLNVQ KSNWEAGNTF 300
TCCSVHLHEGLH NHHTEKSLSH SPGK 324

SEQ ID NO: 116      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
source            note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 116
DIQMTQTSS LSASLGDRVt ISCRASQDIS NRNLNWYQQKP DGTVKLLISy RSRLQSGVPS 60
RFSGSGSGTD YSLTISNLEE EDIATYFCQQ GNTLPPTFGG GTKLEVR 107

SEQ ID NO: 117      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
source            note = CL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 117
RADAAPTVSI FPPSSEQLTS GGASVVCFLN NFYPKDINVK WKIDGSERQN GVLSNSWTQDQD 60
SKDSTYSMSS TLTLTKDEYE RHNSYTCEAT HKTSTSPIVK SFNRNEC 107

SEQ ID NO: 118      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION           1..117
source            note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 118
QVQLQQPGAE LVKPGASVKL SCKASGYTFT DYWMQWVKQR PGQGLEWIGE IDPSDSYTNY 60
NQKFQKGATL TVDTSSSTAY IQLSSLTSDD SAVYYCARSL SGSVDYWGQG TTLTVSS 117

SEQ ID NO: 119      moltype = AA length = 336
FEATURE          Location/Qualifiers
REGION           1..336
source            note = CH
                1..336
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 119
AKTTPPSVYP LAPGCGETTG SSVTLGCLVK GYFPESVTVT WNSGSLSSSG HTFPALLQSG 60
LYTMSSSVTV PSSTWPSQTV TCSVAHPASS TTVDKKLEPS GPINSTINPCP PCKECHKCPA 120
PNLEGGPSVF IFPPNIKDVL MISLTPKVTC VVVDVSEDDP DVRISWFVNn VEVHTAQQT 180
HREDYNSTIR VVSALPIQHQ DWMSGKEFKC KVNNKDLPLP S IERTISKIKG LVRAPQVYIL 240
PPPAEQLSRK DVSLTCLVVG FNPGDISVW TSNGHTEENY KDTAPVLDSD GSYFIYSKLD 300
IKTSKWEKTD SFSCCNVRHEG LKNYYLKKTI SRSPGK 336

SEQ ID NO: 120      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
source            note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 120
DIQMTQTSS LSASLGDRVt ISCRASQDIS NRNLNWYQQKP DGTVKLLISy RSRLQSGVPS 60
RFSGSGSGTD YSLTITNLEQ EDIATYFCQQ GNTLPPTFGG GTKLEVR 107

SEQ ID NO: 121      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = CL

```

-continued

```

source          1..107
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 121
RADAAPTVSI FPPSSEQLTS GGASVVCFLN NFYPKDINVK WKIDGSERQN GVLNSWTQDQ 60
SKDSTYSMSS TLTLTKDEYE RHNSYTCEAT HKTSTSPIVK SFNRNEC                107

SEQ ID NO: 122      moltype = AA  length = 115
FEATURE           Location/Qualifiers
REGION            1..115
note              VH
source             1..115
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 122
EVOLQQSGPE LVKPGASVKI SCKASGYTFT DYMMNWKQHS HGKSLEWIGD INPNNGGTIY 60
NQKFKKGATL TVDKSSSTAY MELRSLTSED SAVYYCASGY LFDYWGPGLT LTVSS        115

SEQ ID NO: 123      moltype = AA  length = 335
FEATURE           Location/Qualifiers
REGION            1..335
note              CH
source             1..335
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 123
AKTTAPSVYP LAPVCGGTG SSVTLGCLVK GYFPEPVTLT WNSGSLSSGV HTFPALLQSG 60
LYTLSSSVTV TSNTWPSQTI TCNVAHPASS TKVDKKIEPR VPITQNPCCP LKECPPCAAP 120
DLLGGPSVFI PPPKIKDVLM ISLSPMVTCV VVDVSEDDP VQISWFVNIN EVHTAQQTQH 180
REDYNSTLRV VSALPIQHQD WMSGKEFKCK VNRRALPSPI EKTISKPRGP VRAPQVYVLP 240
PPAEEMTKKE FSLLTMITGF LPAAEIAWDT SNGRTEQNYK NTATVLDSDG SYFMYSKLRV 300
QKSTWERGSL FACSVVHEGL HNHLLTTKTS RSLGK                         335

SEQ ID NO: 124      moltype = AA  length = 113
FEATURE           Location/Qualifiers
REGION            1..113
note              VL
source             1..113
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 124
DIVMTQSPSS LAMSVGQKVT MSCKSSQSLL NSSNQKNYLW WYQQKPGQSP KLLVYFASTR 60
ESGVVPDRFIG SGSGTDFTLT ISSVQAEDLA AYPCQQHYST PLTFGAGTKL ELK        113

SEQ ID NO: 125      moltype = AA  length = 107
FEATURE           Location/Qualifiers
REGION            1..107
note              CL
source             1..107
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 125
RADAAPTVSI FPPSSEQLTS GGASVVCFLN NFYPKDINVK WKIDGSERQN GVLNSWTQDQ 60
SKDSTYSMSS TLTLTKDEYE RHNSYTCEAT HKTSTSPIVK SFNRNEC                107

SEQ ID NO: 126      moltype = AA  length = 117
FEATURE           Location/Qualifiers
REGION            1..117
note              VH
source             1..117
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 126
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQKFQGRVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTVTVSS        117

SEQ ID NO: 127      moltype = AA  length = 330
FEATURE           Location/Qualifiers
REGION            1..330
note              CH
source             1..330
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 127
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 60
GLYSLSSVVT VPSSSLGTQT YICNVNWKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG 120

```

-continued

PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN	180
STYRVSLSVT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIKAKGQPREPQ VYTLPPSRDE	240
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW	300
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK	330
SEQ ID NO: 128 moltype = AA length = 107	
FEATURE Location/Qualifiers	
REGION 1..107	
source note = VL	
1..107 mol_type = protein	
organism = synthetic construct	
 SEQUENCE: 128	
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NRLNWyQQKP GKAVKLLISY RSRLHSGVPS	60
RFGSGSGSTD YTLTISSLQP EDFATYFCQQ GNSLPPTFGG GTKLEIK	107
SEQ ID NO: 129 moltype = AA length = 107	
FEATURE Location/Qualifiers	
REGION 1..107	
source note = CL	
1..107 mol_type = protein	
organism = synthetic construct	
 SEQUENCE: 129	
RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD	60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC	107
SEQ ID NO: 130 moltype = AA length = 117	
FEATURE Location/Qualifiers	
REGION 1..117	
source note = VH	
1..117 mol_type = protein	
organism = synthetic construct	
 SEQUENCE: 130	
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY	60
NQKFQGRVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTGTVSS	117
SEQ ID NO: 131 moltype = AA length = 330	
FEATURE Location/Qualifiers	
REGION 1..330	
source note = CH	
1..330 mol_type = protein	
organism = synthetic construct	
 SEQUENCE: 131	
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVWS WNSGALTSGV HTFPAVLQSS	60
GLYSLSSVVT VPSSSLGTQT YICCNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELGG	120
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN	180
STYRVSLSVT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIKAKGQPREPQ VYTLPPSRDE	240
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW	300
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK	330
SEQ ID NO: 132 moltype = AA length = 107	
FEATURE Location/Qualifiers	
REGION 1..107	
source note = VL	
1..107 mol_type = protein	
organism = synthetic construct	
 SEQUENCE: 132	
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NRLNWyQQKP GKAVKLLISY RSRLHSGVPS	60
RFGSGSGSTD YTLTISSLQP EDFATYYCQQ GNSLPPTFGG GTKLEIK	107
SEQ ID NO: 133 moltype = AA length = 107	
FEATURE Location/Qualifiers	
REGION 1..107	
source note = CL	
1..107 mol_type = protein	
organism = synthetic construct	
 SEQUENCE: 133	
RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD	60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC	107
SEQ ID NO: 134 moltype = AA length = 117	

-continued

```

FEATURE          Location/Qualifiers
REGION          1..117
source           note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 134
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQKFQGRVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTVTVSS    117

SEQ ID NO: 135      moltype = AA length = 330
FEATURE          Location/Qualifiers
REGION          1..330
source           note = CH
                1..330
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 135
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 60
GLYSLSSVVT VPSSSLGTQT YICCNVNHKPS NTKVDKKKVEP KSCDKTHTCP PCPAPELLGG 120
PSVFLFPKPK KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 180
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIIS KAKGQPREPQ VYTLPPSRDE 240
LTKNQVSLTC LVKGFYPSDI AVEWESENQGP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 300
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK                                330

SEQ ID NO: 136      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source           note = VL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 136
DIVMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRLHSGVPA 60
RFSGSGSGTD YTTLISSLEP EDFAVYFCQQ GNSLPPTFGG GTKLEIK                107

SEQ ID NO: 137      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107
source           note = CL
                1..107
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 137
RTVAAPSVF1 PPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD 60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC                107

SEQ ID NO: 138      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION          1..117
source           note = VH
                1..117
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 138
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQKFQGRVTL TVDTSTSTAY MELSSLRSED TAVYYCARSL SGYVDYWGQG TTVTVSS    117

SEQ ID NO: 139      moltype = AA length = 330
FEATURE          Location/Qualifiers
REGION          1..330
source           note = CH
                1..330
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 139
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 60
GLYSLSSVVT VPSSSLGTQT YICCNVNHKPS NTKVDKKKVEP KSCDKTHTCP PCPAPELLGG 120
PSVFLFPKPK KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 180
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIIS KAKGQPREPQ VYTLPPSRDE 240
LTKNQVSLTC LVKGFYPSDI AVEWESENQGP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 300
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK                                330

SEQ ID NO: 140      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION          1..107

```

-continued

```

source          note = VL
               1..107
               mol_type = protein
               organism = synthetic construct
SEQUENCE: 140
EIVMTQSPAT LSLSPGERAT LSCRASQDIS NRNLWYQQKP GQAVRLLISY RSRRHTGIPA 60
RFSGSGSGTD YTTLISSLQEP EDFAVYYCQQ GNSLPPTFGG GTKLEIK           107

SEQ ID NO: 141      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = CL
source          1..107
mol_type = protein
organism = synthetic construct
SEQUENCE: 141
RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD 60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC           107

SEQ ID NO: 142      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION           1..117
note = VH
source          1..117
mol_type = protein
organism = synthetic construct
SEQUENCE: 142
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60
NQQFTGRFVL SVDTSVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTVTVSS       117

SEQ ID NO: 143      moltype = AA length = 330
FEATURE          Location/Qualifiers
REGION           1..330
note = CH
source          1..330
mol_type = protein
organism = synthetic construct
SEQUENCE: 143
ASTKGPSVK LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 60
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVP KSCDKTHTCP PCPAPELLGG 120
PSVFLFPKPK KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 180
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIK KAKGQPREPQ VYTLPPSRDE 240
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW 300
QQGNVFCSV MHEALHNHYT QKSLSLSPGK                                     330

SEQ ID NO: 144      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = VL
source          1..107
mol_type = protein
organism = synthetic construct
SEQUENCE: 144
DIQMTQSPSS LSASVGDRVVT ITCRASQDIS NRNLWYQQKP GKAVKLLISY RSRLHSGVPS 60
RFSGSGSGTD YTTLISSLQEP EDFATYFCQQ GNSLPPTFGG GTKLEIK           107

SEQ ID NO: 145      moltype = AA length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = CL
source          1..107
mol_type = protein
organism = synthetic construct
SEQUENCE: 145
RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD 60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC           107

SEQ ID NO: 146      moltype = AA length = 117
FEATURE          Location/Qualifiers
REGION           1..117
note = VH
source          1..117
mol_type = protein
organism = synthetic construct
SEQUENCE: 146
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY 60

```

-continued

NQGFTGRFVL SVDTSVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTVTVSS	117
<hr/>	
SEQ ID NO: 147	moltype = AA length = 330
FEATURE	Location/Qualifiers
REGION	1..330
	note = CH
source	1..330
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 147	
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYPPEPVTVS WNSGALTSGV HTFPAVLQSS	60
GLYSLSSVVT VPSSSLGTQT YICNVNHNKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG	120
PSVFLFPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN	180
STYRVRVSVLT VLHQDWLNGE EYKCKVSNKA LPAPIEKTS KAKGQPREPQ VYTLPSSRDE	240
LTKNQVSLTC LVKGFYPSDI AVEWESENQGP ENNYKTTPPV LDSDGFFLY SKLTVDKSRW	300
QQGNVVFSCSV MHEALHNHYT QKSLSLSPGK	330
SEQ ID NO: 148	moltype = AA length = 107
FEATURE	Location/Qualifiers
REGION	1..107
	note = VL
source	1..107
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 148	
DIVMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRLHSGVPA	60
RFSGSGSGTD YTTLTISSLEP EDFAVYFCQQ GNSLPPTFGG GTKLEIK	107
SEQ ID NO: 149	moltype = AA length = 107
FEATURE	Location/Qualifiers
REGION	1..107
	note = CL
source	1..107
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 149	
RTVAAPSVFI PPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD	60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC	107
SEQ ID NO: 150	moltype = AA length = 117
FEATURE	Location/Qualifiers
REGION	1..117
	note = VH
source	1..117
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 150	
QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYWMQWVRQA PGQGLEWIGE IDPSDSYTNY	60
NQGFTGRFVL SVDTSVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTVTVSS	117
SEQ ID NO: 151	moltype = AA length = 330
FEATURE	Location/Qualifiers
REGION	1..330
	note = CH
source	1..330
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 151	
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYPPEPVTVS WNSGALTSGV HTFPAVLQSS	60
GLYSLSSVVT VPSSSLGTQT YICNVNHNKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG	120
PSVFLFPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN	180
STYRVRVSVLT VLHQDWLNGE EYKCKVSNKA LPAPIEKTS KAKGQPREPQ VYTLPSSRDE	240
LTKNQVSLTC LVKGFYPSDI AVEWESENQGP ENNYKTTPPV LDSDGFFLY SKLTVDKSRW	300
QQGNVVFSCSV MHEALHNHYT QKSLSLSPGK	330
SEQ ID NO: 152	moltype = AA length = 107
FEATURE	Location/Qualifiers
REGION	1..107
	note = VL
source	1..107
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 152	
EIVMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRRHTGIPA	60
RFSGSGSGTD YTTLTISSLEP EDFAVYYCQQ GNSLPPTFGG GTKLEIK	107

-continued

```

SEQ ID NO: 153      moltype = AA  length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = CL
source            1..107
mol_type = protein
organism = synthetic construct

SEQUENCE: 153
RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD 60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC 107

SEQ ID NO: 154      moltype = AA  length = 117
FEATURE          Location/Qualifiers
REGION           1..117
note = VH
source            1..117
mol_type = protein
organism = synthetic construct

SEQUENCE: 154
QVQLVQSGSE LKKPGAVKV SCKASGYTFT NYWMNWRQQA PGQGLEWMGE IDPSDSYTNY 60
NQGFTGRFVF SVDTSVSTAY LQISSLKAED TAVYYCARSL SGYVDYWGQG TTVTVSS 117

SEQ ID NO: 155      moltype = AA  length = 330
FEATURE          Location/Qualifiers
REGION           1..330
note = CH
source            1..330
mol_type = protein
organism = synthetic construct

SEQUENCE: 155
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 60
GLYSLSSVVT VPSSSLGTQT YICVNHNKP NTKVDKKVEP KSCDKTHTCP PCPAPELLGG 120
PSVFLFPKPK KDLMISRTP EVTCVVVDVS HEDPEVKPNW YVDGVEVHNA KTKPREEQYN 180
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIIS KAKGQPREPQ VYTLPPSRDE 240
LTKNQVSLTC LVKGFYPSDI AVEWESENQGP ENNYKTTTPV LDSDGSFFLY SKLTVDKSRW 300
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 330

SEQ ID NO: 156      moltype = AA  length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = VL
source            1..107
mol_type = protein
organism = synthetic construct

SEQUENCE: 156
EIVMTQSPAT LSLSPGERAT LSCRASQDIS NRLNWYQQKP GQAVRLLISY RSRRHTGIPA 60
RFSGSGSGTD YTTLTISSLEP EDFAVYYCQQ GNSLPPTFGG GTKLEIK 107

SEQ ID NO: 157      moltype = AA  length = 107
FEATURE          Location/Qualifiers
REGION           1..107
note = CL
source            1..107
mol_type = protein
organism = synthetic construct

SEQUENCE: 157
RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD 60
SKDSTYSLSS TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC 107

SEQ ID NO: 158      moltype = DNA  length = 351
FEATURE          Location/Qualifiers
misc_feature     1..351
note = VH
source            1..351
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 158
cagggtccaaac tgcagcagcc tggggctgag cttgtgaagc ctggggcttc agtggaaactg 60
tccctgcaagg cttctggcta caccctcacc agctactggg tgcagtgggt aaaacagagg 120
cctggacagg gccttgatgt gatcgagag attgatccctt ctgattacta tactaactac 180
aatcaaaaatg tcaaggccaa ggccacattt actgttagaca catccctccag cacagccctac 240
atgcagctca gcagcgtgac atctgaggac tctgcggctt attactgtgc aagatccctc 300
tcaggctacg ttgactactg gggccaaggc accactctca cagtcctc a 351

SEQ ID NO: 159      moltype = DNA  length = 972
FEATURE          Location/Qualifiers

```

-continued

```

misc_feature          1..972
                      note = CH
source               1..972
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 159
gcacaaaacga cacccccata tggcttatcca ctggccctgt gatctgtgc ccaaactaac 60
tccatggtga ccttggtatg cctggtaag ggctatttc ctgagccagt gacagtgacc 120
tggaaactctg gatccctgtc cagcggtgtc cacacccctc cagctgtcct gcagtctgac 180
cttctacactc tgagcagtc agtactgtc cccctccagca cctggcccg ccagaccgtc 240
acctgcaacg ttggccaccc ggcggcaggc accaagggtgg acaagaaaat tggcccgagg 300
gattgtgtt gtaaggcttg catatgtaca gtcccaagaat tatcatctgt cttcatcttc 360
ccccccaaagc ccaaggatgt gtcaccatt actctgactc ctaagggtcac gtgtgttgtg 420
gttagacatca gcaaggatgtg tcccgaggatc cagttcagct ggttttaga tggatgtggag 480
gtgcacacag ctcagacgaa accccgggg gggcggcaggc acagcactt ccgttcagtc 540
agtgaacttc ccatcatgca ccaggactgg ctcacatggca aggagttcaaa atgcagggtc 600
aacagtgcag cttccctgc ccccatcgag aaaaccatct ccaaaccacaa aggccggcagg 660
aagggtccac aggtgtacac cattccaccc cccaaaggcgc agatggccaa ggataaaagt 720
agtctgacatc gcatgataac aaacttcttcc ttcacatggca ttactgtggaa gtggcagttg 780
aatggggcagc cagcgagaa ctcacaaagaa acttcggccca ttcacatggca acatgtgcct 840
tacttcgtct acagcaagct caatgtgcag aagagcaact gggaggcagg aaataacttcc 900
acctgcttg tggatcatga gggccctgcac aaccaccata ctgagaagag cctctccac 960
tctccctggta aa                                         972

SEQ ID NO: 160      moltype = DNA length = 321
FEATURE             Location/Qualifiers
misc_feature        1..321
                      note = VL
source              1..321
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 160
gatatccaga tgacacagag tacatcctcc ctgtctgcct ctctgggaga cagagtcaacc 60
atcaattgca gggcaagtca ggacattaga aatcgtttaa actggatataa gcagaaacca 120
gtatggaaacttcc taaacttccct gatcgactc agatcaagat tacagtccagg agtcccatca 180
aggttcaatgtc gcaatgggtc tggcagacag tattctctca ccattacggaa cctggagccaa 240
gaagacatgtt ccacttattt ttggccacag ggcacatggc ttccctccac gttcgagggg 300
gggaccaacg tggaaagttag a                                         321

SEQ ID NO: 161      moltype = DNA length = 321
FEATURE             Location/Qualifiers
misc_feature        1..321
                      note = CL
source              1..321
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 161
cgggctgtatg ctgcaccaac tggatccatc ttccacatcc ccaatgtggca gttaaacatct 60
ggaggtgcct cagtcgtgtc cttcttgcac aacttctacc ccaaagacat caatgtcaag 120
tggaaagatgt atggcgtatca acgacaaaat ggcgtctgtc acagttggac tgatcaggac 180
acgaaagaca gacccatcagc catgacggc accctcacgt tgaccaagga cgagtatgaa 240
cgacataaca gctatacctg tgaggccact cacaagacat caacttcacc cattgtcaag 300
agttcaaca ggaatgtgtc t                                         321

SEQ ID NO: 162      moltype = DNA length = 351
FEATURE             Location/Qualifiers
misc_feature        1..351
                      note = VH
source              1..351
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 162
caagtccaaac tgcagcagcc tggggctgtatg cttgtgtggc ctggggcttc agtgaagctg 60
tccatggatgg cttcttgcata caccatgttcc aactactggaa tgcaatgtgggaaaacagg 120
cctggacatgg gtcgtgtgtc gatcgagatc attgtatgttca tactaactac 180
aatccaaatgt tcaaggccaa ggcacatgtt acatgttagaca catccctccag cacagccctac 240
atgcagtc gcaatgggtc acatgtggac tctgggttctt attactgtgc aagatccctc 300
tcaggctacg ttgactactg gggccaaaggc accacttcac cagtttcac a                                         351

SEQ ID NO: 163      moltype = DNA length = 1008
FEATURE             Location/Qualifiers
misc_feature        1..1008
                      note = CH
source              1..1008
                      mol_type = other DNA
                      organism = synthetic construct

```

-continued

SEQUENCE: 163

```

gccaaaaacaa cacccccata agtcttatcca ctggcccttg ggtgtggaga tacaacttgt 60
tcctctgtga ctctggatg cctggtaag ggctacttcc ctgagtcagt gactgtgact 120
tggaaactctg gatccctgtc cagcagtgtg cacaccttc cagctctct gcagtctgga 180
ctctacacta tgagcagctc agtgaactgtc ccctccagca cctggccaag tcagaccgtc 240
acctgcacgc ttgtctcaccc agccagcago accacgggtg aaaaaaaact tgagccccgc 300
ggggccattt caacaatcaa cccctgtctc ccatgcaagg agtgcacaa atgcccagct 360
cctaaccctcg agggttgacc atccgtctc atcttccctc caaatatcaa ggatgtactc 420
atgatctccc tgacacccaa ggteacgtgt gtgtgtgtgg atgtgagcga ggatgaccca 480
gacgtcccgga tcagtcgttt tgtaacacaa acacagctca gacacaaacc 540
catagagagg attacaacag tactatccgg gtggtcagtg ccctccctat ccagcacccag 600
gactggatga gtggcaagga gttcaatgc aagggtcaaca acaaagactt cccatcaccc 660
atcgagagaa ccatctcaaa aattaaaggg ctgtcagag ctccacaagt atacatcttgc 720
ccgcccaccc agagcagggt gtccaggaaa gatgtcaactc tcacttgcctt ggtcgtggc 780
ttcaaccctg gagacatcg tggatgtgg accagcaatcg ggcatacaga ggagaactac 840
aaggacacccg caccatgttgc ggttcttact tcatatacag caagtcgtat 900
ataaaaaacaa gcaagtggga gaaaacagat tccttctcat gcaacgtgag acacgagggt 960
ctgaaaaattt actactctgaa gaagaccatc tccctccatc cggttggaa 1008

```

SEQ ID NO: 164 moltype = DNA length = 321

FEATURE Location/Qualifiers
misc_feature 1..321
source note = VL
source 1..321
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 164

```

gatatccaga tgacacagac tacatcctcc ctgtctgcctt ctctgggaga cagagtcaacc 60
atcagttgc gggcaagtca ggacatttgc aatcgtttaa actggatataa gcagaaacca 120
gatggaaacttgc ttaaacttcc tgcgtcaactc agatcaagat tacactcagg agtcccatca 180
aggttcgttgc gcaacttgcgtt ggacatcgat tattctctca ccattagcaa cctggagcaa 240
gaagacatcg ccacttattt ttggcaacag ggttaattcgc ttctccctac gttcgaggaa 300
gggaccaacgc tggaaatgttgc a 321

```

SEQ ID NO: 165 moltype = DNA length = 321

FEATURE Location/Qualifiers
misc_feature 1..321
source note = CL
source 1..321
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 165

```

cgggctgtatc ctgcaccaac tttccacccat ccagtggaca gttaaacatct 60
gggggtgcgtt cagtcgtgtt cttttgcac aacttctacc ccaaagacat caatgtcaag 120
tggaaatggatc atggcgttgc acgacaaaat gggttcttgc acagttggac tgatcaggac 180
agcaaaagaca gcacccatcag catggcago accctcacgt tgaccaagga cgagtatgaa 240
cgacataacaacatcg tggggccactt cacaagacat caacttcacc cattgtcaag 300
agttcaacaacatcg tggggccactt cacaagacat caacttcacc cattgtcaag 321

```

SEQ ID NO: 166 moltype = DNA length = 351

FEATURE Location/Qualifiers
misc_feature 1..351
source note = VH
source 1..351
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 166

```

cagggtccaaatc tggggcttgc ttttttttttcc agttaatcttgc 60
tcctgttgcggatc cttctggatc caccatccacc agttaatcttgc ttttttttttcc agttaatcttgc 120
cctggacatcgatc gtttttttttcc agttaatcttgc ttttttttttcc agttaatcttgc 180
atccaaatcgatc tggggcttgc ttttttttttcc agttaatcttgc 240
atggcgttgc tggggcttgc ttttttttttcc agttaatcttgc 300
tcagggtccaaatcg tggggcttgc ttttttttttcc agttaatcttgc 351

```

SEQ ID NO: 167 moltype = DNA length = 972

FEATURE Location/Qualifiers
misc_feature 1..972
source note = CH
source 1..972
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 167

```

gccaaaaacga cacccccata ttttttttttcc agttaatcttgc 60
tcctgttgcggatc cttctggatc caccatccacc agttaatcttgc 120
tggaaactctg gatccctgtc cagcgtgttgc cacacccatc cagctgttgc gcagtctgac 180
ctctacactc tgagcagctc agtgaactgtc ccctccatc cctggcccttcc 240

```

-continued

acctgtcaac	tgcggccaccc	ggcagcagc	accagggttg	acaagaaaat	tgtgcccagg	300
gattgttgtt	gtaaaggctg	cataatgtaca	gtcccgaaag	tatcatgtgt	cttcatcttc	360
cccccaaaacg	ccaaaggatgt	gctcaccatt	actctgactc	ctaaggbcac	gtgtgttgtg	420
gttagacatc	gcaaggatgtt	ccggaggatgt	cattgtcgt	ggtttgtttaga	tgtatgtggag	480
gtgcacacag	cttcagacgaa	accgggggag	gagccatgtac	acagcactt	ccgttctgtc	540
agtgaacttc	ccatcatgca	ccaggactgg	ctcaatggca	aggagttaaa	atgcgggttc	600
aacatgtcg	ctttcccttc	ccccatcgag	aaaacccatct	ccaaacaaacca	aggccacccg	660
agggttccac	agggttacac	cattttccatct	cccaaggagc	agatggccaa	ggataaaatgt	720
agtctgtactt	gcatgataaa	aaactttctt	ccttggaaatca	ttaactgttgg	gtggccatgg	780
aatggggcagc	cagcggagaa	ctacaagaac	actcagccca	tcatggacac	agatggctct	840
tacttgtctt	acagcaagct	caatgtgcag	aaagacaact	ggggaggccagg	aaatactttc	900
acctgtctgt	tgtttacatgt	gggcctgcac	aaccaccata	ctgagaagag	cctctcccac	960
tcttcgtttaa						972

```

SEQ ID NO: 171      moltype = DNA    length = 1008
FEATURE          Location/Qualifiers
misc_feature     1..1008
                  note = CH
source           1..1008
                  mol_type = other DNA
                  organism = synthetic construct

SEQUENCE: 171
gccaaaacaa cacccccattc agtcttatcca ctggccctgt ggtgtggaga tacaactgg 60
tcctctgtga ctctggatg cctggtaag ggctacttcc ctgagtca 120
tggaaacttgc gatccccctgc cagcgtgtgc cacaccccttc cagcttccct 180
ctctacacta tgagcagtc agtgaacttgc ccctcccgca cctggccaa 240
acccgtttttt ttgtctcaccc agccggccatc accacgggtgg aaaaaaaaaact ttagccccatc 300

```

-continued

```

catagagagg attacaacag tactatccgg gtggtcagtg ccctccccat ccagcacca 600
gactggatga gtggcaagga gttcaaatgc aaggtaaaca acaaagact cccatcaccc 660
atcgagagaa ccatctcaaa aattaaaaggc ctatgtcagag ctccacaagt atacatctt 720
ccggccaccagg cagagcagtt gtccaggaaa gatgtcagtc tcacttgctt ggtcggtggc 780
ttcaaccctg gagacatcag tggatgtgg accagcaatg ggcatacaga ggagaactac 840
aaggacaccg caccagtctt ggactctgat ggttcttact tcatacag caagtcgat 900
ataaaaaacaa gcaagtgggaa gaaaacagat tccttctcat gcaacgtgag acacgagggt 960
ctgaaaaattt actacctgaa gaagaccatc tcccggttcc cggtttaaa 1008

SEQ ID NO: 172      moltype = DNA length = 321
FEATURE             Location/Qualifiers
misc_feature        1..321
                      note = VL
source              1..321
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 172
gatatccaga tgacacacag tacttcctcc ctgtctgcctt ctctgggaga cagagtca 60
atcgatgtca gggcaagtca ggacatttgc aatcggtttaa actggatata gcagaaacca 120
gatggaaacttgc tttaacttccat gatcgatc agatcaagat tacagtccagg agtcccattca 180
aggttcagttt gcaatggggc tggcagat tattctctca ccattaccat cctggaggg 240
gaagacatttgc caccattttt ttgccaacag ggttaatacgcc ttccctccac gttcgagg 300
gggaccaaggc tggaaatgttag 321

SEQ ID NO: 173      moltype = DNA length = 321
FEATURE             Location/Qualifiers
misc_feature        1..321
                      note = CL
source              1..321
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 173
cgggctgtat ctgcaccaac ttttatccatc ttccacatcc ccagtggatca gttaaatct 60
ggagggcttgc ctgtgtgtt cttcttgcac aacttctacc ccaaagacat caatgtcaag 120
tggaaatgttgc atggcgtgtt acggaaaaat gggttcttgc acatgtggac tgatcgagg 180
agcaaaagaca gcacccatcag catggcgcg accctcacgt tgaccaaggaa cgatgtat 240
cgacataaca gttatcttgc tgaggccact cacaagacat caacttcaccat cattgtcaag 300
agttcaaca ggaatgttag 321

SEQ ID NO: 174      moltype = DNA length = 345
FEATURE             Location/Qualifiers
misc_feature        1..345
                      note = VH
source              1..345
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 174
gggttcacgc tgcaacaatc tggacctggat ctgggtgaagg ctgggggttc agtgaagata 60
tcttgtaaagg cttcttgata cacgttactt gactactaca tgaactgggt gaagcagagc 120
catggaaaga gccttgcgtt gattggatgat attaattctca acaatgggtt tactatctac 180
aaccggaaatg tcaaggccaa ggccacatcc agtggtagaca agtccctccag cacggccatc 240
atggagatcc tcggcgttgc atctggggat tctgcgttgc attactgtgc aaggcgatc 300
cttcttgcgtt actggggccca aggccactt ctcacatgtt cctca 345

SEQ ID NO: 175      moltype = DNA length = 1005
FEATURE             Location/Qualifiers
misc_feature        1..1005
                      note = CH
source              1..1005
                      mol_type = other DNA
                      organism = synthetic construct
SEQUENCE: 175
gccaaaacaa cagccccatc ggtctatcca ctggcccttgc tggatgtggggg tacaactggc 60
tcctcggttgc ctcttaggtt cctgggtcaag gggttatttc ctggggccatg gacccatgc 120
tggaaacttgc tggatgtgttgc cttccatccat cttccatccat gacccatgc 180
ctctacaccc ttcggcgttc cttccatccat cttccatccat gacccatgc 240
acctgtcaatg tggccaccc ggcaaggcgc accaaatgtgg acaagaaaat tgacccatc 300
gtggccatataa cttccatccat cttccatccat gacccatgc 360
gacccatgc 420
atctcccttgc gccccatgttgc cttccatccat gacccatgc 480
gtccatccat gacccatgc 540
agagaggattt acaacatgtt cttccatccat gacccatgc 600
tggatgtgttgc gcaaggatgtt caaatgtcaag gtcaacaaca gacccatccat 660
gagaaaaaccatc tctcaaaaaccatc gacccatgc 720
ccaccatccat gacccatgc 780
ttacccatccat gacccatgc 840
aaattgtgttgc gacccatgc 840

```

-continued

aacaccgcaa cagtccctgga ctctgtatgg tcttacttca tgtacagcaa gtcagaga 900
 caaaagagca cttgggaaag aggaagtctt ttgcgcctgtc cagtggtcca cgagggtctg 960
 cacaatcacc ttacgactaa gaccatctcc cggtctctgg gtaaaa 1005

SEQ ID NO: 176 moltype = DNA length = 339
 FEATURE Location/Qualifiers
 misc_feature 1..339
 note = VL
 source 1..339
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 176
 gagattgtga tgacacagtc tecatctcc ctggctatgt cagtaggaca gaaggtcaact 60
 atgagctgca agtcccgatca gagocttta aatagtagca atcaaagaa ctatggcc 120
 tggtaccaggc agaaaaccaggc agactcttc aaacctctgg tataacttgc atccactagg 180
 gaatctgggg tccctgtatcg cttcatagc agtggatctg ggacagatt cactcttacc 240
 atcagcagtc tgcaggctga agccatgtgg aacctacttgc gtccagcaaca ttatagcact 300
 ccgcctacgt tcgggtctgg gaccaagctg gagctgaaa 339

SEQ ID NO: 177 moltype = DNA length = 321
 FEATURE Location/Qualifiers
 misc_feature 1..321
 note = CL
 source 1..321
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 177
 cgggctgtatcg ctgcaccaac tggatccatc ttcccacccat ccagtggaca gttacatct 60
 ggagggtgcct cagtcgtgtc cttcttgaac aacttctacc ccaaagacat caatgtcaag 120
 tggaaatgtt atggcagtc acgacaaaat ggcgtccatc acagttggac tgatcaggac 180
 agccaaagaca gcacccatcag catggcgcac acccttcacgt tgaccaaggc cgatgtgaa 240
 cgacataaca gctataccctg tgaggccact cacaagacat caacttcacc cattgtcaag 300
 agttcaaca ggaatgatgt t 321

SEQ ID NO: 178 moltype = DNA length = 351
 FEATURE Location/Qualifiers
 misc_feature 1..351
 note = VH
 source 1..351
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 178
 caagtgcaggc tgggtcagag cggggccggag gtgaagaagc cggcgccaa cgtgaagggtg 60
 agctgcaggc caageggcta cacccatcacc aactacttgc tgctgtgggt gagacaagcc 120
 cccggccaaag gcctggatgt gatccggcggat atcgcacccatc ggcacagatc caccactac 180
 aatcagaatgt tccaaaggcag atgtaccctg acctgtggaca caacgcggatc caccggctac 240
 agggatgtca gcaaggcttgc aaggcggggatc accggccgttgc actactgtccg tagaaggctg 300
 agcggctacg tggactactg gggccaaaggc accaccgtga cggctctcgag c 351

SEQ ID NO: 179 moltype = DNA length = 990
 FEATURE Location/Qualifiers
 misc_feature 1..990
 note = CH
 source 1..990
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 179
 gccagcacca aagggtccatc cgtgtttccg ctcgcggccgt cctcaaaatc gacccctggaa 60
 ggcactgccc ccctgggtgt cttgtgtcaag gacttattcc cggaaactgt caccgtgtcc 120
 tggaaacagcg ggcgcctgtac ttccggatgtt cacaatcc cccggcttgc gcaatccaggc 180
 ggcctgtact cactgtcatc cgttgtact gtcctgtgtcc ccaaggctggg aacccaaacc 240
 tacatttgcac acgtgtatccaa aacccatccg aataccaagg tggataaagg agtgcggccg 300
 aagtcatcgca acaagactca caccgttgcg ctttgcggccg cccggaaactgt ctcggggcc 360
 ctttgcgggtt tttttttcc gccggaaaggcc aaggacacttc tgatgtatcc acgcacttca 420
 gggtgtactt gctgtgtgtt cttgtgttgc caccggggatc cggaaatgttca attcaacttgc 480
 tatgtcgacg ggggtggaaatgt gctaatatccaa aagacggatc cgggggggggg agactacaac 540
 tccacccatcata gagggttttgc agtcccttacc gtcctccatc aagatgggtt gaaaggaaag 600
 gaggatcaatgt gtaagggttgc gaaaaaggc ttgcggccgcctatcgaaaaa gactatcgcc 660
 aaggccaaag gacacccggcggccggccaa gttgtacaccc tcccgcttc cggggccggcc 720
 ctggaccaagaatc tccatgttgc ctttgcgttgc tgggtggatggatttcaacc ctcggatatc 780
 gcaatgtcaat gggaaatgtggatccaa tggacagccaa gaaaacaact acaagaccac tccccgggtg 840
 ctgcactccg acgggttccctt ctttgcgttgc tggatccatc gggatgttgc cccgtggacaaatc acgtcgttgg 900
 cggcaggaaac cgggttttagt ctgcggccgtt atgcgttgcggatccatc acaactacacc 960
 cagaagtcac ttcgtgttgc cccaggaaag 990

SEQ ID NO: 180 moltype = DNA length = 321

-continued

```

FEATURE          Location/Qualifiers
misc_feature    1..321
                  note = VL
source          1..321
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 180
gcatttgcaga tgacacagag cccttagcago ctgagcgc当地 60
atcacctgca gagaaggccaa agacatcago aacagactga actggatca gcagaaggcc 120
ggcaaggcccg tgaagctgtc gatcgacta aqaaagcqac tgcacacggg cgtgc当地 180
agattcagcg cggcggccag cggcaccgac tacaccctga ccatcagcag cctgc当地 240
gaggacttcg ccacctactt ctgtcagcaa ggcaacagcc tgccccccac ctgc当地 300
ggcacaaggc tcgatcaa g 321

SEQ ID NO: 181      moltype = DNA length = 321
FEATURE          Location/Qualifiers
misc_feature    1..321
source          1..321
                  note = CL
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 181
agaactgtgg ccgcgc当地 cgtgtttatc ttccctccat cggatgaaca gcttaagtcc 60
ggcacggccgt ctgtggcttg cctgtcaat aacttttacc ctggaaagc taaagtccaa 120
tggaaaggccct ataacgcctt gcaatcgat aacagccagg aatcggttac cgaacaggac 180
agcaaggaca gcaactactt ctgtcgtcg actcttactt tgagcaaggc cgattacgg 240
aacgacaagg totacgcctg cgagggtcaco catcaggagc totcgtccccc ggtgacccaaa 300
tccttcaata gaggcgaatc c 321

SEQ ID NO: 182      moltype = DNA length = 351
FEATURE          Location/Qualifiers
misc_feature    1..351
source          1..351
                  note = VH
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 182
caagtgc当地 tggcgc当地 cggggccgag gtgaagaaggc cggcgc当地 cgtgaagg 60
agctgc当地 caaggccgtc cacccatcacc aactacttgc tgcaatggg gagacaaggcc 120
cccgcccaag ggctggatg gatcgccgag atcgaccctt gcaaggccctt caccactac 180
aatcagaagg tccaaggccag agtgc当地 ctggatggaca caagcacaagg caccgc当地 240
atggagctga gcagccgtag aaggcaggac accgc当地 ctggactactt gggccaggc accaccgtga c 351

SEQ ID NO: 183      moltype = DNA length = 990
FEATURE          Location/Qualifiers
misc_feature    1..990
source          1..990
                  note = CH
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 183
gccagcacca aaggccatc cgtgtttccg ctgc当地 cctcaaaggc gacccccc当地 60
ggcaactgc当地 ccctggctg cctgtcaag gactattcc cggaaactgt cacgggttcc 120
tggaaacaggc ggccctgtac ttccggatgtg cacacccctt cccggctctt gcaatccagg 180
ggccctgtact cactgtc当地 ctggatgtg gtc当地 ctggatggg aaccctaaacc 240
tacatttgca acgtgatca caaaaatcg aataccaaagg tgatggaa agtgc当地 300
aagtcatcg acaagactca cacctgtccg cttggccagg ccccgaaact gtc当地 360
ccttc当地 ctggatggg gccgaaggcc aaggacactt tgatgttcc acgc当地 420
gagggtgactt cctgtgggtt cgatgttcc caggaggac ccggaaatggg attcaactgg 480
tatgtcgacgg gggatggaaatg gatcaatggc aagacggccg ccaggggaggc acgtacaaac 540
tccacccata gatggatggg agtccatcc gtc当地 ctggatggct gaacggaaag 600
gagttacaat gtaagggtgc gaaacaaggc ttggccggccc ctatcgaaa gactatcg 660
aaggccaaagg gacaggccgg ggaggccggc gttgtacacc tcccgccctt gggggacgg 720
ctgaccaaga atcaggatgc cttacttgc ctggatggg gattctacc ctcggatatc 780
gcaatcgat gggatggca tggcaggccaa gaaaacaact acaagaccac tccccc当地 840
ctcgactccg acgggttccctt cttctgtac tcgaatgtca ccgtggacaa atcagcgtgg 900
cagcaggaa acgtgttag ctgc当地 cgtgatggg cgctgc当地 aaactacacc 960
cagaatcgatc tctcgatcc cccaggaaag 990

SEQ ID NO: 184      moltype = DNA length = 321
FEATURE          Location/Qualifiers
misc_feature    1..321
source          1..321
                  note = VL
                  mol_type = other DNA

```

-continued

```

organism = synthetic construct
SEQUENCE: 184
gacattcaga tgacacagag ccctagcago ctgagcgcaa gcgtggcga cagagtgacc 60
atcacctgca gagcaagcca agacatcago aacagactga actggatataa gcagaagccc 120
ggcaaggccg tgaagctgt gatcagctac agaagcagac tgcacacggg cgtgccttagc 180
agattcagcg gcagcggcag cggcaccgac tacaccctga ccatcagcag cctgcaggct 240
gaggacttcg ccacctacta ctgtcagcaa ggcaacagcc tgccccccac cttcggcgcc 300
ggcacaaggc tcgagatcaa g 321

SEQ ID NO: 185      moltype = DNA length = 321
FEATURE           Location/Qualifiers
misc_feature      1..321
source            note = CL
                  1..321
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 185
agaactgtgg cccgcggcgtc agtgtttatc ttccctccat cggatgaaca gcttaagtcc 60
ggcacggcgt ctgtggctcg cctgtcaat aacttttacc cttagggaaac taaaatccaa 120
tggaaatgtt ataaacggccct gcagtcagga aacagccagg aatcggttac cgaacaggac 180
agaaggacac gcaacttactc cttgtcgctcg actcttactc tgagcaaggc cgattacgag 240
aagcacaagg tctacgcctg cgaggtcacc catcaggacat tctcgcccc ggtgacccaa 300
tccttcaata gaggcgaatg c 321

SEQ ID NO: 186      moltype = DNA length = 351
FEATURE           Location/Qualifiers
misc_feature      1..351
source            note = VH
                  1..351
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 186
caagtgcacg tgggtcagag cggggccgag gtgaagaagg cccggcgaag cgtgaagggt 60
agctgcaggc caagcggtcta caccttcacc aactactgga tgcagtgggt gagacaagcc 120
cccgcccaag gctgtggatg gateggcgtc atcgaccctt gcgcacgcata caccactac 180
aatcagaagt tccaaaggcag atgtggccatc accgtggacca caagcacaag caccgcctac 240
atggagctga gcagcgttag aaggcaggac accgcgtgtt actactgcgc tagaagctgt 300
agcggctacg tggactactg gggcaaggc accaccgtga ccgtctcgag c 351

SEQ ID NO: 187      moltype = DNA length = 990
FEATURE           Location/Qualifiers
misc_feature      1..990
source            note = CH
                  1..990
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 187
ccgcgcacca aaggccatc cgtgtttccg ctgcggccgt cctcaaaatc gacccggaa 60
ggcaactgcgc cctctggctg ccttgtcaag gactattcc cccgaaatgtt caccgggttcc 120
tggAACAGCG cgcgcctgtac ttccggatgt cacacccctt ccggccgtct gcaatccagg 180
ggccctgtact cactgtcata cgtgtgtact gtcccggtgtt ccagccgtgg aaccggaaacc 240
tatcatgtca acgtgtatca caaaaatcg aataccaaagg tgcataagaa agtcgaggcg 300
aagtcatcgca acaagactca cacctgtccg ctttgcggccat ccccaaaact gctcgccggc 360
ccttcgtgt ttttgttcc gccgaaggccg aaggacactc tgatgtatcc acgcacttca 420
gagggtactt gctgtgtgtt cgtgtgttcc cccggggccgtt ccggggacgg 480
tatgtcgacg ggggtggaaatg gcaatgttcc aagacgaaatc ccggggggggg acagtacaaac 540
tccacccata gagggttttcc acgttccatc gtcctccatc aagatgggtt gaacggaaag 600
gagtcacaaat gtaagggtgtc gaacaaaggc ttggccggccat ctatcgaaaa gactatcagc 660
aaggccaaag gacagccgcgc ggagccgcgg gttgtacacc tcccgccctc gccggggccgg 720
ctgaccaaga atcagggtgtc ctttacttgc ctgggtgggg gattttatcc ctggatatc 780
gcacgtcaat gggaaatcgaa tggacagccaa gaaaacaaact acaagacccat tcccccgggt 840
ctcgactccg acgggttccctt ctteccgtac tgcacgtgtc ccgtggacaa atcagcgtgg 900
cagcaggggaa acgtgttttag ctgcacgtgt atgcacgtgg ccgtgtccat aaatcactacacc 960
cagaaggcactc tctcgctcag cccaggaaag 990

SEQ ID NO: 188      moltype = DNA length = 321
FEATURE           Location/Qualifiers
misc_feature      1..321
source            note = VL
                  1..321
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 188
gacatcgtaa tgacacagag ccccgccgacc ctgagctgtt ccccccgtga gagagctacc 60
ctgagctgca gagcaagcca agacatcago aacagactga actggatataa gcagaagccc 120
ggcacaaggccg tgagactgtt gatcagctac agaagcagac tgcacacggg cgtgccttagc 180

```

-continued

agattcagcg gcagcggcag cgccaccgac tacaccctga ccatcagcag cctggaggct	240
gaggacttcg ccgtgtactt ctgtcagcaa ggcaacagcc tgcccccac cttcggccgc	300
ggcacaaga tcgagatcaa g	321
SEQ ID NO: 189 moltype = DNA length = 321	
FEATURE Location/Qualifiers	
misc_feature 1..321	
note = CL	
source 1..321	
mol_type = other DNA	
organism = synthetic construct	
 SEQUENCE: 189	
agaactgtgg ccgcgcgctc agtgtttatc ttccctccat cggatgaaca gcttaagtcc	60
ggcacgcgct ctgtgttctg cctgtcaat aacttttacc cttagggaaac taaaatccaa	120
tggaaatgtgg aatacgcctt gcagtcggaa aacagccagg aatcggttac cgaacaggac	180
agcaaggaca gcaactactt cttgtcgact actcttactt tgagcaaggc cgattacqag	240
aagcacaagg tctacgcctg cgaggtcacc catcagggac ttcgtcccc ggtgaccaaa	300
tccttcataa gaggegaatc c	321
 SEQ ID NO: 190 moltype = DNA length = 351	
FEATURE Location/Qualifiers	
misc_feature 1..351	
note = VH	
source 1..351	
mol_type = other DNA	
organism = synthetic construct	
 SEQUENCE: 190	
caagtgcgc tggtgcagag cggggccgag gtgaagaagc cccggcgaag cgtgaaggtg	60
agctgcgaagg caagcggcta cacccatcacc aactactgaa tgcagtgggt gagacaagcc	120
cccccggcaag ggctggagtg gatcgccgag atcgaccctt cgcacagctt caccacatc	180
aatcagaatgttccaaggcgc agtgcgttcc accgtggaca caagcacaag caccgcctac	240
atggagatgtg cggcgcttag aaggcggac accggcgatgt actactgcgc tagaagctg	300
aggcgctacgg tggactactt gggccaaaggc accaccgtga ccgtctcgag c	351
 SEQ ID NO: 191 moltype = DNA length = 990	
FEATURE Location/Qualifiers	
misc_feature 1..990	
note = CH	
source 1..990	
mol_type = other DNA	
organism = synthetic construct	
 SEQUENCE: 191	
gccagcacca aaggccatc cgtgtttccg ctggcccgct cctcaaaatc gacctccgg	60
ggcactgcgc ccctggctgc ctttgcataa gactatttc cccaaatctgt cacgggttcc	120
tggaaacagcg ggcgcctgac ttccggatgt cacacccctt cccgcgtctt gcaatccagc	180
ggccgttactt cactgtcatc ctttgcgtact gtccgttgcgtt ccagcgtggg aacccaaacc	240
taatccatgttca acgtgaatca caaaatccatc aatccaatcg tggataaaggaa agtgcggccg	300
aagtcatgcgttca aacccatcg ctttgcgtccg ccccgaaact gctcggccgc	360
ccttcgggttgc ttttgcgtcc gccaaaggcc aaggacactt tggatgttcc acgcacttca	420
gagggtgactt ggcgtgggtt cgatgtttccg ccccgaaact tggatgttcc acgcacttca	480
ttatgtgcgcg ggggtggaaat gcataatgcc aagacgcggc cgaggggaggaa acatgttacac	540
tccacccatca gaggatgttcc agtccatccatc aatgggttcc gaaatgggttcc gaaatgggttcc	600
gaggatgttcc gaaatgggttcc gaaatgggttcc gaaatgggttcc gaaatgggttcc gaaatgggttcc	660
aaggccaaatg gacccgcgc ggagccgcaat gtttgcgttcc tcccgccctt gcccggccgc	720
ctggccatcaatg atccggatgtc ctttgcgttcc gtttgcgttcc tcccgccctt gcccggccgc	780
gcaatgggttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc	840
ctccggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc	900
cggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc	960
cggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc	990
 SEQ ID NO: 192 moltype = DNA length = 321	
FEATURE Location/Qualifiers	
misc_feature 1..321	
note = VL	
source 1..321	
mol_type = other DNA	
organism = synthetic construct	
 SEQUENCE: 192	
gagatcgatccatc tgacacacatc ccccccgcacc ctggccgttgc ccccccgggttgc gagatcgatccatc	60
ctggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc	120
ggcccaaggccg tgatgttcc gggatgttcc gggatgttcc gggatgttcc gggatgttcc	180
agattcagcg gcagcggcag cgccaccgac tacaccctga ccatcagcag cctggaggct	240
gaggacttcg ccgtgtactt ctgtcagcaa ggcaacagcc tgcccccac cttcggccgc	300
ggcacaagaatc tcgagatcaa g	321
 SEQ ID NO: 193 moltype = DNA length = 321	

-continued

```

FEATURE          Location/Qualifiers
misc_feature    1..321
                  note = CL
source          1..321
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 193
agaactgtgg cccgcgcgtc agtgttata ttcccctcat cggatgaaca gcttaagtcc 60
ggcacggcg ctgtggctg cctgtcaat aacctttacc ctagggaaac taaagtccaa 120
tggaaagtgg ataacccctc gcgtcgagg aacagccagg aatcggtiac cgaacaggac 180
agcaaggaca gcacttactc ctgtcgctg actttaactc tgagcaaggc cgattacgag 240
aagcacaagg tctacgcctg cgaggtcacc catcaggac ttcgtcccc ggtgaccaa 300
tccttcaata gagggcaatg c 321

SEQ ID NO: 194      moltype = DNA length = 351
FEATURE          Location/Qualifiers
misc_feature    1..351
                  note = VH
source          1..351
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 194
caagtgcagc tggtgcagag cggcagcgag ctgaagaagc cgggcgaag cgtgaaggtg 60
agctgcgaagg caagcgcta cacattcacc aactactgg a tgcagtgggt gagacaagcc 120
ccggcgaag ggctggagt gatcgccgag atcgacccta gcgacagcta caccactac 180
aaccaggct tcacccggcag attcgtgtc agcgtggaca caagcgtgag caccgcctac 240
ctcgagatca gcagcctgaa ggccgaggad accgcgtgt actactgcg tagaagctg 300
agcggctacg tggactactg gggcaaggc accaccgtga ccgtctcgag c 351

SEQ ID NO: 195      moltype = DNA length = 990
FEATURE          Location/Qualifiers
misc_feature    1..990
                  note = CH
source          1..990
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 195
gccagcacca aaggccatc cgtgttccg ctgcggccgt cctcaaagtc gacccggga 60
ggcaactgcg ccctggctg cttgtcaag gactatttc cccgaaacctgt cacggtgtcc 120
tggAACACGCTGAC cccggccgtac cacaccccttc gcaatccagc 180
ggctgtact cactgtcatc cgtgtgact gtcccggtcg ccagccctgg aacccaaacc 240
tacatttgca acgtgaatca caaaccatcg aataccaaagg tcgataagaa agtcgagccg 300
aaatcatcgca acaagactca caccgtcgccg ccccaact gctcgccggc 360
ccttcgggtgt tttgttcc gccgaagccg aaggacactc tgatgtatc acgcaactcca 420
gagggtactt gggtgggtgt cgatgttcc cagggaggac cggaaatgtaa attcaactgg 480
tatgtcgacg ggggtggaaatgtcgacg gctataatggc aagacgaagg cgagggagga acagtacaac 540
tccacccatca gaggatccacg agtccatcc gtcctccatc aagatgtgt gaacggaaag 600
gaggatccatca gaggatgttc gaaacaaaggc ttgcggccctt statcgaaa gactatcagc 660
aaggccaaatg gacagccgcg ggagccgcaatgttacacc cccgcgttc gccggacgag 720
ctgaccaaga atcagggttc ctttacttgc ctgggtgaagg gatttctacc ctcggatatc 780
gcagtcgaat gggaaatcgaa tggacaggca gaaaacaatc acaagaccac tcccccgggt 840
ctcgacttcg acgggttccctt ctttctgtac tcgaagctga ccgtggacaa atcacgtgg 900
cagcaggaa acgtgtttag ctgcagcgatc atgcgttggg cgtgcataa tcaactacacc 960
cagaagtcaatc ttcgtcgatc cccaggaa 990

SEQ ID NO: 196      moltype = DNA length = 321
FEATURE          Location/Qualifiers
misc_feature    1..321
                  note = VL
source          1..321
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 196
gacattcaga tgacacagag cccttgcgcg ctgtggccaa gcgtggccgca cagagtggacc 60
atcacctgca gagcaaggccca agacatcgcg aacagactga actggatatca gcagaaggccc 120
ggcaaggccg tgaactgtgtc gatcgatc agaaaggccgac tgcacagccg cgtgcgtac 180
agattcagcg gcagcggcag cggccaccgc tacaccctgtc ccatcagcag cctgcagcc 240
gaggacttcg ccacccatctt ctgtcgatca ggcaacagcc tgccccccac cttccggccg 300
ggcaccaagg tcgatcgatca g 321

SEQ ID NO: 197      moltype = DNA length = 321
FEATURE          Location/Qualifiers
misc_feature    1..321
                  note = CL
source          1..321
                  mol_type = other DNA

```

-continued

```

SEQUENCE: 197          organism = synthetic construct
agaactgtgg ccgcgcgctc agtgtttatc ttccctccat cggatgaaca gcttaagtcc 60
ggcacggcgt ctgtggctcg cctgtcaat aactttacc ctagggaaac taaagtccaa 120
tggaaagtgg ataacgcctc gcagtcagga aacagccagg aatcggtac cgaacaggac 180
agaaggacca gcaactactc ctgtcgctcg actcttactc tgagcaaggc cgattacgag 240
aagcacaagg tctacgcctg cgaggctacc catcaggacat tctcgcccc ggtgaccaa 300
tccttcataa gagcgaatgc 321

SEQ ID NO: 198         moltype = DNA length = 351
FEATURE                 Location/Qualifiers
misc_feature            1..351
source                  note = VH
                      1..351
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 198
caagtgcagg tgggtcgagg cggcagcgag ctgaagaagc cggcgcaag cgtgaagggt 60
agctgcagg caagcgctc cacccatc aactactgg tgcagtgggt gagacaagcc 120
ccccggcaag gctggagggt gatcgccagg atcgaccctt cgcacactca caccactac 180
accaggct tcacccggcagg attcgtgtc agcgtggacca caagcgtgag caccgcctac 240
ctgcagatca gcagcctgaa ggccgaggac accggccgtgt actactgcgc tagaagcctg 300
agcggctacg tggactactg gggccaaaggc accaccgtga cctgtctcgag 351

SEQ ID NO: 199         moltype = DNA length = 990
FEATURE                 Location/Qualifiers
misc_feature            1..990
source                  note = CH
                      1..990
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 199
gccagcacca aaggccatc cgtgtttccg ctgcggcccg cctcaaagtgc gaccccccgg 60
ggcaactgcg ccctgggctg cctgtcaag gactattcc cccgaaacctgt cacgggtgtcc 120
tggaaacaggc ggcggccgtac ttccggaggat cacccatc cccggcgctc gcaatccaggc 180
ggccgtgtact cactgtcatc cgtgtgtact gtcccggtcg ccacccgtggg aacccaaacc 240
tacatttgca acgttaatca caaaacatcg aataccaaagg tcgataaaggaa agtcgaggccg 300
aagtcatcgca acaagactca cacctgtccg cttggcccaag ccccaagaact gctcgccgc 360
ccttcgtgtt ttttgttcc gccaaaggc aaggacactc tgatgtatc acgcaactcca 420
gagggtgactt cggtgggttccgatgtgttccg cccggaggacatcggaa attcaacttgg 480
tatgtcgacg ggggtggaaatgcataatccca aagacgaaac cggaggaggaa acgtacaaac 540
tccacccatac agtgggttccgatcttccatc gtcctccatc aagattggct gaacggaaag 600
gajtacaaat gtaagggtgtc gaacaaaggc ttggccggccctatcggaaa gactatcaggc 660
aaggccaaaggc gacacccgcg ggagccgcgaatgtacccctccggccctc gggggacgg 720
ctggccaaaggc atcagggtgtc ccttacttgc ctggtaaggattctacccctcgatatc 780
gcagtcgaat gggaaatcgaa tggacagccaa gaaaacaact acaagaccac tccccgggtg 840
ctcgactccg acgggtccctt ctccgtgtac tcgaaatgtcggacaa atcactgtgg 900
caggcaggaa acgtgttttag ctgcagctgatcgtgag cctgtccatcaa tcaactacacc 960
cagaagtacatc tctcgctcggccaggaa 990

SEQ ID NO: 200         moltype = DNA length = 321
FEATURE                 Location/Qualifiers
misc_feature            1..321
source                  note = VL
                      1..321
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 200
gacategtaa tgacacacagg ccccgccgatc ctgagctgtc ccccccgggtga gagagctacc 60
ctgagactgca gagaacgc aacagactcaga actggatatca gcaagggccc 120
ggccaaaggcggc tgagactgtc gatcgactac aagaaggcagac tgcacaggccg cgtggccgt 180
agattcaggc gcaaggccggcggcggccac tacaccctgtac ccacccgtggacatcgg 240
gaggacttgcg cctgtgtactt ctggtaaggaa ggcaacacggc tgccccccac ctggccggc 300
ggccaccaaggc tcgagatcaa g 321

SEQ ID NO: 201         moltype = DNA length = 321
FEATURE                 Location/Qualifiers
misc_feature            1..321
source                  note = CL
                      1..321
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 201
agaactgtgg ccgcgcgctc agtgtttatc ttccctccat cggatgaaca gcttaagtcc 60
ggcacggcgt ctgtggctcg cctgtcaat aactttacc ctagggaaac taaagtccaa 120
tggaaagtgg ataacgcctc gcagtcagga aacagccagg aatcggtac cgaacaggac 180

```

-continued

agcaaggaca gcacttactc cttgtcgctg actcttactc tgtagcaaggc cgattacgag 240
 aagcacaagg tctacgcctg cgagggtcacc catcaggggc ttcgtcccc ggtgacccaaa 300
 tccttcaata gaggcgaatg c 321

SEQ ID NO: 202 moltype = DNA length = 351
FEATURE Location/Qualifiers
misc_feature 1..351
source note = VH
source 1..351
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 202
 caagtgcagc tgggtcagag cgccgcgcag ctgaagaagc cccggcgaag cgtgaagggtg 60
 agctgcaggc caagcggtca caccttacc aactactgg a tgcagtgggt gagacaagcc 120
 cccggcgaag gcctggagt gatcgccgcg atcgaccctt ggcgcacta cacaactac 180
 aaccagggtc tccacccggcag attcgtctg a ggcgtggaca caagcggtg caccgcctac 240
 ctgcgcataca gcaaggcttggc ggcgcaggac acccgccgtg actactgcgc tagaaggctg 300
 agggcgtacg tggactacty ggcccaggc accaccgtga ccgtctcgag c 351

SEQ ID NO: 203 moltype = DNA length = 990
FEATURE Location/Qualifiers
misc_feature 1..990
source note = CH
source 1..990
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 203
 gccagcacca aagggtccatc cgtgtttccg ctgcgcggcgt cctcaagtc gacccggaa 60
 ggcactgcgg ccctgggtg ccttgtaaag gactattttcc cggaaacctgt caccgtgtcc 120
 tggaaacacgc ggcgcctgac ttccggagtg cacaacttcc cccgcgttctt gcaatccaggc 180
 ggcctgtact cactgtcatc cgtgtgtact gtcccggtgtt ccagcgttggg aacccaaacc 240
 tacattttca acgtgaatca caaaccatcg aataccaagg tgcataagaa agtcgagccg 300
 aagtcatcg acaagactca caccgttccg ctttgcggccag ccccgaaact gctcgccgg 360
 ccttcgtgtt ttttgtttcc gcccggggccg aaggacactc tggatgttcc acgcactcca 420
 gagggtactt gctgtgtgtt cgtatgtttcc caccggggccggaaatgttacttgcg 480
 tatgtcgacg ggggtggaaatg gcataatcc aagacgaagc cgaggggaggaa acagtacaac 540
 tccaccatca gagggtttttcc agtctttaacc gtcctccatc aagatgttgc gaaacggaaag 600
 gaggatcaat gtaagggttgc caaaaaaageg ttgcggggccatcgtaaaaa gactatcaggc 660
 aaggccaaag gacagccggcgg gggccgcggaa ttgtacacc tcccgccctt gggggacggag 720
 ctgaccaaga atcagggttgc ctttacttgc ctgggttggg gatttttacc ctcggatatac 780
 gcaatcgaaat gggaaatccaa tggacacccca gaaaacact acaagacccatcccccgggtg 840
 ctgcgtccatc acgggttccctt ctccgtatc tggatgttgc ccgtggacaa atcagctgg 900
 caccggggaa acgtgttttag ctgcgcgttgc atgcatgttgg ccgtgcataa tcaactacc 960
 cagaagtcaat ttcgttccatc cccaggggaaag 990

SEQ ID NO: 204 moltype = DNA length = 321
FEATURE Location/Qualifiers
misc_feature 1..321
source note = VL
source 1..321
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 204
 gaaatcgatca tgacacacggc ccccgccgacc ctggccgttgc ccccccgggtga gagagctacc 60
 ctggactgtca gaggcaaggc aagatcatcg aacagactgt aactgttatca gcagaaggccc 120
 ggcacccggcgt tgtagactgtt gatcgatc a gaaacggaa gacacccgg catcccggtt 180
 agattcagcg gcaaggccggcgg cggccaccgtac tacacccttgc ccatcagcg cctggaggct 240
 gaggacttgc ccgtgtacta ctgtcagca ggcacacggc tgccccccac ctccggccggc 300
 ggcaccaaggc tcgatgttgc g 321

SEQ ID NO: 205 moltype = DNA length = 321
FEATURE Location/Qualifiers
misc_feature 1..321
source note = CL
source 1..321
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 205
 agaactgtgg cccgcggcgtc agtgtttatc ttcccttccat cggatgttgc gcttaagtcc 60
 ggcacccggcgt ctgtgttgc tctgttccat aacttttacc ctggggaaatc taaatgtccaa 120
 tggaaatgttgc ataaacggccctt gcaatgttgc aacaggccagg aatcggttac cgaacaggac 180
 agcaaggaca gcacttactc cttgtcgctg actcttactc tgtagcaaggc cgattacgag 240
 aaggcacaagg tctacgcctg cgagggtcacc catcaggggc ttcgtcccc ggtgacccaaa 300
 tccttcaata gaggcgaatg c 321

SEQ ID NO: 206 moltype = DNA length = 351

-continued

```

FEATURE          Location/Qualifiers
misc_feature    1..351
                  note = VH
source           1..351
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 206
caagtgcagc tgggtcagag cggcagcgag ctgaagaagg ccggcgcaag cgtgaaggtg 60
agctgcaagg caagcgcta cacccacc aactactgaa tgaactgggt gagacaagcc 120
cccgccaaag gcttggatg gatggcgagc atcgacccta gcgcacgcta cacaactac 180
aaccaaggct tcaccggcag attcgatgatc agcggtggaca caagcgtagg caccgcctac 240
ctgcagatca gcagcctgaa ggcccggatc actactcgcc tagaaggctg 300
agcggtacg tggactactg gggccaaaggc accaccgtga cggctctcgag c 351

SEQ ID NO: 207      moltype = DNA length = 990
FEATURE          Location/Qualifiers
misc_feature    1..990
                  note = CH
source           1..990
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 207
gcacgcacca aagggtccatc cgtgtttccg ctgcggcccg cctcaaagtc gaccccgga 60
ggcaactcgcc ccttggctg ctttgtcaag gactattcc cccgaaacctg caccgtgtcc 120
tggAACAGCG ggcgcctgac ttccggatg cacaccccttcc cccgcgtct gcaatccagc 180
ggccctgtact cactgtcatc cgttgcgtact gtcccgatcg ccagcgtggg aacccaaacc 240
tacatttgcg acgtgatca caaaccatcg aataccatcg tggataaggaa agtcgaggcg 300
aagtcatgcg caaagactca caccgttccg ctttgcggccccc cccagaact gctcggccgc 360
ccttcgtgt ttttgttcc gccgaaggcg aaggacactc tgatgtatc acgcactcca 420
gagggtgactt gctgtgttgcg cgatgtttcc caccggggccg cggaaatgtgaa attcaactgg 480
tatgtcgacg ggggtggaaatg gcataatgcg aagacgaaaggc cgaggggaggaa acatgacaaac 540
tccacccatac gagggttttc agtccattacc gtcctccatc aagatgggt gaacggaaag 600
gagttacaat gtaagggtgtc gaacaaaggcg ttgcggccccc ctatcgaaaa gactatcagc 660
aaggccaaag gacagcccgccg ggagccgcaatgttacacc tcccgccctc gcggggacgag 720
ctgaccatcga atcagggtgtc ctttgcgttgc ctgtgttgcg gatttaccc ctggatatc 780
gcagtcgaat gggaaatcgaa tggacggcccaaaaact acaagaccac tcccccggtg 840
ctcgactccg acgggtccctt cttctgtac tcgaaatgtc cccgtggacaa atcaccgtgg 900
cagcaggaaac acgtgttttag ctgcagcgtg atgcgttgggg cgctgcataa tcactacacc 960
cagaagtacatc tctcgatcg cccaggaaag 990

SEQ ID NO: 208      moltype = DNA length = 321
FEATURE          Location/Qualifiers
misc_feature    1..321
                  note = VL
source           1..321
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 208
gagatcgtaa tgacacagag ccccgccgacc ctgagcgtgtt ccccggtgtt gggatgtacc 60
ctgagctgca gagaacgca aagatcgacc aacagactgaa actggatataa gcagaaggccc 120
ggccaaaggcg tggatgtgtt gatcgatcg aagacgaaaggc aacacacccg catcccccgt 180
agattcagcg gcaacggccg cggcaccgc tacaccctgtt ccatcagcgtt cttggacccgt 240
gaggacttccg ccgtgtacta ctgtgttgcg gggaaatcgaa tggccacccat cttccggccgc 300
ggcaccaaggc tcgatcgatcaa g 321

SEQ ID NO: 209      moltype = DNA length = 321
FEATURE          Location/Qualifiers
misc_feature    1..321
                  note = CL
source           1..321
                  mol_type = other DNA
                  organism = synthetic construct
SEQUENCE: 209
aagaactgtgg cccgcgcgtc agtgtttatc ttccctccat cggatgttac gcttaatgtcc 60
ggcacccgggt ctgtgttgcg cttgtgttgcg aacttttacc ctggatgttac taaatgtccaa 120
tggaaatgtgg ataaacggccctt gcaatgttgcg aacagccagg aatcggttac cgaacaggac 180
agcaaggaca gcaatgttgcg cttgtgttgcg acttttactc tgatgttgcg cgttacccgt 240
aaggcacaagg tctacgcctt cggatgttgcg catcgaggac tctcgatcccc ggtgacccaa 300
tccttcaataa gaggcgtatcg c 321

SEQ ID NO: 210      moltype = AA length = 18
FEATURE          Location/Qualifiers
REGION           1..18
                  note = alpha-LGR5 epitope peptide
source           1..18
                  mol_type = protein

```

-continued

```

SEQUENCE: 210          organism = synthetic construct
SSPRSGVLLR GCPTHCHC                                         18

SEQ ID NO: 211          moltype = AA  length = 260
FEATURE
source
1..260
mol_type = protein
organism = synthetic construct

SEQUENCE: 211
MPLLLPLL WAGALAEIVM TQSPATLSLS PGERATLSCR ASQDISNRLN WYQQKPGQAV 60
RLLISYRSRR HTGIPARFSG SGSGTDYTLT ISSLEPEDFA VYYCQQQNSL PPTFGGGTKL 120
EIKGGGGSGG GGSGGGGSGG GGSQVQLVQS GAEVKKPGAS VKVSCKASGY TFTNYWMQWV 180
RQAPGQGLEW IGEIDPSDSY TNYNQKFQGR VTLTVDTSTS TAYMELSSLR SEDTAVYYCA 240
RSLSGYVDYW QQGTTVTVSS                                         260

SEQ ID NO: 212          moltype = AA  length = 11
FEATURE
source
1..11
mol_type = protein
organism = synthetic construct

SEQUENCE: 212
RASQDISNRL N                                         11

SEQ ID NO: 213          moltype = AA  length = 7
FEATURE
source
1..7
mol_type = protein
organism = synthetic construct

SEQUENCE: 213
YRSRRHT                                         7

SEQ ID NO: 214          moltype = AA  length = 9
FEATURE
source
1..9
mol_type = protein
organism = synthetic construct

SEQUENCE: 214
QQGNNSLPPT                                         9

SEQ ID NO: 215          moltype = AA  length = 5
FEATURE
source
1..5
mol_type = protein
organism = synthetic construct

SEQUENCE: 215
NYWMQ                                         5

SEQ ID NO: 216          moltype = AA  length = 17
FEATURE
source
1..17
mol_type = protein
organism = synthetic construct

SEQUENCE: 216
EIDPSDSYTN YNQKFQG                                         17

SEQ ID NO: 217          moltype = AA  length = 8
FEATURE
source
1..8
mol_type = protein
organism = synthetic construct

SEQUENCE: 217
SLSGYVDY                                         8

SEQ ID NO: 218          moltype = DNA  length = 780
FEATURE
source
1..780
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 218
atgccgtcgc tgctactgct gccccctgctg tgggcagggg cgcttagctga gatcgatg 60
actcaaagcc ccggccacact gagectatct cccggcgaga gagccacgct gagctgtaga 120
gcaagccaag acatcagcaa cagactgaac tggtatcagc agaagccggg ccaagccgt 180
agactgctga tcagctacag aagcagaaga cacaccggca tccccgctag attcagccgc 240
agccggcagcg gcaccgacta caccctgacc atcagcagcc tggagctga ggacttcgct 300
gtatactact gccaacaagg caacagccctg ccggccaaacct tcggaggccg cacgaagctg 360

```

-continued

```

gagatcaagg gcgggttgtgg atcggggcgcc gggggcagcg ggggttgtgg ttctgttgtga 420
ggggggctcac aagtgcacgt ggtgcagago ggggcccggagg tgaagaaggcc cggcgcaagc 480
gtgaagggtga gtcgaaggc aagcggtcac accttccacca actactggat gcagtgggtg 540
agacaagccc cccggccaagg cctggagtgg atcggcgaga tcgaccctag cgacagctac 600
accaactaca atcagaagtt ccaaggcaga gtgaccctga ccgtggacac aagcacaagc 660
acccgcatac tggagcttag cagccgtgaga agcgaggaca ccgcgggtta ctactgcgt 720
agaaggctga gggctacgt ggactactgg ggcacaaggca ccaccgtgac cgtgagcagc 780

SEQ ID NO: 219      moltype = RNA length = 21
FEATURE
source
        Location/Qualifiers
        1..21
        mol_type = other RNA
        organism = synthetic construct
SEQUENCE: 219
gctgctgcag ctggcgaccg g                                21

SEQ ID NO: 220      moltype = RNA length = 21
FEATURE
source
        Location/Qualifiers
        1..21
        mol_type = other RNA
        organism = synthetic construct
SEQUENCE: 220
gcgccggcc gcctctctgc g                                21

SEQ ID NO: 221      moltype = DNA length = 42
FEATURE
source
        Location/Qualifiers
        1..42
        mol_type = other DNA
        organism = synthetic construct
SEQUENCE: 221
gacagactga gtcgccccggg acgegtccca ccatgccgct gc      42

SEQ ID NO: 222      moltype = DNA length = 27
FEATURE
source
        Location/Qualifiers
        1..27
        mol_type = other DNA
        organism = synthetic construct
SEQUENCE: 222
gcgtcggtt gtcgtcacg gtcacgg                                27

SEQ ID NO: 223      moltype = DNA length = 26
FEATURE
source
        Location/Qualifiers
        1..26
        mol_type = other DNA
        organism = synthetic construct
SEQUENCE: 223
cgtgagcgc accacgacgc cagcgc                                26

SEQ ID NO: 224      moltype = DNA length = 39
FEATURE
source
        Location/Qualifiers
        1..39
        mol_type = other DNA
        organism = synthetic construct
SEQUENCE: 224
caccatggtg gcgaccgggtg gatccccagg gggcaggc                                39

```

1. An antibody or fragment thereof which binds to LGR5, wherein the antibody binds an epitope located within amino acids 22-37 of SEQ ID NO.1.
2. The antibody or fragment thereof of claim 1, wherein the antibody binds an epitope which consists of amino acids 22-37 of SEQ ID NO.1.
3. The antibody or fragment thereof of claim 1 or 2 wherein the V_H of the antibody comprises the following CDR1, CDR2 and CDR3:
 - a) a CDR1 of SEQ ID No. 50 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 51 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 52 or a sequence with at least 90% homology thereto; or
 - b) a CDR1 of SEQ ID No. 2 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 3 or a

- sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 4 or a sequence with at least 90% homology thereto; or
- c) a CDR1 of SEQ ID No. 8 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 9 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 10 or a sequence with at least 90% homology thereto; or
- d) a CDR1 of SEQ ID No. 14 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 15 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 16 or a sequence with at least 90% homology thereto; or
- e) a CDR1 of SEQ ID No. 20 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 21 or

- a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 22 or a sequence with at least 90% homology thereto; or
- f) a CDR1 of SEQ ID No. 26 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 27 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 28 or a sequence with at least 90% homology thereto; or
- g) a CDR1 of SEQ ID No. 32 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 33 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 34 or a sequence with at least 90% homology thereto; or
- h) a CDR1 of SEQ ID No. 38 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 39 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 40 or a sequence with at least 90% homology thereto; or
- i) a CDR1 of SEQ ID No. 44 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 45 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 46 or a sequence with at least 90% homology thereto; or
- j) a CDR1 of SEQ ID No. 56 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 57 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 58 or a sequence with at least 90% homology thereto; or
- k) a CDR1 of SEQ ID No. 62 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 63 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 64 or a sequence with at least 90% homology thereto; or
- l) a CDR1 of SEQ ID No. 68 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 69 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 70 or a sequence with at least 90% homology thereto; or
- m) a CDR1 of SEQ ID No. 74 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 75 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 76 or a sequence with at least 90% homology thereto.
- 4.** The antibody or fragment thereof according to any preceding claim wherein the V_L of the antibody comprises the following CDR1, CDR2 and CDR3:
- a) a CDR1 of SEQ ID No. 53 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 54 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 55 or a sequence with at least 90% homology thereto; or
 - b) a CDR1 of SEQ ID No. 5 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 6 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 7 or a sequence with at least 90% homology thereto; or
 - c) a CDR1 of SEQ ID No. 11 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 12 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 13 or a sequence with at least 90% homology thereto; or
 - d) a CDR1 of SEQ ID No. 17 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 18 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 19 or a sequence with at least 90% homology thereto; or
 - e) a CDR1 of SEQ ID No. 23 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 24 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 25 or a sequence with at least 90% homology thereto; or
 - f) a CDR1 of SEQ ID No. 29 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 30 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 31 or a sequence with at least 90% homology thereto; or
 - g) a CDR1 of SEQ ID No. 35 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 36 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 37 or a sequence with at least 90% homology thereto; or
 - h) a CDR1 of SEQ ID No. 41 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 42 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 43 or a sequence with at least 90% homology thereto; or
 - i) a CDR1 of SEQ ID No. 47 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 48 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 49 or a sequence with at least 90% homology thereto; or
 - j) a CDR1 of SEQ ID No. 59 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 60 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 61 or a sequence with at least 90% homology thereto; or
 - k) a CDR1 of SEQ ID No. 65 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 66 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 67 or a sequence with at least 90% homology thereto; or
 - l) a CDR1 of SEQ ID No. 71 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 72 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 73 or a sequence with at least 90% homology thereto; or
 - m) a CDR1 of SEQ ID No. 77 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 78 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 79 or a sequence with at least 90% homology thereto.
- 5.** The antibody or fragment thereof according to any preceding claim, comprising a V_H sequence selected from SEQ ID NOS: 96, 80, 82, 84, 86, 88, 90, 92, 94, 98, 100, 102, 104.
- 6.** The antibody or fragment thereof according to any preceding claim, comprising a V_L sequence selected from SEQ ID NOS: 97, 81, 83, 85, 87, 89, 91, 93, 95, 99, 101, 103, 105.
- 7.** The antibody or fragment thereof according to any preceding claim comprising:
- i) a V_H sequence of SEQ ID NO: 96 and a V_L sequence of SEQ ID NO: 97;
 - b) a V_H sequence of SEQ ID NO: 80 and a V_L sequence of SEQ ID NO: 81;
 - c) a V_H sequence of SEQ ID NO: 82 and a V_L sequence of SEQ ID NO: 83;

- d) a V_H sequence of SEQ ID NO: 84 and a V_L sequence of SEQ ID NO: 85;
- e) a V_H sequence of SEQ ID NO: 86 and a V_L sequence of SEQ ID NO: 87;
- f) a V_H sequence of SEQ ID NO: 88 and a V_L sequence of SEQ ID NO: 89;
- g) a V_H sequence of SEQ ID NO: 90 and a V_L sequence of SEQ ID NO: 91;
- h) a V_H sequence of SEQ ID NO: 92 and a V_L sequence of SEQ ID NO: 93;
- i) a V_H sequence of SEQ ID NO: 94 and a V_L sequence of SEQ ID NO: 95;
- j) a V_H sequence of SEQ ID NO: 98 and a V_L sequence of SEQ ID NO: 99;
- k) a V_H sequence of SEQ ID NO: 100 and a V_L sequence of SEQ ID NO: 101
- l) a V_H sequence of SEQ ID NO: 102 and a V_L sequence of SEQ ID NO: 103; or
- m) a V_H sequence of SEQ ID NO: 104 and a V_L sequence of SEQ ID NO: 105.

8. The antibody or fragment thereof according to any preceding claim comprising a sequence of an antibody clone as shown in Table 3 or a sequence with at least 70%, 80% or 90% homology thereto.

9. The antibody or fragment thereof according to claim **1** or claim **2** wherein the fragment is an scFV comprising SEQ ID NO. 211 or a sequence with at least 70%, 80% or 90% homology thereto.

10. The antibody or fragment thereof according to any preceding claim wherein the antibody binds to human LGR5.

11. The antibody or fragment thereof according to any preceding claim wherein the antibody is a monoclonal antibody.

12. The antibody or fragment thereof of any preceding claim, wherein the antibody is a human, humanized, or chimeric antibody.

13. The antibody or fragment thereof of any preceding claim, wherein the antibody is conjugated to a toxin, enzyme, radioisotope, label, therapeutic agent or other chemical moiety.

14. The antibody or fragment thereof of any preceding claim, wherein the antibody is capable of binding LGR5 with a Kd of less than around 4 nM.

15. The antibody or fragment thereof according to any preceding claim wherein the fragment comprises a Fab, scFv or single domain antibody.

16. An immunoconjugate comprising an antibody or fragment thereof according to any one of claims **1-15** linked to a therapeutic agent.

17. The immunoconjugate according to claim **16** wherein said therapeutic agent is a toxin, enzyme, radioisotope or other chemical moiety.

18. A pharmaceutical composition comprising an antibody according to any one of claims **1-15** or an immunoconjugate according to claim **16** or **17** and a pharmaceutical carrier.

19. An antibody or fragment thereof according to any one of claims **1-15**, an immunoconjugate according to claim **16** or **17** or a pharmaceutical composition according to claim **18** for use as a medicament.

20. An antibody or fragment thereof according to any one of claims **1-15**, an immunoconjugate according to claim **16**

or **17** or a pharmaceutical composition according to claim **18** for use in the treatment or diagnosis of a cancer or an inflammatory disease.

21. A method for treating a cancer comprising administering a therapeutically effective amount of an antibody or fragment thereof according to any one of claims **1** to **15**, an immunoconjugate according to claims **16** to **17** or a pharmaceutical composition according to claim **18**.

22. The antibody or fragment thereof for use of claim **20** or the method of claim **21** wherein the cancer is an LGR5-positive cancer.

23. The antibody or fragment thereof for use of claim **22** or the method of claim **22** wherein the cancer overexpresses LGR5.

24. The antibody or fragment thereof for use of any of claims **20**, **22** or **23** or the method of any of claims **21** to **23** wherein the cancer is selected from cancer of the head or neck, uterine cancer, colorectal cancer, stomach cancer, carcinoma of the endometrium, cancer of the esophagus, leukemia, such as acute lymphoblastic leukemia (ALL), liver cancer, such as hepatocellular carcinoma, or pancreatic cancer.

25. An isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody or fragment thereof according to any of claims **1-15**.

26. A vector comprising a nucleic acid according to claim **25**.

27. A host cell comprising a nucleic acid according to claim **25** or a vector according to claim **26**.

28. A method of detecting LGR5 in a biological sample comprising contacting the biological sample with the antibody according to any of claims **1-15** under conditions permissive for binding of the antibody to LGR5, and detecting whether a complex is formed between the antibody and LGR5.

29. The method of claim **28** wherein the biological sample is a cancer sample selected from cancer of the head or neck, uterine cancer, colorectal cancer, stomach cancer, carcinoma of the endometrium, cancer of the esophagus, leukemia, such as acute lymphoblastic leukemia (ALL), liver cancer, such as hepatocellular carcinoma or pancreatic cancer.

30. An antibody or fragment thereof which binds to LGR5 wherein the VH of the antibody comprises the following CDR1, CDR2 and CDR3:

- a) a CDR1 of SEQ ID No. 50 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 51 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 52 or a sequence with at least 90% homology thereto; or

- b) a CDR1 of SEQ ID No. 2 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 3 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 4 or a sequence with at least 90% homology thereto; or

- c) a CDR1 of SEQ ID No. 8 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 9 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 10 or a sequence with at least 90% homology thereto; or

- d) a CDR1 of SEQ ID No. 14 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 15 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 16 or a sequence with at least 90% homology thereto; or

- e) a CDR1 of SEQ ID No. 20 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 21 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 22 or a sequence with at least 90% homology thereto; or
 - f) a CDR1 of SEQ ID No. 26 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 27 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 28 or a sequence with at least 90% homology thereto; or
 - g) a CDR1 of SEQ ID No. 32 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 33 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 34 or a sequence with at least 90% homology thereto; or
 - h) a CDR1 of SEQ ID No. 38 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 39 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 40 or a sequence with at least 90% homology thereto; or
 - i) a CDR1 of SEQ ID No. 44 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 45 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 46 or a sequence with at least 90% homology thereto; or
 - j) a CDR1 of SEQ ID No. 56 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 57 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 58 or a sequence with at least 90% homology thereto; or
 - k) a CDR1 of SEQ ID No. 62 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 63 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 64 or a sequence with at least 90% homology thereto; or
 - l) a CDR1 of SEQ ID No. 68 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 69 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 70 or a sequence with at least 90% homology thereto; or
 - m) a CDR1 of SEQ ID No. 74 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 75 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 76 or a sequence with at least 90% homology thereto.
- 31.** An antibody or fragment thereof according to claim **30** which binds to LGR5 wherein the VL of the antibody comprises the following CDR1, CDR2 and CDR3:
- a) a CDR1 of SEQ ID No. 53 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 54 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 55 or a sequence with at least 90% homology thereto; or
 - b) a CDR1 of SEQ ID No. 5 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 6 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 7 or a sequence with at least 90% homology thereto; or
 - c) a CDR1 of SEQ ID No. 11 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 12 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 13 or a sequence with at least 90% homology thereto; or
 - d) a CDR1 of SEQ ID No. 17 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 18 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 19 or a sequence with at least 90% homology thereto; or
 - e) a CDR1 of SEQ ID No. 23 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 24 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 25 or a sequence with at least 90% homology thereto; or
 - f) a CDR1 of SEQ ID No. 29 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 30 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 31 or a sequence with at least 90% homology thereto; or
 - g) a CDR1 of SEQ ID No. 35 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 36 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 37 or a sequence with at least 90% homology thereto; or
 - h) a CDR1 of SEQ ID No. 41 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 42 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 43 or a sequence with at least 90% homology thereto; or
 - i) a CDR1 of SEQ ID No. 47 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 48 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 49 or a sequence with at least 90% homology thereto; or
 - j) a CDR1 of SEQ ID No. 59 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 60 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 61 or a sequence with at least 90% homology thereto; or
 - k) a CDR1 of SEQ ID No. 65 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 66 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 67 or a sequence with at least 90% homology thereto; or
 - l) a CDR1 of SEQ ID No. 71 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 72 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 73 or a sequence with at least 90% homology thereto; or
 - m) a CDR1 of SEQ ID No. 77 or a sequence with at least 90% homology thereto, a CDR2 of SEQ ID No. 78 or a sequence with at least 90% homology thereto, a CDR3 of SEQ ID No. 79 or a sequence with at least 90% homology thereto.
- 32.** An antibody or fragment thereof which binds to LGR5 according to claim **30** or **31**, comprising a VH sequence selected from SEQ ID NOS: 96, 80, 82, 84, 86, 88, 90, 92, 94, 98, 100, 102, 104.
- 33.** An antibody or fragment thereof which binds to LGR5 according to claim **30** to **32**, comprising a VL sequence selected from SEQ ID NOS: 97, 81, 83, 85, 87, 89, 91, 93, 95, 99, 101, 103, 105.
- 34.** A chimeric antigen receptor comprising an antibody or fragment according to any of claims **1** to **15** or **30** to **33**.
- 35.** A CAR comprising SEQ ID NO. 211 or a sequence with at least 70%, 80% or 90% homology thereto.
- 36.** A cell or cell population expressing a CAR of claim **34** or **35**.

- 37.** The cell or cell population according to claim **36** wherein the cell is an immune cell.
- 38.** The cell or cell population according to claim **37** wherein the immune cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), tumor infiltrating lymphocyte (TIL), TCR-expressing cell, dendritic cell, or NK-T cell and a regulatory T cell.
- 39.** The cell or cell population according to claims **36** to **38** wherein the cell or is an autologous T cell or an allogeneic T cell.
- 40.** A cell or population of cells according to any of claims **36** to **39** for use in adaptive immunotherapy.
- 41.** An immune cell engager, such as a BiTE or TriKE, comprising an antibody or fragment according to any of claims **1** to **15** or **30** to **33**.
- 42.** A BiTE according to claim **41** comprising SEQ ID NO. 211 or a sequence with at least 70%, 80% or 90% homology thereto.
- 43.** A method of producing an antibody comprising culturing the host cell according to claims **1** to **15** or **30** to **33** under conditions suitable for expression of the polynucleotide encoding the antibody and isolating the antibody.
- 44.** An isolated synthetic or recombinant peptide comprising an epitope, the peptide consisting of residues 22 to 37 of SEQ ID NO: 1.
- 45.** A method of diagnosing or assessing progression of cancer comprising assessing expression of LGR5 and/or protein levels of LGR5.
- 46.** The method according to claim **45** further comprising comparing the level of expression to a threshold level.
- 47.** The method according to claim **46** wherein said threshold level is the level of expression in normal tissue.
- 48.** The method according to claim **47** further comprising selecting a treatment if the level of expression is above the threshold.
- 49.** The method according to claim **48** further comprising administering said treatment.
- 50.** The method according to claim **49** wherein the treatment is an antibody or antibody fragment of any of claims **1** to **15** or **30** to **33**.
- 51.** The method according to claim **50** wherein the protein level is assessed using an antibody or antibody fragment of any of claims **1** to **15** or **30** to **33**.

* * * * *